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Abstract 
 
 
Recent estimates indicate that globally there are over 33 million people infected with Human 
Immunodeficiency Virus type 1 (HIV-1). The epidemic is particularly severe in sub-Saharan 
Africa which accounts for 67% of all infected individuals and 72% of AIDS deaths in 2007. While 
current therapies, particularly in combination as a cocktail of highly active antiretroviral therapy 
(HAART), have had an important positive impact on the morbidity and mortality of HIV-related 
illness, there remain significant limitations. These include toxicities, resistance and the inability 
to eradicate a latent infection. In addition, most therapeutic agents have been developed to 
target HIV-1 subtype B, which affects individuals predominantly in Western Europe and North 
America. These concerns, along with ensuring patient compliance with treatment and the high 
cost of improved treatment regimens, have prompted the search for innovative and globally-
effective therapies to eradicate HIV infection. More recently, gene therapy strategies based on 
the naturally-occurring RNA interference (RNAi) pathway has provided an exciting new 
mechanism to inhibit rogue gene expression. RNAi represents a set of highly conserved cellular 
pathways whereby double-stranded RNA (dsRNA) precursors are processed into shorter 
dsRNAs by the successive action of ribonucleases Drosha and Dicer. Processed, 21-23 
nucleotide, short interfering RNAs (siRNAs) or antisense RNAs (asRNAs), associate with 
members of the Argonaute family of proteins to regulate gene expression at the transcriptional 
and post-transcriptional level.  
 
By exploiting the biogenesis of the endogenous mammalian RNAi pathway, several exogenous 
RNAi pathway mimics have been developed to inhibit unique sequences, including viral targets 
such as HIV. In the context of HIV, a combinatorial system that allows for the simultaneous 
suppression of multiple targets is important in preventing viral mutational escape of this rapidly 
evolving pathogen. The studies presented in this thesis add significantly to the newly emerging 
body of research on combinatorial RNAi strategies by focusing on the two novel technological 
approaches using mammalian expression systems. Both RNA Pol III-generated long-hairpin 
RNAs (lhRNAs) and RNA Pol II-generated polycistronic primary microRNAs (pri-miRNAs) were 
developed as systems for generating combinatorial RNAi precursors from single transcriptional 
units that induce post-transcriptional silencing of several highly conserved sequences of HIV-1. 
These included established therapeutic sites targeted to coding and non-coding regions of the 
HIV-1 long terminal repeat (LTR), Polymerase, Tat and Integrase. Expressed lhRNAs with ~63 
bp duplex dsRNA regions and defined 5' and 3' termini were targeted to the transcribed region of 
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the HIV 5' LTR and effectively suppressed two distinct sites within this region across both 
subtypes B and C HIV sequences. In addition, to assess whether lhRNAs could inhibit basal 
levels of HIV transcription, the lhRNAs were shown to suppress Tat-mediated (processive) and 
Tat-independent (non-processive) transcription when targeting episomal and integrated LTR-
driven sequences. Portions of the lhRNAs that produced the most active siRNAs were dissected 
by using tiled LTR targets cloned into a luciferase reporter gene and by using northern blot 
analyses. Dicer-processing of expressed lhRNAs was shown to be most effective from the base 
of the duplex and decreased in efficiency towards the loop, suggesting that a gradient of siRNAs 
production is possible from a single lhRNA but with decreasing efficacy. This work laid the 
foundation for improved expressed lhRNAs whereby multiple unique anti-HIV siRNAs were 
produced from a single lhRNA. The second combinatorial RNAi strategy made use of RNA Pol 
II-expressed pri-miRNA mimics, where each mimic was derived from a different endogenous 
scaffold.  Polycistronic transcripts consisting of four different pri-miRNA scaffolds and targeting 
four separate sites in HIV were tested in several combinatorial systems. The pri-miRNA 
backbone chosen was shown to dramatically affect the concentration and inhibitory efficacy of 
each generated effector strand, and this was largely independent of the sequence used. A 
strategy to combine four of the most effective pri-miRNA scaffolds into one expression cassette 
was developed and significant inhibition of an HIV infectious molecular clone as well as a wild 
type HIV isolate was demonstrated. Finally, in an attempt to uncover additional asRNAs capable 
of inducing inhibition via transcriptional gene silencing of the HIV LTR promoter, indiscriminate 
cell-wide gene activation was shown to occur as result of an unintended off-target effect. These 
observations demonstrated that caution should be exercised when interpreting RNA-induced 
gene activation results. Overall, this thesis provides a detailed description of the efficacy of two 
novel combinatorial RNAi approaches based on single promoter expression systems that are 
aimed at generating multiple RNAi effector sequences targeted to HIV. These approaches pave 
the way towards a better understanding of the efficacy of combinatorial RNAi and an effective 
and sustained gene therapy of HIV. 
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Chapter one: general introduction 
 
 
1.1 Introduction  
 
The World Health Organisation (WHO) currently estimates that there are 33.0 million (30 million 
to 36 million) people infected with the human immunodeficiency virus (HIV) worldwide with that 
number having grown by 2.7 million (2.2 million to 3.2 million) cases in 2007 alone. South Africa 
has the highest number of infections globally with 5.7 million (4.9 million to 6.6 million) HIV 
positive people (UNAIDS 2008). Currently available drugs to treat the infection are highly 
effective at reducing HIV-related deaths as well as opportunistic infections that occur as part of 
the broader HIV-induced disease referred to as AIDS (acquired immunodeficiency syndrome). 
Treatment success is tightly correlated with patient compliance which can be poor as a result of 
toxic side effects of the drugs or their by-products, accessibility of chronic treatment and viral 
resistance that almost inevitably emerges. This could be dramatically improved through the use 
of a single intervention that would aid the patient for life but current treatment formulations 
require repeat administrations to be effective. An alternative strategy that could provide a 
solution to the problems associated with conventional HIV therapies is gene therapy.     
Gene therapy is defined as the use of a nucleic acid sequence administered to human 
patients with the intention of regulating, repairing or replacing a targeted genetic sequence 
(Verma and Somia 1997). One type of gene therapy in particular utilises a naturally occurring 
pathway to silence expression of genes. The pathway, known as RNA interference (RNAi) is 
triggered by double stranded (ds) RNA and results in homology-dependent control of gene 
expression (Elbashir, Lendeckel et al. 2001). The dsRNAs required to initiate the pathway can 
be designed against any sequence of interest and can be generated synthetically or expressed 
within a host cell. Importantly, these RNAi triggers are highly amenable to combination thereby 
allowing for the simultaneous generation of multiple RNAi suppressors known as small 
interfering RNAs (siRNAs). Effective combinations of RNAi inhibitors present a new and exciting 
addition to current gene therapy strategies that warrants further investigation.  
The work contained in this thesis contributes to the field of gene therapy through the use of 
various RNAi suppressors in combination against HIV. Of particular interest is the incorporation 
of an assorted set of RNAi substrates into a simple expression system that can be readily 
manipulated to release potent anti-HIV siRNAs. Plasmid vectors were generated that expressed 
multiple siRNAs from different precursor dsRNAs. These expression systems were tested using 
assays specifically designed to assess the abilities of each system to generate multiple 
functional anti-HIV siRNAs. By characterising the effects of siRNAs generated from distinct 
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combinatorial systems, the feasibility of developing effective concentrations of multiple siRNAs 
from single expressed precursor substrates was established. This strategy is of particular value 
in the context of rapidly evolving viruses such as HIV.   
 
1.2 HIV biology and origins 
 
HIV is an enveloped retrovirus belonging to the lentivirus genus and is capable of infecting 
primate immune cells bearing a CD4+ surface receptor, including CD4+ helper lymphocytes, 
CD8+ cytotoxic lymphocytes and macrophages. The term lentivirus is derived from the Latin 
word lentus which means ‗slow‘ and refers to viruses, such as HIV, that exhibit a characteristic 
long incubation period. Infection with HIV causes CD4+ cells to die and their decrease in number 
over time leads to a weakened immune system that allows for opportunistic infections to occur. 
Once the CD4+ helper lymphocyte count falls to less than 350 per mm3 of blood HIV-infected 
individuals enter a disease state referred to as AIDS that can span years or even decades (Levy 
2009). HIV has evolved a number of strategies to elude the host immune system including 
integration of the viral genome into the host chromosome thereby providing a permanent 
blueprint for virion production [reviewed in (Taylor, Sobieszczyk et al. 2008)]. The viral reverse 
transcriptase enzyme, required for generating a DNA copy of the RNA genome, lacks proof-
reading ability that results in a high viral mutation rate of 3.4 x 10-5 mutations per base pair (bp) 
per replication cycle. This translates to 1010 HIV variants produced in a single day within one 
patient (Perelson, Neumann et al. 1996; Lee, Perelson et al. 2008). In addition, recombination is 
common where multiple infections have occurred within a single patient and this further 
increases viral genomic diversity (Templeton, Kramer et al. 2009). 
HIV-1 originated from three independent cross-species transmissions of Simian 
Immunodeficiency Virus (SIV). These occurred from infected chimpanzees (Pan troglodytes 
troglodytes and P. t. schweinfurthii) to humans sometime before the 20th century in west central 
Africa (Gao, Bailes et al. 1999; Korber, Muldoon et al. 2000; Sharp, Bailes et al. 2001). Genetic 
analyses have revealed a single change within the viral genome that occurred independently 
during cross-species transfer from apes to humans (Wain, Bailes et al. 2007) and strongly 
implies a host-specific adaptation of the virus (Hahn, Shaw et al. 2000). An independent 
zoonotic event from sooty mangabeys (Cercocebus atys) to humans has led to HIV-2 which is 
geographically restricted to Cameroon (Gao, Yue et al. 1992). The chimpanzee zoonotic events 
gave rise to three separate groups of HIV-1 namely M (major), N (non-major) and O (outlier). A 
fourth HIV-1 group distinct from groups M, N and O was recently reported and shown to be 
closely related to gorilla SIV (Plantier, Leoz, et al. 2009). Group M viruses are responsible for 
the worldwide HIV pandemic although the reasons for this remain unclear (Hahn, Shaw et al. 
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2000; Keele, van Heuverswyn et al. 2006). Further heterogeneity exists as group M viruses can 
be classified into subtypes A to J (Cohen, Anderson et al. 2005; Taylor, Sobieszczyk et al. 
2008). Currently 15 % of global infections are caused by subtype B viruses while 48 % are 
subtype C infections (UNAIDS 2008).  
 
1.3 HIV genome and protein organisation 
 
The HIV genome is approximately nine kilobases (kb) and comprises two copies of positive 
strand RNA that encode a total of nine genes. These include information for three structural, two 
regulatory and four accessory proteins (Figure 1). The structural genes encode Gag (group 
specific antigen), Pol (polymerase) and Env (envelope) proteins. The regulatory genes encode 
Rev (regulator of expression of viral protein) and Tat (transcriptional transactivator) proteins. The 
four accessory genes encode Nef (negativity factor), Vif (viral infectivity factor), Vpr (viral protein 
R) and Vpu proteins [viral protein U or viral protein X (Vpx) in HIV-2; (Li, Hui et al. 1992)]. The 5' 
and 3' long terminal repeats (LTRs) are common to all retroviruses and serve as promoter 
sequences for the transcription of viral mRNAs as well as full length genomic transcripts (Gifford, 
Katzourakis et al. 2008). The gag gene is transcribed as a myristoylated precursor protein that is 
cleaved by viral protease into core protein components, p17 (matrix), p24 (capsid), p7 and p6 
(nucleocapsid). The pol gene overlaps the gag gene at a UUUUUUAG sequence and a stem 
loop structure is present downstream of this junction. This causes ribosomal slippage on the 
RNA resulting in a -1 frameshift that produces a Gag-Pol precursor protein. This polyprotein is 
cleaved by viral protease into integrase (IN), RNAse H (RNH), reverse transcriptase (RT) and 
protease (PR) (Saliou, Bourgeois et al. 2009). The Env protein is produced as a precursor 
glycoprotein complex (gp160) that is cleaved into surface (gp120) and membrane (gp41) 
subunits by host proteases. The regulatory and accessory genes are translated as single 
proteins that do not require proteolytic cleavage to initiate function.  
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Figure 1. The HIV genome and viral proteins. Two copies of positive strand RNA make up the nine kb 
genome of HIV. Nine partially overlapping genes encode structural (gag, pol and env), regulatory (tat and 
rev) and accessory (nef, vif, vpr, and vpu or vpx in HIV-2) information. Transcription occurs at various 
stages throughout the viral life cycle driven by the 5' LTR promoter following integration into the host 
genome. The 3' LTR is used during reverse transcription of the RNA genome to generate a viral cDNA 
copy. The Env protein (shown in blue) is produced as a precursor glycoprotein complex (gp160) that is 
cleaved by host proteases into surface (gp120) and membrane (gp41) subunits. Viral polymerase (shown 
in purple) is a polyprotein cleaved by viral protease (PR) into reverse transcriptase (RT), RNAseH (RNH) 
and integrase (IN). The remaining regulatory and accessory proteins do not require cleavage to function. 
 
 
1.4 The viral life cycle 
 
1.4.1 Entry 
 
HIV infection occurs in CD4+ cells when HIV Env proteins bind the host CD4+ receptor and a 
chemokine co-receptor (Figure 2, number 1). Membrane-embedded mature gp120 and gp41 
Env proteins are linked by non-covalent interactions and associate as trimeric molecules on the 
surface of viral particles (Wyatt, Kwong et al. 1998; Liu, Bartesaghi et al. 2008). The most 
variable portions of gp120 are highly glycosylated loop regions exposed at the surface of the 
virus. The sugars serve to mask large regions of gp120 and gp41 (Perdomo, Levi et al. 2008). 
Attachment of HIV is initially mediated by non-specific interactions between the glycosylated 
variable loops and charged glycolipids and glycoproteins of host cells. While insufficient for 
entry, this binding allows for subsequent receptor recognition by gp120 (Brelot and Alizon 2001). 
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CD4 is the major receptor for gp120 and while each monomer within the trimeric complex has a 
binding site for CD4, engagement at only one position is sufficient to induce conformational 
changes in all three glycoproteins that are required for viral entry (Salzwedel and Berger 2000). 
These changes allow for interactions with one of a number of chemokine co-receptors although 
chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) are commonly utilised 
by macrophage tropic (M-tropic) and T cell tropic (T-tropic) HIV respectively (Agrawal, Maxwell 
et al. 2009). The engagement of CD4-bound gp120 and its co-receptor triggers a rearrangement 
of gp41 trimers to form a rod-shaped bundle with three leucine zippers aligned as a coiled coil 
(Clapham and McKnight 2002). The exact events that lead to fusion are unclear but 
reorganisation of the gp41 bundle culminates in the merging of host  membranes with viral 
envelope (Campbell and Hope 2008; Liu, Bartesaghi et al. 2008).  
 
 
(Figure 2 is on the following page) 
 
Figure 2. The life cycle of HIV. Infection occurs in cells that express CD4 receptors (shown in green) such 
as macrophages and T cells. Attachment of the virus (1) requires binding between HIV gp120, host CD4 
and either a CCR5 (shown in dark purple) or CXCR4 (shown in light purple) co-receptor. This causes 
fusion of the host and pathogen membranes and penetration of the virus. Once in the cytoplasm, 
uncoating (2) of the viral genome from the capsid releases a reverse transcription complex (RTC). For 
simplicity, a single positive strand RNA genome is depicted in red bound to viral integrase (IN – purple 
circle) and Vpr (orange circle). The RTC triggers reverse transcription of the RNA genome (3) forming a 
double stranded DNA copy (shown in light blue). Vpr binds the DNA genome copy to form a pre-
integration complex (PIC) and mediates nuclear entry (4). IN causes integration (5) of the viral genome 
(termed a provirus) into the host chromosome (shown in light green). Transcription (6) from the provirus 
generates primary transcripts that are either packaged as new genomes, or spliced to form numerous 
mRNAs. Non-transcribed 1-LTR and 2-LTR circles abound in the nucleus but do not successfully give rise 
to progeny. Viral Rev exports (7) nascent mRNAs into the cytoplasm where translation occurs (8). Gag 
proteins are transported to the host cell membrane and self-assemble (9) into capsid shells containing 
viral genomic RNA and accessory proteins. HIV Env protein is translated in the rough endoplasmic 
reticulum (ER) and cleaved into gp120 and gp41 in the Golgi complex. The latter subunit anchors the Env 
complex into the host membrane while covalently interacting with gp120.  The concluding stage in 
assembly involves the coating of viral particles with Env-studded host membrane as they bud out of 
infected cells (10). After release, viral protease cleaves Gag/Pol precursors and initiates a structural 
rearrangement cascade of proteins that generates mature virus in the extracellular host environment (11).   
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1.4.2 Uncoating and reverse transcription 
 
The internal core of the HIV virion is composed of p17 matrix proteins that contain the viral 
genome and auxiliary viral proteins (Figure 3). This is surrounded by p24 capsid proteins that 
associate with the envelope boundary of the virion. The protective p24 shell is stable but 
following fusion of the viral envelope and host cell membrane, a necessary pH-induced 
conformational change allows the capsid to disassemble, the matrix to uncoat and the genomic 
RNA to be released (Figure 2, number 2). The detailed mechanism of this process is poorly 
understood (Ehrlich, Liu et al. 2001; Dvorin and Malim 2003). Once uncoated, the viral genome 
remains bound to p17 as well as nucleocapsid proteins (p7 and p6), Gag-Pol polyprotein 
cleavage products and Vpr in a complex referred to as the reverse transcription complex (RTC) 
(Freed 2001). Both p6 and p7 nucleocapsid proteins contain two zinc finger motifs (Cys-X2-Cys-
X4-His-X4-Cys) and are involved in dimerisation and stabilisation of the viral genomic RNA 
(Zhang and Crumpacker 2002). The role of Vpr in the RTC is controversial but it may improve 
the fidelity of the process by modulating the mutation rate of HIV and diminishing mutations 
acquired during reverse transcription (Le Rouzic and Benichou 2005). For more details on the 
subject of reverse transcription, please refer to a review by (Harrich and Hooker 2002).  
Binding of the RTC to cellular actin triggers reverse transcription of the viral genome by 
RT to form a 181 nucleotide (nt) single stranded (ss) negative sense DNA product (Davis, Carr 
et al. 2008). This serves as a primer that switches strands and hybridises to the 3' end of the 
viral genome to allow for completion of negative strand synthesis (Figure 2, number 3). The 
resultant molecule is a DNA/RNA hybrid and viral RNAse H (part of the RT complex) is 
responsible for degrading the RNA strand (Freed 2001). Positive strand DNA synthesis is 
initiated by DNA-dependent DNA polymerase and following a second strand transfer event a 
dsDNA copy of the viral genome is completed (Li, Stephenson et al. 1993). Importantly, the 
process of reverse transcription results in the copying of U3 and U5 sequences to form complete 
LTRs at either end of the dsDNA viral genome required for integration of HIV.  
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Figure 3. The HIV virion. The virion has a diameter of approximately 120 nm with surface studs of trimeric 
glycoproteins (gp120 and gp41) encoded by env that are embedded in a host-derived membrane. The 
viral p24 capsid (encoded by gag) is within the membrane and protects a conical gag-encoded 
nucleocapsid matrix (p17). Within the matrix core, two positive strand copies of the viral RNA genome and 
several viral proteins, including Vpr (orange circle) and polymerase (purple circle) can be found. The latter 
protein is cleaved into protease (p15), reverse transcriptase (p55), RNAseH (p66) and integrase (p32). 
 
1.4.3 Integration 
 
Synthesis of the DNA copy of the viral genome, referred to as a provirus, produces the pre-
integration complex (PIC) (Li and Craigie 2009). Integration of the provirus into the chromatin of 
the infected host cell is a key feature of retroviruses and vital for the completion of the HIV life 
cycle as once integrated, the viral DNA is transcribed and replicated along with cellular DNA (Li 
and Craigie 2009). Unsuccessful integration events lead to re-circularised forms of the provirus 
termed 1-LTR or 2-LTR circles that can be detected in the nuclei of infected cells. Viral genes 
are not efficiently expressed from these substrates and do not give rise to successful progeny 
(Wiskerchen and Muesing 1995). For integration to take place the PIC is required to relocate, via 
microtubules, to the nucleus (Nisole and Saïb 2004). En route to the nucleus, the PIC protects 
the provirus from cellular DNAses and other host cytoplasmic sensors that may trigger an anti-
viral response [Figure 2, number 4 and (Yoder, Sarasin et al. 2006; Borden, Sen et al. 2007)]. 
HIV Vpr forms part of the PIC and despite not encoding a canonical nuclear localisation signal 
may interact with host nuclear pore components to enhance transport of the PIC through the 
nuclear pore (Popov, Rexach et al. 1998). Notably, lentiviruses such as HIV can integrate within 
quiescent cells as dissociation of the nuclear membrane is not required for the virus to enter the 
nucleus (Heinzinger, Bukrinsky et al. 1994; Miller, Farnet et al. 1997). Additional information 
describing nuclear entry of retroviruses is available in the following reviews (Goff 2001; Suzuki 
and Craigie 2007).  
Once inside the nucleus, viral IN preferentially mediates integration of the provirus at 
regions of host chromatin that are transcriptionally active (Engelman, Oztop et al. 2009; Felice, 
Cattoglio et al. 2009).  During the first of two steps required for integration, two nt are removed 
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from the 3' end of one of the strands of the provirus to expose the terminal hydroxyl group and 
generate a recessed end (Figure 2, number 5). Secondly, DNA strand transfer takes place and 
the 3' provirus hydroxyl groups attack the phosphodiester backbone of host chromosomal DNA 
generating an integration intermediate in which the 3' viral ends are covalently bound to the 5' 
target DNA ends (Li and Craigie 2009). Host repair enzymes fill in the gaps to complete the 
process (Engelman 2003).  
 
1.4.4 Proviral expression and nuclear export of transcripts 
 
Regulation of proviral expression is mediated by the transcriptional transactivator protein, Tat, 
that is expressed shortly after integration and stimulates the elongation of RNA Polymerase II 
(RNA Pol II) to ensure full-length viral transcripts are produced [Figure 2, number 6 and 
(Barboric and Peterlin 2005)]. The HIV LTR promoter element is composed of U5 (unique 5' 
end), R (repeat) and U3 (unique 3' end) regions (Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The HIV promoter. The HIV LTR acts as a promoter element and is composed of U3, R and U5 
regions. The U3 region spans 454 bp (defined in relation to the transcription start site at +1) and can be 
divided into a negative regulatory (NRE) or modulatory element (-340 to -180), an enhancer (-105 to -79) 
and a promoter element (-78 to +1). The initial 60 bp of the R region (+1 to +95) fold into a loop structure 
(TAR) that binds Tat during productive transcription. The U5 region spans approximately 200 bp (+95 to 
+300) and contains a tRNA binding site (+181). The transcription start site of the LTR is at the R/U3 
junction (+1) with a TATA box located 25 bases upstream in the U3 portion. Numerous Sp1 (blue ovals), 
NF-κβ (green circles) and other motifs serve as transcription factor binding sites for host proteins.  
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The transcription start site is at the R/U3 junction with a TATA box located 25 bases upstream in 
the U3 portion (Gifford, Katzourakis et al. 2008). At the start of eukaryotic transcription, a pre-
initiation complex of general transcription factors, including the TATA box binding protein (TBP) 
and 12 to 15 TBP-associated factors, bind at the TATA box and direct RNA Pol II binding at this 
site. Two of the TBP-associated factors (IIE and IIH) unwind the DNA (Kim, Ebright et al. 2000) 
and transcription initiation proceeds whereby two nucleotide triphosphates (NTPs) are joined to 
form a phosphodiester bond (Dvir, Conaway et al. 1996). This allows promoter clearance of 
RNA Pol II although due to the instability of the early transcription complex, these transcripts are 
released before they have been elongated (Pal and Luse 2002). Elongation and productive 
transcription requires phosphorylation of serine 5 within the C-terminal domain of Rpb1, an RNA 
Pol II subunit [Figure 5 and (Ramanathan, Rajpara et al. 2001)].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Transcription of the HIV provirus. Expression from the provirus (shown in light blue) can be 
divided into Tat-independent and Tat-dependent phases. In the absence of Tat (upper panel), RNA Pol II 
(shown in dark red) binds the transcription start site of the 5' LTR downstream of the TAR loop (shown in 
black) and initiates transcription. Un-phosphorylated RNA Pol II is non-productive and generates truncated 
transcripts. Some low levels of full length transcript are also produced, sufficient to generate Tat protein 
that transactivates transcription. During productive transcription (lower panel), Tat (pink circle) binds the 
TAR loop and recruits CyclinT1 (green oval), CDK9 (purple circle) and TRBP (blue oval). CDK9 
phosphorylates (yellow circles) RNA Pol II allowing for elongation of transcripts.  
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Phosphorylation is mediated by the cyclin dependent kinase (CDK9) catalytic domain of positive 
transcription elongation factor b (pTEF-b) that phosphorylates RNA Pol II and ensures 
processive transcription [(Price 2000) and reviewed in (Sims III, Belotserkovskaya et al. 2004)]. 
HIV-1 Tat activates transcriptional elongation of the integrated provirus by recruiting pTEFb to 
the transactivating responsive (TAR) element that forms a stable RNA loop structure at the 5' 
end of all viral transcripts (Richter, Ping et al. 2002). The TAR loop was thought to comprise the 
initial 80 bp of the 5' LTR but deletion studies have established the minimal domain required for 
Tat binding comprise nucleotides 19 to 42 (Garcia, Harrich et al. 1989). TAR RNA folds with a 
six nt loop and contains two stem regions separated by a three bp pyrimidine bulge that is 
essential for Tat binding (Dingwall, Ernberg et al. 1990). Activation of RNA Pol II occurs 
following the formation of a co-operative Tat-pTEFb-TAR complex. Tat specifically interacts with 
the cyclin T1 subunit of pTEFb and the TAR loop adopts a conformation that allows Tat to bind 
at the tri-nucleotide bulge (Richter, Cao et al. 2002). This results in phosphorylation of both 
serine 2 and serine 5 of Rbp1 to activate RNA Pol II (Zhou, Halanski et al. 2000; Kim, Bourgeois 
et al. 2002). Importantly, regardless of the site of proviral integration, the 5' LTR is always 
packaged by two nucleosomes (Nuc 0, -413 to -253 and Nuc +1, +1 to +155) the second of 
which is located close to the transcriptional start site. The binding of cellular transcription factors 
upstream of Nuc +1 induces remodelling of this nucleosome and subsequent transcription 
[reviewed in (Weinberg and Morris 2006)]. Thus, the chromatin state at the site of HIV 
integration aids in ensuring proviral silencing.  
HIV, like all retroviruses, uses a post-transcriptional mechanism to generate multiple 
mRNAs from a single proviral template (Lee, Culver et al. 2008). The viral transcripts expressed 
from the LTR include (1) un-spliced mRNAs that function as Gag-Pol precursors and genomic 
RNA for progeny virions, (2) incompletely spliced mRNAs that express Env, Vif, Vpr and Vpu 
proteins, and (3) abundantly spliced mRNAs that code for Rev, Tat and Nef proteins (Freed 
2001). While the latter transcripts (~2 kb) are constitutively transported via cellular machinery to 
the cytoplasm, translocation of the intron-containing transcripts requires an additional 
mechanism that bypasses cellular splicing machinery [Figure 2, number 7 and reviewed in 
(Pollard 1998)]. Rev functions to shuttle un-spliced and partially spliced mRNAs to the cytoplasm 
by binding the Rev responsive element (RRE) conserved within these transcripts (Pond, 
Ridgeway et al. 2008). At low Rev concentrations, nascent un-spliced and partially spliced 
mRNAs are degraded but once a critical concentration of Rev has been reached export of the 
mRNAs to the cytoplasm via the Crm-1 pathway occurs (Fridell, Bogerd et al. 1996).  
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1.4.5 Translation, assembly and budding 
 
In the host cytoplasm, expression of a complete set of viral proteins leads to concurrent 
assembly and budding of new virions [Figure 2, numbers 8 to 10 and (Zhang and Nguyen 
2008)]. Within minutes of their production, structural Gag proteins are transported to and 
associate with the host cell membrane via myristoylation signals in their N-termini (Campbell and 
Hope 2008). Here Gag proteins self-arrange in a radial fashion and interact with matrix proteins 
that have enveloped viral genomic RNA (Gottlinger 2001; Lanman, Sexton et al. 2002). 
Incorporation of the RNA is mediated by an encapsidation signal (ψ) located in gag and p7 and 
p6 nucleocapsid proteins are involved in dimerisation of two viral genomic RNA strands (Zhang 
and Crumpacker 2002). HIV Env protein is translated in the rough endoplasmic reticulum (ER) of 
host cells as a gp160 precursor and cleaved into its gp120 and gp41 subunits in the Golgi 
complex before the latter becomes anchored in the host cell membrane (Liu, Bartesaghi et al. 
2008). The concluding stages in assembly involve the coating of viral particles in host 
membrane studded with Env spikes as they bud out of infected cells and subsequent maturation 
of immature virions (Ganser-Pornillos, Yeager et al. 2008). Maturation is initiated by proteolysis 
of Gag-Pol precursors leading to a structural rearrangement cascade of proteins that finally 
generates mature virus in the extracellular host environment [Figure 2, number 11 and (Moore, 
Fu et al. 2008)].   
 
1.4.6 Viral accessory proteins 
 
The HIV accessory proteins interact with various host proteins in order to enhance virion 
production and counteract certain host-mediated anti-viral mechanisms [reviewed in (Malim and 
Emerman 2008)]. Briefly, Vpu aids gp160 maturation by sequestering CD4 proteins in the ER 
and mediating their ubiquitination and degradation. This ensures gp160 translocation to the host 
cell surface where it can be incorporated into budding virions (Göttlinger 2008; Salim and Ratner 
2008). Vif interacts with a member of the APOBEC (apolipoprotein B mRNA-editing catalytic 
polypeptide) protein family to prevent deamination of cytoplasmic viral genomic RNA in budding 
virions [reviewed in (Goila-Gaur and Strebel 2008)]. In addition to its role in the RTC, Vpr 
induces cell cycle arrest in the G2 phase of infected cells. The biological relevance of this is 
unclear but G2 arrest may favour LTR transcription (Le Rouzic and Benichou 2005; Andersen, 
Le Rouzic et al. 2008). The HIV Nef protein is expressed early in the viral life cycle and ensures 
establishment and persistence of infection by enhancing fusion at the plasma membrane and 
uptake of virions via the cytosolic pathway (Schaeffer, Geleziunas et al. 2001). This action is 
mediated in a CD4-independent manner but Nef also mediates down-regulation of surface-
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bound CD4 receptors, accelerating their degradation via lysis and preventing sequestration of 
the viral Env protein (Das and Jameel 2005). This surface down-regulation prevents super-
infection of the host cell which would otherwise lead to cell, and subsequent viral, death (Foster 
and Garcia 2008).  
 
1.5 HIV latency 
 
A major obstacle to eradicating HIV is the establishment of a latent infection.  Thymus-derived 
(T) cells bearing a CD4 receptor undergo a reversible resting phase during their natural life cycle 
and HIV infection and subsequent integration into these cells provides a blueprint for viral 
production that is extremely stable and can persist for the lifetime of the patient (Chun, Finzi et 
al. 1995; Finzi, Blankson et al. 1999; Siliciano, Kajdas et al. 2003). In addition to CD4+ T cells, 
macrophages and dendritic cells can serve as reservoirs for HIV as internalised virions can 
remain infectious for weeks within cellular endosomes and be transmitted to neighbouring T 
cells (Pelchen-Matthews, Kramer et al. 2003; Sharova, Swingler et al. 2005).  CD4+ T cells are 
the main source of latent infection which can occur either pre- or post-integration of the provirus 
into host chromatin [reviewed in (Lassen, Han et al. 2004)]. Should HIV infection occur just prior 
to cellular transition from an active to resting state, integration may be blocked and this is 
referred to as pre-integration latency (Chiu, Soros et al. 2005). When these infected cells are 
activated by mitogens in their surrounding environment, the extra-chromosomal provirus can 
integrate and generate progeny (Pierson, Zhou et al. 2002). A more stable form of latency 
occurs post-integration when CD4+ T cells that carry a provirus revert to a resting state. While 
integration into centromeric heterochromatin partly accounts for repressive transcription (Jordan, 
Defechereux et al. 2001), additional host and viral factors play a role in maintaining latency 
[reviewed in (Marcello 2006)]. 
The U3 region of the HIV LTR encodes a number of consensus sequences within the 
modulatory region (Figure 4) for binding of host transcription factors such as NFAT (nuclear 
factor of activated T cells) and NF-κβ (nuclear factor kappa-beta) (Williams and Greene 2005; 
Williams, Chen et al. 2006). Both of these transcription factors are sequestered in the cytoplasm 
of resting T cells but are recruited to the nucleus following cellular activation by T-cell receptor 
(TCR) binding or cytokine signalling via interleukin 2 (IL-2) or tumour necrosis factor alpha 
(TNFα) (Pereira, Bentley et al. 2000). Once in the nucleus, NFAT and NF-κβ can initiate 
transcriptional activation through binding the U3 region of the HIV LTR and in this way, HIV 
transcription is linked to T cell activation (Scripture-Adams, Brooks et al. 2002; Hogan, Chen et 
al. 2003). Furthermore, the HIV LTR contains three Sp-1 sites for binding of general transcription 
activators and these may play a role in initiating basal levels of non-processive transcription in 
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resting T cells when NFAT and NF-κβ are unavailable (Lassen, Bailey et al. 2004). In addition to 
boosting transcription (described in section 1.4.4), the interaction of HIV Tat with the TAR loop is 
associated with a co-incident recruitment of histone acetyl-transferases such as p300 and CBP 
(cyclic-AMP responsive transcription factor binding protein). These proteins modulate various 
interactions at the nucleosome such as acetylation of the p50 subunit of NF-κβ (Benkirane, 
Chun et al. 1998; Lusic, Marcello et al. 2003). Furthermore, acetylation of Tat‘s activation 
domain by p300/CBP-associated factor (PCAF) has been shown to stabilise the TAR-Tat-cyclin 
T1 interaction and improve transcription from integrated provirus (D‘Orso and Frankel 2009). All 
these interactions are evidence that HIV latency is a complex state and not simply a result of 
inaccessibility of the provirus to host transcription machinery in quiescent cells. Indeed, HIV has 
recently been shown to modulate its own expression and latency through manipulation of 
members of the RNAi pathway (Han and Siliciano 2007; Huang, Wang et al. 2007; Triboulet, 
Mari et al. 2007) and a full discussion of these modulations is described in section 5.2. The key 
issue with HIV latency is that unless the small pool of infected resting T cells can be eliminated, 
HIV cannot be eradicated within a patient and activation of the reservoir resumes productive 
infection and disease. Current therapies cannot solve this issue but new gene therapy strategies 
discussed in section 4.4 may be able to specifically affect the state of latent HIV. 
 
1.6 HIV pathogenesis and treatment 
 
The course of HIV infection can be divided into an acute and chronic phase, the former of which 
is characterised by poor to no HIV-specific antibody detection, low copies of viral RNA in the 
patient (termed viral load) and severe destruction of gut associated lymphoid tissue [reviewed in 
(Paiardini, Frank et al. 2008)]. This phase reflects immense interactions between HIV and the 
human immune system, with the viral load at the end of this stage determining a total burden of 
disease or ‗set point‘. The set point has considerable implications for the spread of HIV as the 
greater the viral load, the higher the chance of transmission (Cohen, Anderson et al. 2005). The 
heterogeneity of the virus may also play a role in spreading infection as within one infected 
individual a cosmopolitan mix of genotypes exist, some of which are favoured during 
transmission events – a postulate related to the overwhelming occurrence of subtype C 
infections worldwide [reviewed in (Taylor, Sobieszczyk et al. 2008)]. During the chronic phase, 
the viral load increases gradually, the CD4+ T cell count declines slowly and clinical latency 
occurs. Over time, but specifically in the absence of anti-HIV drugs, the viral load rebounds and 
CD4+ T cells die off leaving the patient severely immune-compromised.  
Since the 1996 introduction of drugs targeted to HIV, morbidity and long-term prognoses 
of patients have substantially improved (Palella, Delaney et al. 1998; Walensky, Paltiel et al. 
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2006). The remarkable genetic diversity coupled with the high mutation rate of the virus led to 
the use of combinations of drugs for the suppression of viral replication and this is referred to as 
highly active antiretroviral therapy (HAART). While only a few drugs were initially available, there 
are currently more than 20 approved antiretroviral drugs (ARVs) that can be divided into four 
distinct classes based on their modes of action (Keiser, Orrell et al. 2008). Entry inhibitors block 
HIV binding to host cells, either by preventing the formation of a gp41 bundle (Wild, Shugrass et 
al. 1994) or by allosteric, non-competitive binding of the CCR5 co-receptor (Watson, Jenkinson 
et al. 2005; Hunt and Romanelli 2009).  The biggest class of ARVs are reverse transcriptase 
inhibitors (RTIs) that can be nucleoside/nucleotide (NRTI) or non-nucleoside (NNRTI) based. 
NRTIs inhibit reverse transcription of HIV as they are incorporated into newly synthesized viral 
DNA and prevent elongation (Hang, Li et al. 2007). NNRTIs directly bind the RT enzyme and 
prevent its functioning (Hang, Li et al. 2007). Integrase inhibitors (INIs) prevent integration of the 
provirus into host chromatin by interfering with viral IN binding or the strand transfer events in 
the process (Sato, Motomura et al. 2006). The fourth class of ARVs currently available are 
protease inhibitors (PIs) that prevent cleavage of viral polyproteins in immature budding viruses 
(Flexner 1998).  
A key issue with conventional drugs is resistance either from mutations developed by 
actively replicating HIV, transmission of resistant viral strains or stable viral reservoirs that permit 
low level replication in the presence of therapeutic agents and subsequent resistance mutation 
events [reviewed in (Richman, Margolis et al. 2009)]. Within a single patient, the impressive 
heterogeneity of HIV means there is a litany of possible mutants and a single mutation can 
induce resistance to an entire drug class (Rimsky, Shugars et al. 1998; Tuaillon, Gueudin et al. 
2004; Johnson, Brun-Vézinet et al. 2008; Pillay, Pillay et al. 2008; Hunt and Romanelli 2009). As 
only four drug classes are currently available, reformulating HAART cocktails is limited and fresh 
clinical trials to reassess efficacy and safety may be required, with a significant possibility of HIV 
evolving resistance to the new combination. Novel drug classes, such as maturation inhibitors 
are being investigated but have only been evaluated for safety in healthy volunteers and require 
further testing before use in HIV infected patients (Martin, Blum et al. 2007; Martin, Blum et al. 
2007). Furthermore, despite the lowered toxicities in the newer generation ARVs, the cumulative 
effects of these treatments long-term is a concern given that most of the drugs affect lipid 
metabolism and mitochondrial functioning [reviewed in (Mallon 2007)]. Thus while the successes 
of HAART regimens cannot be ignored, their shortcomings open avenues for experimental 
approaches such as nucleic acid based therapies that may solve some of the concerns related 
to current treatments.  
Nucleic acid treatments differ fundamentally from conventional drugs in their mode of 
action as nucleic acid drugs function specifically by hybridising to unique target sequences. 
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Theoretically this means any specific sequence within a gene or RNA transcript can be targeted 
thereby hugely expanding the possibilities for HIV inhibition. In addition, as nucleic acid 
therapies share the same modalities, the pharmacokinetic and pharmacodynamic profiles are 
the same thus one safety profile should provide sufficient data for different agents to be 
combined. This would dramatically reduce costs involved in clinical trials and allow for therapies 
to reach patients in a significantly shorter period of time. Finally, the relative ease with which 
nucleic acids can be synthesised means regimens could be rapidly altered and customised as 
infection profiles changed.  
 
1.7 Nucleic acid based therapies 
 
Nucleic acid therapy falls into the broader class of gene therapy and involves the use of 
intracellularly expressed exogenous genes to inhibit unwanted viral or cellular replication. The 
exogenous gene (transgene) can either be introduced via a transfer vector and expressed within 
the target cell(s) or the transgene product (RNA or protein) can be directly introduced to initiate 
the silencing effect (Klug and Cummings 2000).  A number of gene therapy strategies have been 
explored over the last fifteen years that include RNA as well as protein based agents. The 
former involves RNA oligonucleotides that hybridise to a complementary target while the latter 
uses a competitive inhibition approach akin to conventional drugs. While some examples are 
currently in developmental phases and remain highly experimental, certain modalities have 
undergone rigorous assessment and been tested in clinical trials. The following section provides 
a snapshot of different nucleic acid modalities used against HIV as opposed to a comprehensive 
review. 
 
1.7.1 Nucleic acid therapies that have been tested in clinical trials 
 
Antisense oligonucleotides (ASOs) are ssDNA molecules that bind via sequence 
complementarities to cognate mRNA forming a stable RNA/DNA hybrid that undergoes 
ubiquitous and constitutive RNAse H degradation (Chan, Lim et al. 2006). To induce a 
therapeutic silencing effect, ASOs need to avoid nuclease degradation en route to the target 
cell, escape lysosomal-mediated degradation and maintain integrity within the cell at clinically 
relevant concentrations [reviewed in (White, Anastasopoulos et al. 2009)]. Early versions of 
ASOs were unstable in vivo due to nuclease digestion. Chemical modifications such as 
phosphorothioate linkages improved this but overall mRNA target affinity of the modified ASOs 
was reduced (Geary, Henry et al. 2002). Further alterations to the ribose ring of ASOs increased 
their target specificities but rendered them refractory to RNAse H degradation (Prakash and 
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Bhat 2007). New generation ASOs include phosphorothioate linkages and a morpholino ring 
backbone that enhances serum stability and RNAse H cleavage in vivo (Summerton 2007). 
Various malignancies as well as a range of pathogenic viruses including HIV have been targeted 
by ASOs [reviewed in (Rayburn and Zhang 2008; Spurgers, Sharkey et al. 2008)]. HIV Vif 
(Barnor, Miyano-Kurosaki et al. 2004), RRE (Prater, Saleh et al. 2007), RNAse H (Heinrich, 
Mathur et al. 2009) and TAR (Chaubey, Tripathi et al. 2007) have all been targeted using 
expressed forms of ASOs. Interestingly, a phase I clinical trial assessing an anti-HIV env ASO 
demonstrated long-term expression of the construct in vivo but no antiviral effects of the ASO 
were detected (Levine, Humeau et al. 2006). This may have been the result of inherent 
inefficiencies in the RNAse H pathway, suboptimal delivery of the ASOs to their targets cells or 
non-specific mRNA binding (Summerton 2007). These issues relate to all ASOs and thus a 
number of improvements are required before they can enjoy wide-spread use.  
Ribozymes are non-coding RNAs with catalytic abilities that can be designed to target 
specific RNA sequences [reviewed in (Sarver, Cantin et al. 1990)].  Ribozymes can cleave in cis 
or trans and have intrinsic requirements for specific magnesium chloride (MgCl2) concentrations 
(Goila and Banerjea 1998) and water molecules (Rhodes, Reblova et al. 2006). Both HIV and 
various host factors required for infection have been targeted using ribozymes (Ojwang, Hampel 
et al. 1992; Goila and Banerjea 1998; Bai, Gorantla et al. 2000; Cagnon and Rossi 2000; Bai, 
Rossi et al. 2001) and extensive data laid the foundations for clinical trials to be conducted. 
Initial phase I clinical trials revealed that retroviral vectors could successfully deliver anti-HIV 
ribozymes to haematopoetic stem cells from patients (Michienzi, Castanotto et al. 2003; Amado, 
Mitsuyasu et al. 2004; Ngok, Mitsuyasu et al. 2004; Macpherson, Boyd et al. 2005). However, 
while the method of delivery was a viable option, the in vivo efficacies of the transduced cells 
were poor despite their long-term stable persistence. A recent phase II clinical trial also utilised 
autologous transplantation of transduced haematopoetic stem cells (HSCs) to assess a 
ribozyme targeted to the overlapping tat/vpr ORF (Mitsuyasu, Merigan et al. 2009).  No adverse 
effects were noted and despite no change in viral load over 48 weeks, CD4+ T cell counts were 
higher for the patients who received the anti-HIV ribozyme. Taken together the clinical trial data 
suggests that ribozymes can be safely delivered to target cells but the in vivo efficacies of these 
gene therapy agents need to be improved.  
RNA decoys are homologues of RNA targets such as RRE and TAR that bind natural 
viral proteins and competitively inhibit the native ligands necessary for HIV replication 
(Sullenger, Gallardo et al. 1990; Browning, Cagnon et al. 1999). U16 small nucleolar RNA 
(snoRNA) has been used to deliver TAR and RRE decoys with appreciable inhibition of HIV 
noted for both (Banerjea, Li et al. 2004; Michienzi, de Angelis et al. 2006). A clinical trial has 
been conducted using an RRE decoy delivered by a retroviral vector into HSCs from HIV 
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positive patients (Kohn, Bauer et al. 1999). No adverse effects following the procedure were 
detected but the number of circulating transduced cells was too low to assess any anti-HIV 
activity. Protein homologues of RNA decoys, referred to as trans-dominant negative derivatives, 
mimic viral proteins such as Rev or Tat but lack vital functional moieties. Over-expression of 
these trans-dominant proteins titrates out their endogenous counterparts interfering with regular 
viral functioning (Trono, Feinberg et al. 1989; Caputo, Grossi et al. 1996; Woffendin, Ranga et 
al. 1996). Clinical trials to assess the efficacies of TAR decoys and trans-dominant Rev proteins 
have been conducted in paediatric patients. HSCs from HIV positive children were transduced 
with either a TAR decoy or a transdominant Rev protein and significant long-term survival even 
in the presence of a high viral load was demonstrated in at least 50 % of the patients (Morgan, 
Walker et al. 2005; Podsakoff, Engel et al. 2005). While these data strongly suggest that decoys 
are effective inhibitors of HIV in vivo their efficacy is strongly correlated with immune 
reconstitution following stem cell transduction and HIV resistance can rapidly develop in the 
presence of suboptimal decoy concentrations. 
 
1.7.2 Rationale for additional gene therapy strategies 
 
Further development of the gene therapy approaches mentioned in section 1.7.1 have been 
hampered by serum instabilities, suboptimal delivery and toxicity as a result of the modifications 
required for their optimal functioning in a cellular environment [reviewed in (Rossi, June et al. 
2007)]. Serum instability and toxicity are often related as the modifications required for stability 
of naked nucleic acids in serum may be immunogenic. However those agents that are not 
modified may have little effect as they are rapidly degraded in host cells. Delivery methods have 
typically involved retroviral vectors that carry gene therapy payloads but success depends on 
the transduction of a critical number of patient cells. Lentiviral vectors have an added advantage 
of being able to transduce non-dividing cells and could theoretically improve the overall number 
of genetically modified cells, but insertional mutagenesis as well as the possibility of 
recombination events between the vector and wild type virus remains a concern when using 
these vectors in the context of HIV (Morris and Rossi 2006). Ideally what is required is a nucleic 
acid based strategy that harnesses the simplicity and elegance of simple Watson-Crick base-
pairing to achieve a highly specific and efficacious gene silencing effect with limited toxicity in 
vivo. The discovery that a natural highly conserved RNA-mediated gene regulatory pathway 
exists opened a new paradigm of opportunities for gene therapy known as RNA interference 
(RNAi). This pathway utilises dsRNA to guide homology-dependent silencing of target RNA in a 
manner similar to ASOs and ribozymes. Notably though, as RNAi is an endogenous pathway the 
canonical silencing molecules are non-toxic and highly efficacious in vivo with potencies far 
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greater than other exogenous RNA molecules (Robinson 2004; Haasnoot, Westerhout et al. 
2007). Since the official discovery of RNAi in 1998 there has been an explosion in our 
understanding of the pathway itself allowing RNAi to be modified for multiple purposes including 
antiviral therapy.  
 
1.8 RNA interference 
 
RNAi phenomena were initially described in tobacco plants following infection (Wingard 1928) 
and later in petunias after the introduction of exogenous pigment genes (Napoli, Lemieux et al. 
1990). In lower eukaryotes RNAi functions as an antiviral mechanism whereas higher 
eukaryotes utilise the pathway as a robust regulator of gene expression (Stefani and Slack 
2008) with links to embryonic development, cell differentiation, proliferation, metabolism and 
death [reviewed in (Bartel and Chen 2004; Singh, Bhadra et al. 2008; Stefani and Slack 2008; 
Yekta, Tabin et al. 2008)]. Pioneering experiments in Caenorhabditis elegans revealed that 
dsRNA was the trigger of RNAi, and that the effects could be systematic and heritable (Fire, Xu 
et al. 1998). Viral replication, transcription of convergent genes, self-annealing cellular 
transcripts and mobile genetic elements can all generate dsRNA substrates that are converted 
to small interfering RNAs (siRNAs) to guide cleavage of cognate mRNA targets by RNAi 
machinery (Elbashir, Lendeckel et al. 2001). Hundreds of RNAi silencing molecules have since 
been identified in animals although many of their targets have not been defined.(Lagos-
Quintana, Rauhut et al. 2001; Lee and Ambros 2001; Lewis, Shih et al. 2003) Two recent 
reviews have suggested a classification system based on RNAi precursors, biogenesis 
pathways and associated proteins (Ghildiyal and Zamore 2009; Kim, Han et al. 2009).  Many 
classes of small RNAs that feed into the RNAi pathway exist but for the purposes of this thesis 
only the mammalian RNAi pathway encompassing microRNAs (miRNAs) and siRNAs is 
described.  
 
1.8.1 Mammalian microRNA biogenesis 
 
Expression and nuclear processing 
Endogenous miRNAs are usually generated from RNA polymerase (Pol) II promoters (Lee, Kim 
et al. 2004) although some, usually Alu-repeat-associated, are transcribed by Pol III (Borchert, 
Lanier et al. 2006). Approximately 40 % of miRNA loci are located within introns of non-coding 
transcripts, 10 % are positioned in exons of non-coding transcripts and 40 % are situated in the 
introns of protein-coding transcripts (Lewis, Shih et al. 2003). Interestingly, many miRNAs occur 
as clusters of two or more miRNAs with highly correlated expression (Kim and Nam 2006). 
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Clustered miRNAs have also been shown to have functional relatedness and thus while they are 
not strictly polycistronic transcripts they may be referred to as ‗polycistronic miRNAs‘ (Yuan, Liu 
et al. 2008). Pol-II generated primary miRNA transcripts (pri-miRNAs) are generally several kb in 
length, contain several stem-loop structures, have ssRNA flanking segments and are processed 
in two compartmentalised steps [Figure 6 and (Lee, Jeon et al. 2002)]. The initial step involves 
an RNAse-III protein family member Drosha that cleaves at the stem of the pri-miRNA to release 
a hairpin structure termed a pre-miRNA (Lee, Ahn et al. 2003; Han, Lee et al. 2004). Drosha is 
comprised of two RNAse III domains and a dsRNA binding domain (dsRBD), the latter of which 
is insufficient for substrate binding (Jinek and Doudna 2009). A helper protein, the DiGeorge 
syndrome critical region gene 8 (DGCR8) co-interacts with Drosha and the pri-miRNA to form a 
650 kiloDalton (kDA) Microprocessor complex (Denli, Tops et al. 2004; Gregory, Yan et al. 2004; 
Han, Lee et al. 2004). DGCR8 specifically recognises the stem of a pri-miRNA (approximately 
33 bp) as well as the junction between the ss and dsRNA regions and directs Drosha-mediated 
cleavage 11 bp from this site (Zeng and Cullen 2005; Han, Lee et al. 2006). The resultant pre-
miRNA is approximately 70 bp and includes a 5' phosphate and two-nucleotide 3' overhang. 
Regulation of the Microprocessor complex occurs post-transcriptionally (Han, Pedersen et al. 
2009). Vertebrate DGCR8 mRNA transcripts contain two conserved hairpins with features 
similar to pri-miRNAs. These structures are cleaved by Drosha resulting in suppression of 
DGCR8. Notably, the cleavage is less efficient than with genuine pri-miRNAs – a feature that is 
consistent with a regulatory role. DGCR8 protein in turn stabilises Drosha through a protein-
protein interaction thereby completing a positive feedback loop (Han, Pedersen et al. 2009).  
Interestingly, pri-miRNA processing may occur co-transcriptionally and prior to intronic 
splicing in the nucleus (Morlando, Ballarino et al. 2008). Drosha-mediated cleavage of intronic 
miRNAs does not impair transcript splicing (Kim and Kim 2007) but if the miRNA is located 
exonically, Drosha processing destabilises the transcript and affects downstream protein 
translation (Han, Pedersen et al. 2009). Cellular splicing machinery also plays a role in the 
biogenesis of a distinct class of miRNAs that bypass Drosha-mediated cleavage (Berezikov, 
Chung et al. 2007; Ruby, Jan et al. 2007)]. Termed mirtrons, these intronic miRNAs are derived 
from Pol II-transcribed primary-mirtron precursors that encode canonical splice sites (Figure 6). 
Host splicing machinery recognises the splice sites and cleaves the transcript generating a 
hairpin structure that resembles a Drosha product (Ying and Lin 2006; Okamura, Hagen et al. 
2007). 
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Figure 6. The mammalian RNAi pathway. Endogenous miRNAs and siRNAs begin their genesis from 
RNA Pol II promoters (shown as red squares). The miRNA biogenesis pathway (left hand panel) is chiefly 
initiated by transcription of pri-miRNAs from gene-coding regions. Pri-miRNAs have a stem-loop structure 
approximately 33 bp in length flanked by single stranded regions. The RNAseIII protein Drosha (lilac 
square) complexed to dsRBD DGCR8 (blue oval) forms a Microprocessor complex that binds the pri-
miRNA and cleaves (red arrows) to release a pre-miRNA hairpin structure with characteristic 2 nucleotide 
3' overhangs. Pre-miRNAs can also be generated without Drosha. Pri-miRNAs transcribed from intronic 
sequences are termed mirtrons, have similar characteristics to exonic pri-miRNAs but contain splice donar 
and acceptor sites that are recognised by host splicing machinery to yield a pre-miRNA in the absence of 
Drosha. Both forms of pre-miRNA are exported from the nucleus by Exp5 (green square) that recognises 
and binds the 2 nucleotide 3' overhang. In the cytoplasm, the loop of the pre-miRNA is cleaved (red 
arrows) by Dicer (yellow oval) and its dsRBD partner TRBP (blue oval) to liberate a miRNA duplex with 2 
nucleotide 3' overhangs. AGO2 (pink oval) binds the miRNA duplex to form RISC – a complex that 
mediates silencing of the target mRNA. The miRNA duplex is unwound leaving the guide strand (mature 
mRNA) to pair covalently with its cognate mRNA. If this pairing is incompletely complementary, 
translational suppression occurs in P-bodies. If the mature miRNA pairs 100 % with the target mRNA, 
AGO2 mediated cleavage of the latter occurs. Endogenous siRNAs (right hand panel) are transcribed 
either as long hairpin structures with stems between 40 and 400 bp or as duplex structures composed of 
separate complementary transcripts. It is unclear if they are processed in the nucleus prior to export or if 
Crm1 (light green squares) mediates their transport to the cytoplasm. There may be multiple processing 
steps involving Dicer/TRBP to yield a siRNA duplex that is loaded into RISC. The mature strand of the 
duplex (guide siRNA) pairs with 100 % complementarity to the target mRNA and guides AGO2-mediated 
cleavage.    
 
 
Nuclear export, cytoplasmic processing and Argonaute loading 
Following nuclear cleavage, pre-miRNAs need to be transported to the cytoplasm for the second 
processing step to occur (Lee, Jeon et al. 2002). Exportin-5 (Exp5) is responsible for 
transporting pre-miRNAs and does so by binding its cargo in a sequence-independent fashion at 
high RanGTP levels in the nucleus, translocating the Ran·Exp5·pre-miRNA complex to the 
cytoplasm and releasing the pre-miRNA and Ran upon GTP hydrolysis (Lund and Dahlberg 
2006). The Exp5 can then return to the nucleus to facilitate another round of transport (Yi, Qin et 
al. 2003; Bohnsack, Czaplinski et al. 2004). Once in the cytoplasm, the loop of the pre-miRNA is 
cleaved by another RNAse III enzyme called Dicer to release a miRNA duplex (Bernstein, 
Caudy et al. 2001). Dicer comprises two copies of a conserved RNAse III domain, a dsRBD in 
the carboxy-terminus, an amino-terminus helicase domain, a domain of unknown function (DUF) 
and a PAZ (Piwi-Argonaute-Zwille) domain (Jaskiewicz and Filipowicz 2008). The distance 
between the PAZ and RNAse III domains within Dicer corresponds well with the average length 
(25 bp) of a pre-miRNA stem duplex (Macrae, Li et al. 2006). Dicer thus functions as a 
'molecular ruler' (Jinek and Doudna 2009) by anchoring the 3' end of the pre-miRNA duplex in 
the PAZ domain and cleaving at a fixed distance from that end to generate miRNA products 21 
bp in length with characteristic 5' phosphate groups and two-nucleotide 3' overhangs [(Elbashir, 
Harborth et al. 2001; Elbashir, Lendeckel et al. 2001) and section 1.14]. Interestingly, the 
helicase domain may play a regulatory role as this domain imposes a non-functional 
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conformation on the whole protein that must be re-arranged for catalysis to occur (Ma, Macrae 
et al. 2008).  
Human Dicer interacts with two proteins, TRBP (TAR RNA binding protein) and PACT 
(Protein Kinase R activator). TRBP is a dsRBD protein (Chendrimada, Gregory et al. 2005; 
Daniels, Melendez-Peña et al. 2009), PACT upregulates PKR activity (Lee, Hur et al. 2006) and 
both proteins contribute to the formation of an RNA-induced silencing complex (RISC). Following 
Dicer cleavage, the miRNA duplex is released from Dicer but remains bound to TRBP and PACT 
(Lee, Hur et al. 2006; Daniels, Melendez-Peña et al. 2009). Specifically, the PAZ domain of 
TRBP recognises the two-nucleotide 3' overhangs in the miRNA duplex and anchors the 
substrate within RISC (Lingel, Simon et al. 2003; Kawamata, Seitz et al. 2009). A protein from 
the Argonaute (AGO) family binds TRBP to complete the formation of RISC (Hammond, 
Bernstein et al. 2000; Zamore, Tuschl et al. 2000; Martinez, Patkaniowska et al. 2002; Preall 
and Sontheimer 2005). One strand of the miRNA duplex remains bound within RISC as the 
mature miRNA or guide strand while the remaining passenger strand is degraded 
(Chendrimada, Gregory et al. 2005). The relative thermodynamic stability of the 5' end of the 
miRNA duplex determines which strand is the mature miRNA (Schwarz, Hutvagner et al. 2003). 
Typically, the strand with less stable 5' base pairing remains bound within RISC although this 
does not apply to all miRNAs (Khvorova, Reynolds et al. 2003; Han, Lee et al. 2006). The 
endonucleolytic activity of AGO2 is responsible for cleavage of the passenger strand and an 
unidentified helicase then unwinds and releases this strand (Matranga, Tomari et al. 2005; Preall 
and Sontheimer 2005; Rand, Petersen et al. 2005).  
 
Target mRNA recognition and processing 
Mature miRNAs regulate post-transcriptional protein synthesis by base pairing to cognate 
mRNAs. Depending on the degree of complementarity between the mature miRNA and its 
target, as well as the specific AGO protein involved in RISC loading, multiple mRNA silencing 
modes can occur [reviewed in (Brodersen and Voinnet 2009)]. These include accelerated 
exonucleolytic mRNA decay, site-specific endonucleolytic cleavage or translational repression 
(Azuma-Mukai, Oguri et al. 2008; Eulalio, Huntzinger et al. 2008). All four human AGO proteins 
bind miRNAs although endonuclease activity is a property of AGO2 alone (Liu, Carmell et al. 
2004; Meister, Landthaler et al. 2004; Miyoshi, Tsukumo et al. 2005).  The initial bases from 
positions 2 to 7 of the mature miRNA are termed the seed sequence and they provide most of 
the pairing specificity [reviewed in (Eulalio, Huntzinger et al. 2008; Filipowicz, Bhattacharyya et 
al. 2009). Complete pairing between the seed region and target mRNA is sufficient to mediate 
AGO2-associated RISC cleavage of the cognate phosphodiester backbone (Yekta, Shih et al. 
2004; Brennecke, Stark et al. 2005). However, target site accessibility and relative 
36 
 
concentrations of the miRNA and its cognate sequence also play key roles in determining RISC-
mediated transcriptional regulation (Doench and Sharp 2004; Ameres, Martinez et al. 2007; 
Kertesz, Iovino et al. 2007; Obernosterer, Tafer et al. 2008). Typically, cleavage activity of 
siRNA-loaded RISC is severely impaired by mismatched pairing in the seed region and 
translational inhibition occurs (Martinez and Tuschl 2004; Nilsen 2007) although the mechanism 
remains unclear (Chekulaeva and Filipowicz 2009). Notably, imperfect pairing can occur multiple 
times within the same transcript in animals leading to cooperative inhibition of transcription 
(Saetrom, Heale et al. 2007; Tay, Zhang et al. 2008).  
 
1.9 RNAs in transcriptional regulation 
 
The field of RNAi has revolutionised our understanding of gene regulation. However, homology-
dependent RNA interactions are not exclusively linked to RNAi pathways or its protein 
components. Indeed, transcriptional regulation by non-coding RNAs has been linked to X 
inactivation, dosage compensation, imprinting, and polycomb silencing [reviewed in (Zaratiegui, 
Irvine et al. 2007)]. Importantly, these non-coding RNAs are distinct from siRNAs and can range 
in size from 100 bp to 100 kb [reviewed in (Lee 2009)]. The vast majority of non-coding RNAs 
are complementary to protein-coding genes and cause inhibition via an antisense mechanism 
(He, Vogelstein et al. 2008). Interestingly, a small group originate in promoter regions and it has 
been suggested that these non-coding RNAs may induce transcriptional gene silencing (TGS) 
through binding of promoters and subsequent heterochromatin formation (Zaratiegui, Irvine et al. 
2007). This is poorly understood in mammals, although both exogenous siRNAs and 
endogenous miRNAs have been shown to induce TGS (Ting, Schuebel et al. 2005; Kim, 
Villeneuve et al. 2006; Han, Kim et al. 2007; Kim, Sætrom et al. 2008).   
Despite the involvement of some RNAi pathway components such as AGO2 and siRNAs, 
TGS is generally not considered to be part of the canonical RNAi pathway (Hawkins, Santosom 
et al. 2009).  Typically, small promoter-associated RNAs bind the antisense strand of 
complementary promoter-targeted RNAs (Han, Kim et al. 2007) and induce silencing marks 
such as di- or tri-methylations of lysine (K) residues on histone 3 (H3K9me2 or H3K27me3). 
These silencing marks can be detected downstream of the targeted site suggesting a possible 
mechanism for establishing and spreading of the silent state [reviewed in (Hawkins and Morris 
2008)]. AGO1 and AGO2, DNA methyl transferases 3a (DNMT3a) and histone deacetylase 1 
(HDAC1) are required to initiate silencing in human cells, and DNMT1 is necessary for 
maintaining the effect (Janowski, Huffman et al. 2006; Weinberg, Villeneuve et al. 2006; 
Hawkins, Santosom et al. 2009). Interestingly, the involvement of DNMT1 suggests that the 
silencing effects may be heritable as this protein is involved in maintaining long-lasting 
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epigenetic marks during DNA replication and cell division (Weber, Hellmann et al. 2007). In 
contrast, histone modifications have also been associated with long-term gene activation linked 
to small RNAs that bind promoter regions with low GC content (Kim, Villeneuve et al. 2006; Li, 
Okino et al. 2006; Janowski, Younger et al. 2007). This transcriptional gene activation (TGA) 
effect has also been found to occur in human liver cells where a liver-specific miRNA was shown 
to positively regulate Hepatitis C Virus (HCV) replication (Jopling, Yi et al. 2005). 
Importantly, as TGS can elicit permanent epigenetic modifications, harnessing this 
phenomenon may offer a mechanism of sustained inhibition of gene expression that is heritable. 
However, to date little is known about all the factors involved in the TGS pathway or the long-
term implications of chromatin remodelling. Post-transcriptional gene silencing (PTGS), the 
central feature of traditional RNAi, is more completely understood and provides exciting new 
avenues for harnessing gene expression. Manipulation of the factors involved in canonical RNAi, 
specifically the miRNA biogenesis pathway, allows researchers to generate a desired silencing 
effect of a specific target gene at the level of the mRNA. Several strategies exist whereby 
exogenous RNAi ‗mimics‘ can be introduced into the RNAi pathway at various levels and induce 
their effects in a manner parallel to that of endogenous RNAi effectors.  
 
1.10 Exogenous RNAi mimics as gene therapy tools 
 
Since its discovery, the exquisite sequence-specificity of the RNAi pathway has been exploited 
as a tool to uncover the functions of numerous genes in a variety of organisms. This has largely 
been via the introduction of siRNAs that have provided a robust method to establish strong links 
between gene identity and gene function. In addition, RNAi has been utilised as a novel gene 
therapy strategy whereby siRNAs and miRNAs have been targeted to specific genes associated 
with disease processes [reviewed in (Haussecker 2008; López-Fraga, Wright et al. 2008)]. 
Typically, this involves the generation of exogenous RNAi effector sequences that mimic their 
endogenous counterparts. Theoretically it is possible to exploit the RNAi machinery to target any 
gene of interest and two main strategies can be employed to achieve this, namely synthetic 
siRNAs and expressed RNAi mimics. The former are introduced directly into the cytoplasm of 
target cells and serve as RISC substrates. While highly effective even at low concentrations, 
siRNAs can only induce a silencing effect for up to seven days in cells with a rapid turnover rate 
and several weeks in slow-diving cells because of dilution or degradation over time (Bartlett and 
Davis 2006). Repeat administration of siRNAs is feasible but expression of RNAi mimics that 
enter the pathway as substrates for Drosha or Dicer present a longer-term alternative (Figure 7). 
Expressed mimics can be transcribed either from RNA Pol II or Pol III promoters depending on 
the desired downstream effects and their design is affected by the RNAi machinery required to 
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process each type of mimic. Similarly to endogenous siRNAs, the most critical sequence of any 
RNAi mimic is the seed region that determines target match. Given that the seed sequence 
spans only six bp, unintended mRNA targeting [referred to as an off-target effect (OTE)] seems 
inevitable (Jackson, Burchard et al. 2006). Thus the choice and sequence of mimic as well as 
target accessibility require thorough consideration if the required silencing effect is to be 
achieved with a high level of efficacy and minimal unintended seed region pairing. An important 
objective of this thesis was to explore the development of various RNAi mimics as gene therapy 
modalities against HIV.  
 
1.10.1 Synthetic RNAi molecules 
 
Synthetic siRNAs were the first RNAi mimics tested (Elbashir, Harborth et al. 2001) and have 
been used to knock down target genes related to a variety of diseases [reviewed in (Whitehead, 
Langer et al. 2009)]. As substrates for RISC, synthetic siRNAs are generated as 21 to 23 bp 
duplex molecules with characteristic two nucleotide 3' overhangs (Grishok, Pasquinelli et al. 
2001) and include G:U (guanine : uracil) mismatches in the stem region. These G:U wobbles 
cause one strand of the duplex to be less stably paired at its 5' end biasing the selection of the 
preferred strand into RISC (Khvorova, Reynolds et al. 2003; Schwarz, Hutvagner et al. 2003; 
Seitz and Zamore 2006). Longer duplex molecules (27 bp) have also been used. These enter 
the RNAi pathway as Dicer substrates (Kim, Longo et al. 2004; Shiota, Ikeda et al. 2006; 
Nishina, Unno et al. 2008) and may induce more potent inhibition at lower concentrations than 
synthetic 21 bp siRNAs encoding the same guide sequences (Hefner, Clark et al. 2008). Due to 
the ubiquitous presence of RNAses within the cellular environment, siRNAs are inherently 
unstable unless modified [reviewed in (Manoharan 2004; Behlke 2008)]. Traditionally 
phosphorothioate linkages have been introduced to prevent serum nuclease degradation but 2‘ 
ribose modifications such as 2'-O-methyl (2'-OMe) or 2'-fluoro (2'-F) have the added advantages 
of enhancing duplex stability, avoiding the innate immune system and reducing OTEs (Jackson, 
Burchard et al. 2006; Muhonen, Tennilä et al. 2007; Robbins, Judge et al. 2007). Locked nucleic 
acids included at limited sites within the siRNA backbone have also been shown to improve 
duplex stability and nuclease protection (Mook, Baas et al. 2007) but may result in hepatotoxicity 
in vivo (Swayze, Siwkowski et al. 2007). Importantly, thorough testing of these compounds is 
critical as the chemical modifications applied to siRNAs can alter their efficacy or induce an 
immune response.   
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1.10.2 Expressed RNAi mimics 
 
Pre-miRNA mimics 
Early studies revealed that the guide region of endogenous pre-miRNAs could be substituted 
with artificial sequence and as long as the two nucleotide 3' overhangs required for Dicer 
recognition were present, successful inhibition of target mRNA occurred (Zeng, Wagner et al. 
2002; Boden, Pusch et al. 2004; Liu, Haasnoot et al. 2007). This led to the development of pre-
miRNA mimics transcribed from DNA vectors that had been introduced into target cells of 
interest. Although Pol II-based plasmids have been tested (Ren, Fang et al. 2007; Giering, 
Grimm et al. 2008) Pol III-based vectors encoding U6 or H1 transcription elements are more 
commonly used. These latter promoters express short RNA transcripts with defined 5' and 3' 
ends that mimic pre-miRNAs and are Dicer substrates (Paul, Good et al. 2002; Tuschl and 
Borkhardt 2002; Yu, DeRuiter et al. 2002; Cheng and Chang 2007). Referred to as short hairpin 
RNAs (shRNAs), pre-miRNA mimics generally comprise a sense region (anti-guide) connected 
to an antisense (guide) counterpart via a loop sequence (McIntyre and Fanning 2006). There is 
no consensus regarding an optimal shRNA structure but a duplex stem of no less than 19 nt (Li, 
Lin et al. 2007) with a loop of between 3 and 23 nts yields positive target suppression (Zeng and 
Cullen 2003; Vlassov, Korba et al. 2007). Similarly to siRNAs, disruption of three or more base 
pairings in the seed region of shRNAs has a marked deleterious effect on silencing although 
single point mutations have been shown to reduce but not eliminate target inhibition (Zeng and 
Cullen 2003).  
Importantly, as shRNAs generally comprise a duplex stem of ~23 bp, they are processed 
by Dicer into single siRNA species and thus function as monotherapies. Owing to the rapid 
development of resistant HIV strains following the introduction of single therapeutic interventions 
(see section 1.6) combinatorial approaches need to be devised. Expressed pre-miRNA mimics 
represent promising candidates for the development of a combinatorial RNAi-based strategy, 
especially with regard to ease of synthesis and specificity. However, the design of pre-miRNA 
mimics capable of simultaneously generating multiple anti-HIV siRNAs has not been thoroughly 
explored.   
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Figure 7. Exogenous mimics in the RNAi pathway. Mimics can enter the RNAi pathway as substrates for 
Drosha, Dicer or RISC. Pri-miRNA mimics are Drosha substrates that are expressed from RNA Pol II 
(shown in red) based vectors. Transcription generates a mimic with a stem loop structure and prototypical 
single stranded flanking sequences that is recognised by DGCR8 and cleaved by Drosha to form a pre-
miRNA. RNA Pol III (shown in green) expressed constructs produce stem loop hairpin structures that 
resemble pre-miRNAs and enter the RNAi pathway as substrates for Dicer. These mimics are termed 
shRNAs or lhRNAs depending on the length of the duplex stem region. Dicer processes shRNAs into 
siRNAs of one species while a single lhRNA can be processed to form multiple siRNAs. RISC is the final 
protein complex in the pathway that interacts with mimics generated from pri-miRNAs, shRNAs, lhRNAs 
or with synthetic siRNA duplexes introduced directly into the cytoplasm of a cell.   
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Pri-miRNA mimics 
Pol III promoters are constitutively active and while shRNAs expressed from these constructs 
are potent (Boudreau, Mas Monteys et al. 2008), they may induce lethal toxicities due to 
saturation of endogenous RNAi pathway components [(Grimm, Streetz et al. 2006) and 
described further in section 5.3]. One alternative involves the use of Pol III promoters such as 
tRNA that produce Dicer substrates at lower expression levels than typical cassettes driven by 
U6 or H1. In addition, tRNAs that are not processed by RNAse Z may be exported by exportin-t 
and therefore do not saturate exportin-5 transport (Boden, Pusch et al. 2003; Scherer, Frank et 
al. 2007). Another option involves RNA Pol II promoters that generate pri-miRNA mimics 
(Chung, Hart et al. 2006; Ely, Naidoo et al. 2008; Zhen, Alhousseynou et al. 2008). As 
substrates for Drosha these mimics comprise at least 40 bp of ssRNA flanking sequence on 
either side of the central hairpin structure (Figure 7). In addition, the natural loop sequences and 
secondary structures within the pri-miRNA ensure efficient transport and downstream 
processing (McManus, Petersen et al. 2002; Zeng, Wagner et al. 2002).  
Several expressed pri-miRNA mimics have been developed whereby endogenous pri-
miRNAs have been used as ‗scaffolds‘ for the generation of artificial guide sequences 
(McManus, Petersen et al. 2002; Zeng, Wagner et al. 2002; Stegmeier, Hu et al. 2005; Chung, 
Hart et al. 2006). Since pri-miRNAs are naturally expressed from Pol II promoters, tissue-specific 
or inducible gene regulation of pri-miRNA mimics is possible, allowing for greater control of 
dosage and cell-specific expression. A pri-miRNA mimic under the control of a heat-shock-
responsive promoter induced expression only under conditions of stress in mammalian cells 
(Yang and Paschen 2008). Separately, the presence of tetracycline in embryonic stem cells 
containing a pri-miRNA mimic under the control of a tetracycline-inducible promoter switched on 
expression (Wang, Theunissen et al. 2007). A similar mechanism has been used to generate 
transgenic mice that express tetracycline-inducible pri-miRNAs targeted to the tumour 
suppressor Trp53 following doxycycline addition to their drinking water (Dickins, McJunkin et al. 
2007).  
As Pol II promoters can be regulated by cell-specific environmental factors, they have 
recently become more popular for the expression of pri-miRNA mimics. However, Pol III-
expressed pre-miRNA mimics (shRNAs) remain the most widely used RNAi tools for sustained 
viral gene suppression, and are the most robust system available for generating sufficient 
concentrations of siRNAs to induce potent target inhibition. Unlike shRNAs that can be readily 
generated based on a target sequence of interest, pri-miRNA mimics require knowledge of the 
endogenous sequence, as well as secondary structures within the folded RNA. Most pri-miRNA 
studies to date have been based on only a few endogenous backbones (pri-miR31 and pri-
miR155) and thus little is known about the efficacy of using other structures as RNAi-based 
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mimics. Studies that explore the abilities of different endogenous pri-miRNAs to produce 
exogenous guide sequences will provide valuable information on the design of these mimics. In 
addition, as mature miRNAs can be excised from either arm of a pri-miRNA stem or even from 
both arms (Khvorova, Reynolds et al. 2003), results obtained using discrete pri-miRNA scaffolds 
that generate guide strands from different arms would be or particular importance. Finally, as 
single interventions against a highly mutable virus such as HIV cannot be seriously considered, 
data that explores the capacity for pri-miRNA mimics to be incorporated in a combinatorial 
strategy would be invaluable.   
 
1.11 RNAi-mediated targeting of HIV 
 
Viral infections caused by influenza A virus or respiratory syncitial virus have been successfully 
treated using siRNAs delivered directly to the lungs of infected patients (Bitko, Musiyenko et al. 
2005; Bitko and Barik 2008). This mode of gene therapy is particularly suited to acute infections 
in the respiratory tract as siRNAs mediate a transitory effect and the upper airways can be 
readily targeted via aerosol delivery [reviewed in (Berkhout and ter Brake 2009)]. However, for 
chronic infections such as HIV, constitutive expression of shRNAs is required to ensure lifelong 
treatment. Theoretically two forms of HIV RNA can be targeted by RNAi. These include incoming 
viral genomic RNA and newly synthesised viral transcripts produced from integrated provirus. In 
addition, host factors required for HIV infection present alternative sites for RNAi-mediated 
inhibition. However, not all viral RNAs are equally sensitive to RNAi and inhibition of cellular 
targets may be detrimental to the host.  
 
1.11.1 Incoming viral genomic RNA as a target 
 
Incoming, uncoated HIV RNA is an enticing target for RNAi-mediated inhibition. Blocking viral 
replication at this stage would prevent proviral integration and subsequent viral gene expression 
and replication. There is still some debate as to whether incoming RNA is accessible to RNAi-
mediated attack. Several early studies suggested that incoming RNA could be targeted using 
siRNAs (Capodici, Kariko et al. 2002; Coburn and Cullen 2002; Jacque, Triques et al. 2002). 
However, the viral mRNAs in these studies were not introduced directly into the cell but rather 
transcribed from a plasmid co-transfected with the siRNAs and this is significantly different to 
incoming viral RNA that is bound to various proteins. Incoming viral RNA, represented by two 
viral RNA genomes, is continually bound by proteins such as p17 matrix, integrase and reverse 
transcriptase (Dvorin and Malim 2003). This association may limit access of the RNAi machinery 
to the target HIV genomic RNA. Also, following membrane fusion between the host cell and 
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virion, the viral core particle is only partially dissolved while the RNA genome is reverse 
transcribed and transported towards the nucleus. Furthermore, reverse transcription usually 
occurs within 6 hours of viral entry into lymphocytes (Zack, Arrigo et al. 1990), providing a very 
short window of opportunity for RNAi-mediated inhibition of incoming viral RNA. Indeed two 
thorough investigations using synthetic siRNAs and shRNAs against a wide range of HIV targets 
indicated that the newly-released viral genome remains encapsidated or partially-encapsidated 
during reverse transcription, thus blocking access to guide strand-loaded RISC (Westerhout, ter 
Brake et al. 2006; Gao, Lobritz et al. 2008). These studies indicate that targeting of viral mRNAs 
is a better approach to achieving RNAi-mediated HIV inhibition. 
 
1.11.2 Inhibition of HIV mRNAs and viral escape  
 
Targeting of viral mRNA species transcribed from integrated provirus has been more successful 
and RNAi strategies have been used against every coding and non-coding genomic sequence to 
inhibit viral replication. The rev ORF was one of the first viral genes to be targeted using siRNAs 
and shRNAs (Coburn and Cullen 2002; Lee, Dohjima et al. 2002). These initial investigations 
showed that viral transcripts generated early during the life cycle were accessible to RNAi-
mediated inhibition, but not all sites were susceptible to silencing. In addition, some non-specific 
decrease in tat gene expression was also reported but this was due to overlap between the tat 
and rev ORFs. The effect was alleviated by designing siRNAs to target non-overlapping portions 
of the coding sequences (Coburn and Cullen 2002). Further information on HIV target site 
accessibility was gathered using siRNAs/shRNAs against the TAR stem-loop of the 5' LTR. The 
TAR target was found to be refractory to RNAi knockdown and this data highlighted that 
secondary folding of RNAs could render them inaccessible to siRNAs (Jacque, Triques et al. 
2002; Yoshinari, Miyagishi et al. 2004; Nishitsuji, Kohara et al. 2006). Notwithstanding the TAR 
loop, the HIV LTR remains an attractive target particularly as non-coding RNAs and siRNAs 
have been shown to shut down gene expression by targeting promoter sequences (section 1.9). 
This presents an especially attractive alternative to traditional post-transcriptional gene silencing, 
as chromatin changes associated with transcriptional gene silencing could cause the provirus to 
become stably heterochromatised. Intriguingly, the potential for TGS-mediated inhibition of the 
LTR has not been explored and offers an interesting prospect for a gene therapeutic against 
HIV.    
         Single nucleotide substitutions within target mRNA, especially in the seed region, are 
sufficient for viral protection from RNAi effectors (Gitlin, Karelsky et al. 2002). In one example, a 
shRNA targeted to tat mRNA became ineffective after 25 days and viral genome analysis 
showed that a single base substitution within tat was responsible for the resistance (Boden, 
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Pusch et al. 2003). Similarly, escape mutants appeared following several weeks of exposure to 
a shRNA targeting nef mRNA. Further analysis revealed that base substitutions or deletions 
within nef modified the shRNA target (Das, Brummelkamp et al. 2004). These two examples 
involved targeting of non-essential viral genes but designing siRNAs against essential genes 
also resulted in emergence of resistance (Senserrich, Pauls et al. 2008; von Eije, ter Brake et al. 
2008). Inhibition of infection with three different HIV primary isolates in the presence of a single 
siRNA targeted to overlapping env/rev mRNA was not absolute. Escape mutants bearing two 
point mutations in the target sequence readily evolved (Senserrich, Pauls et al. 2008). The use 
of shRNAs targeted to essential viral sequences did not arrest all viral escape, although there 
was restriction of escape possibilities. Mutations were limited to non-silent changes that 
presumably allowed RNAi resistance while maintaining viral fitness (von Eije, ter Brake et al. 
2008).  
Viral escape from RNAi does not always involve target sequence mutations. Sequencing 
of two viral mutants replicating in the presence of nef-specific shRNAs revealed substitution 
mutations upstream of the siRNA target. Resistance was caused by alterations in the viral 
mRNA secondary structures which probably prevented access of activated RISC to its cognate 
sequence (Westerhout, Ooms et al. 2005). Even more unexpected was the emergence of 
escape through the modulation of transcription. Mutations in non-targeted LTR promoter 
sequences have been shown to compensate for RNAi-mediated inhibition by up-regulating viral 
gene transcription (Leonard, Shah et al. 2008). Notwithstanding these additional factors 
associated with resistance, focus has shifted to targeting conserved vital sequences within the 
HIV genome, since HIV is less able to mutate these sites without loss of fitness (Han, Wind-
Rotolo et al. 2004; Morris, Chung et al. 2004; Chang, Liu et al. 2005; Lee 2005; Naito, Nohtomi 
et al. 2007; von Eije, ter Brake et al. 2008). Further evidence of the extent of RNAi tolerance to 
sequence polymorphisms emerged from a study using expressed shRNAs against three targets: 
a highly variable rev sequence, a gag site conserved across subtype B strains only, and a vif 
sequence conserved across all subtypes (Lee 2005). Rev-specific shRNAs inhibited the least 
number of isolates, regardless of subtype. The gag-specific shRNAs protected against subtype 
B virus alone and the anti-vif shRNAs were effective against all isolates (Lee 2005). These 
results are particularly intriguing as they suggest that many separate strains of HIV may be 
silenced by targeting conserved sequences. This is particularly relevant in the context of wild 
type HIV infection where the viral strains are not isogenic but rather comprise a pool of similar 
but non-identical sequences. Studies that explore the capacities of RNAi mimics to inhibit 
conserved HIV sites when assessed against wild type HIV isolates will be extremely valuable. 
HIV dosage has also been shown to play a key role in determining whether RNAi-
mediated inhibition is effective. Specifically, shRNAs designed to target HIV IN showed some 
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inhibition of HIV replication when shRNA-expressing CD4+ T cells were challenged with virus at 
a low dose (100 pg of p24) of infection (Nishitsuji, Kohara et al. 2006). This effect was abrogated 
during long-term (22 days) culture or following a high-dose (10 000 pg of p24) infection 
(Nishitsuji, Kohara et al. 2006). Similarly, increased dosages of HIV were used to select for 
various anti-HIV shRNAs that displayed robust and sustained inhibitory effects in the presence 
of highly concentrated virus (von Eije, ter Brake et al. 2009). Together, this data suggests that 
although highly conserved viral sequences have allowed for the discovery of many effective anti-
HIV siRNAs/shRNAs (Naito, Nohtomi et al. 2007; ter Brake, Hooft et al. 2008; McIntyre, 
Groneman et al. 2009), the long-term inhibitory effects against actively evolving HIV infection 
need to be evaluated (von Eije, ter Brake et al. 2008).  
 
1.11.3 RNAi-mediated inhibition of host cell targets required for HIV infection 
 
Although using RNAi to target viral sequences is important, it is clear that targeting viral 
sequences alone may not be sufficient to ensure long-term viral suppression. Since HIV requires 
a large number of cellular host factors for successful replication, these are potential therapeutic 
targets for RNAi-mediated inhibition. A significant advantage of targeting host genes is that they 
are not under selective pressure, and therefore to gain resistance, HIV would need to evolve an 
entirely new set of cellular associations to bypass the requirement for an important host factor. 
The major CD4 receptor required for HIV docking was one of the first host cell sequences 
targeted using siRNAs (Novina, Murray et al. 2002). While these results were promising, there 
has been a shift away from targeting CD4 as a result of the ubiquitous presence of this receptor 
on various host cells and its function in normal immune pathways. The chemokine co-receptors 
required for HIV entry offered more attractive alternatives and there have been numerous 
studies describing RNAi-mediated suppression of CCR5 (Martinez, Gutierrez et al. 2002; Qin, 
An et al. 2003; Song, Lee et al. 2003) and CXCR4 (Martinez, Gutierrez et al. 2002; Anderson, 
Banerjea et al. 2003). CCR5 was particularly enticing as a deletion mutant allele was found to be 
present at a frequency of 0.092 in Caucasian populations, and individuals homozygous for the 
deletion are highly resistant to M-tropic HIV infection (Samson, Libert et al. 1996). Unfortunately 
this strategy remains inadequate for complete protection against HIV-1 as T-tropic and dual 
tropic strains can still gain access to cells. One study using HIV-2 showed CXCR4 to be 
sufficient for entry even in the absence of CD4 (Endres, Clapham et al. 1996). Furthermore, 
although less common, there exist primary HIV isolates that utilize CCR3 and CCR2b as co-
receptors to gain access to CD4+ cells (Choe, Farzan et al. 1996; Doranz, Rucker et al. 1996). 
RNAi-mediated inhibition of expression of other proteins involved in HIV transcription, such as 
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NFκβ, cyclin T1, CDK9 and TRBP have also been shown to down-regulate viral replication 
(Surabhi and Gaynor 2002; Chiu, Cao et al. 2004; Christensen, Daher et al. 2007).  
Differences in the viral life cycle in T cells and in macrophages present a further 
challenge to the development of RNAi-based HIV therapy. Specifically, in T cells, nascent viral 
mRNAs transcribed from the provirus are the most attractive targets for RNAi as they are 
shuttled to the cytoplasm by Rev. However, in macrophages new virions do not assemble and 
bud at the plasma membrane. Instead viruses may bud into endocytic organelles and 
accumulate in these vacuoles before being released as an exosome. The advantage for HIV is 
that exosomes escape immune surveillance but importantly these organelles are also 
inaccessible to antiviral therapies and RNAi-based gene silencing [reviewed in (Verani, Gras et 
al. 2005)]. Thus the identification of host factors that are required for HIV infection, and which 
are common to all cells infectable by the virus, has become more important for the development 
of gene expression-based antiviral silencing approaches. Recent advances in high-throughput 
screens using robotic instrumentation and genome-wide siRNA libraries have resulted in novel 
reverse genetics applications to monitor host-pathogen interactions. Last year alone, three 
influential papers were published describing the use of large-scale RNAi screens to uncover 
host dependency factors (HDFs) required for HIV replication [(Brass, Dykxhoorn et al. 2008; 
Konig, Zhou et al. 2008; Zhou, Xu et al. 2008) and described in section 5.1]. The genes 
identified in all three studies have established novel RNAi targets that may also serve as potent 
drug targets. However, further investigation will be required to verify a genuine role of HDFs in a 
physiological context. 
Another important consideration is the delivery method required to introduce anti-HDF 
siRNAs to their target sites. Lentiviral vectors are one of the most promising candidates for 
delivering and stably expressing anti-HIV RNAi payloads [reviewed in (Morris and Rossi 2006)]. 
Retroviral and mobilisation-competent vectors have been used to deliver siRNAs or shRNAs 
targeted to NF-κβ sites within the HIV 5' LTR (Turner, De La Cruz et al. 2009; Yamagishi, Ishida 
et al. 2009). Long-term silencing (1 to 12 months) was observed and chromatin 
immunoprecipitation assays (ChIP) demonstrated rapid, sustained induction of heterochromatin 
structures enriched for histone silencing marks. In addition, no evidence of viral resistance was 
observed suggesting that RNAi-mediated transcriptional silencing of the HIV promoter could 
provide a long-term therapeutic strategy. However, no studies have been completed using 
promoter-directed RNAi against wild type HIV or high doses of the virus and related pre-clinical 
studies in animal models of HIV infection have yet to be published.   
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1.12 Pre-clinical studies for the therapeutic application of RNAi 
 
Current gene therapy protocols have focused mainly on achieving long term suppression of HIV 
by using retroviral or lentiviral vectors that generate stably expressed RNAi transgenes. Viruses 
are capable of delivering payloads to a variety of host cells depending on the tropism of the viral 
envelope proteins. Lentiviruses are particularly useful in this regard as they have the capacity to 
transduce non-dividing cells and integrate within the host genome thereby ensuring cellular-
mediated transcription of the provirus [reviewed in (Morris and Rossi 2006)]. In a seminal paper, 
primary haematopoetic progenitor cells transduced by lentiviral vectors encoding anti-rev 
siRNAs underwent successful maturation into mature macrophages or T cells (Banerjea, Li et al. 
2003). Importantly, stable transduction of the progenitor cells resulted in marked resistance to 
wild type HIV infection that was characteristic of the mature cells as well. These in vitro data 
were further assessed using a humanised mouse model of HIV infection. In this model lentiviral 
vector-transduced human haematopoetic stem cells (HSCs) are used to reconstitute the T-
lymphoid compartment of SCID (severe combined immunodeficiency) mice that do not express 
immune cells (Akkina, Rosenblatt et al. 1994). Engraftment of siRev-transduced progenitor cells 
into these mice (SCID-hu) resulted in reconstitution of thymocytes that matured and responded 
to mitogenic stimulation as expected for normal T cells. Encouragingly, significant viral 
resistance was also observed following ex vivo HIV challenge of differentiated, transduced 
macrophages and T cells collected from the mice (Banerjea, Li et al. 2003).  
While useful, the SCID-hu mouse model has low engraftment levels with limited systemic 
spread of HIV following infection. This has prompted subsequent research to be performed 
using modified SCID mice. One model is the non-obese diabetic/SCID (NOD/SCID) mouse 
which harbours a complete null mutation in the common cytokine receptor γ chain that 
abrogates interleukin 2 binding (NOD/SCID/IL2rγnull) (Ishikawa, Yasukawa et al. 2005). In these 
mice T and B cell development is disrupted as the γ chain receptor is required for innate 
immunity (Watanabe, Ohta et al. 2007). An elegant study used single chain antibodies (scFv) 
against the CD7 surface antigen present on human T cells as a highly specific delivery vehicle 
for anti-HIV siRNAs in NOD/SCID/IL2rγnull mice (Kumar, Ban et al. 2008). Anti-vif and anti-tat 
siRNAs conjugated to scFvs via an arginine tag and introduced into both NOD/SCID/IL2rγnull and 
SCID-hu mice successfully prevented HIV infection and prevented CD4+ T cell loss without any 
observed toxicity. Using a mouse model derived from a recombination activating gene (RAG)–
deficient strain that also lacks a γ chain receptor (BALB-Rag2nullγnull), HSCs tranduced with a 
lentivector encoding an anti-nef shRNA showed significant inhibition of HIV replication ex vivo 
(ter Brake, Legrand et al. 2009).  
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All of the mouse models described above have demonstrated the utility of lentiviral vector 
deliver of anti-HIV RNAi mimics into HSCs, providing a foundation for similar approaches in 
human patients. Using a non-human primate model, successful stable T-cell expression of 
shRNAs directed to CCR5 in rhesus macaques has been reported (An, Donahue et al. 2007). 
Following transplantation of rhesus HSCs, consistent down-regulation of CCR5 expression was 
observed for up to 14 months in mature T cells. These cells were also less susceptible to SIV 
infection ex vivo (An, Donahue et al. 2007). Concerns remain that macaque and murine models 
of HIV infection utilise marginally matured progenitor cells as opposed to true stem cells and 
long-term adverse effects may occur (ter Brake, Legrand et al. 2009). Despite this, a number of 
human clinical trials assessing anti-HIV gene therapies have been conducted or are currently 
underway [reviewed in (Rossi, June et al. 2007)].  
 
1.13 Anti-HIV RNA-based clinical studies 
 
A number of anti-HIV gene therapies including ribozymes, RRE decoys, transdominant Rev 
proteins and RNAi have all been tested in human phase one or two clinical trials with varying 
efficacies depending on the transfer vector used and whether T cells or HSCs were transduced 
(Woffendin, Ranga et al. 1996; Kohn, Bauer et al. 1999; Macpherson, Boyd et al. 2005; 
Mitsuyasu, Merigan et al. 2009). The first example of RNAi in a stem cell setting is currently 
being conducted by John Rossi and collaborators at the City of Hope Medical Centre in Duarte, 
California. This trial involves a pilot study of transduced HSCs in AIDS lymphoma patients to 
assess the safety and therapeutic feasibility of using a lentiviral vector encoding three anti-HIV 
modalities (Li, Li et al. 2006). The study was initiated when a lentiviral construct expressing a 
snoRNA nucleolar localising Pol III (U6)-driven TAR RNA decoy, a U6-expressed shRNA 
complementary to the tat/rev overlapping region and a Pol III (VA1)-promoted anti-CCR5 
ribozyme was shown to successfully transduce primary HSCs (Li and Rossi 2005) and induce 
long-term inhibition of HIV in these cells (Li, Kim et al. 2005). Vector-transduced HSCs were also 
able to differentiate normally into different lymphocyte lineages without evidence of untoward 
effects. Protected HSCs gave rise to phenotypically normal T cells that were HIV resistant when 
engrafted into SCID-hu mice (Anderson, Li et al. 2007). For the human trial, bone marrow 
lymphocytes were removed from four patients and cultured ex vivo to enrich for progenitor cells. 
Following enrichment, the HSCs were transduced with the lentiviral vector before autologous 
reintroduction into patients who had undergone bone marrow ablation (Anderson, Li et al. 2007). 
Outcomes from these studies are keenly awaited and will be of importance for refinement of this 
exciting new technology. Importantly, the emergence of resistant HIV strains will be closely 
monitored as this presents a daunting challenge that confounds all anti-HIV therapies. HIV 
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resistance was observed very early on following the introduction of conventional ARV 
monotherapies prompting the development of combinations of drugs in the form of HAART. Viral 
resistance to single RNA-based gene therapy approaches have also been observed and 
transdominant proteins, RNA decoys and ribozymes have all been combined in strategies akin 
to HAART (Gervaix, li et al. 1997; Barnor, Miyano-Kurosaki et al. 2005; Li, Kim et al. 2005; 
Asparuhova, Barde et al. 2008). However, very few attempts have been made using RNAi 
mimics alone. Multi-target gene silencing presents an advantage over traditional HAART in that 
there are many conserved RNAi-susceptible sequences within the HIV-1 genome. This 
emerging field of gene therapy, referred to as combinatorial RNAi, has provided a plethora of 
research opportunities and this thesis specifically focuses on the simultaneous generation of 
multiple RNAi mimics targeted to HIV. 
 
1.14 Combinatorial RNAi 
 
The aim of any combinatorial anti-HIV strategy is to inhibit multiple target sites thereby 
maximising the overall suppressive efficacy to decrease the chance of escape mutants. The 
target sites could be conserved viral sequences and HDFs. At this stage it is premature to 
predict the long-term efficacy of multiple targeting methods, however it has been proposed that 
assuming equal and effective inhibition, the simultaneous targeting of at least four RNAi-
susceptible sequences may be sufficient to prevent or, at the very least, severely delay the 
emergence of RNAi-resistant variants (Wiethoff and Middaugh 2003; Leonard and Schaffer 
2005; Berkhout and Haasnoot 2006; Berkhout and ter Brake 2009). There are several strategies 
for inhibiting multiple target sites on HIV-1, the most promising of which involve the use of 
expressed RNAi mimics.  
 
1.14.1 Multiple shRNA expression 
 
Short hairpin RNA expression cassettes using RNA Pol III promoters (U6, H1, tRNA and VA1) 
can be placed adjacent to each other within a single delivery vector for the combined expression 
of multiple shRNAs. In an early study, shRNAs targeted to HIV integrase (shIN) showed potent 
short-term inhibition of HIV although shIN-resistant strains soon emerged (Nishitsuji, Kohara et 
al. 2006). Subsequently, a combination of expressed shRNAs designed to target wild type and 
escape mutant sequences showed an overall decrease in antiviral activity. This was possibly a 
result of diminished siRNA access to their cognate sequences and suggested a potentially 
detrimental effect when administering multiple shRNAs targeted to the same site (Nishitsuji, 
Kohara et al. 2006). Strategies which have targeted up to three separate conserved sites have 
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yielded more promising results (Anderson, Banerjea et al. 2003; ter Brake, Konstantinova et al. 
2006; Song, Giang et al. 2007). However, most show the emergence of viral escape in culture, 
although at a delayed rate when compared to single shRNAs alone. In a seminal study, a single 
lentiviral vector was used to produce stably transduced T cells containing four tandem anti-HIV 
shRNA expression cassettes (ter Brake, Hooft et al. 2008). This multi-shRNA approach 
prevented emergence of escape mutants over an 80 day period in culture. However it was noted 
that some low-level viral replication occurred in the presence of the inhibiting multi-RNAi mimics, 
which was attributed to the lack of silencing of incoming RNA and incomplete viral RNA 
suppression. As this study assessed efficacy against a single molecular clone of HIV, it remains 
to be determined whether sustained repression of a more diverse viral population (such as 
primary virus from an infected individual) is possible. Additionally, different promoters were used 
to produce each shRNA, since multiple copies of the U6 promoter were subject to deletion 
during lentiviral recombination (ter Brake, Hooft et al. 2008). It has been noted that the additive 
effect of using multiple promoters in tandem results in an overall decrease in guide strand 
production (ter Brake, Konstantinova et al. 2006; ter Brake, Hooft et al. 2008). Also, a 
combinatorial system with heterogenous promoters produces different amounts of each RNAi 
hairpin precursor and subsequent guide sequences. Theoretical computational analyses of 
escape kinetics highlighted the importance of ensuring efficient delivery to HIV-1 susceptible 
cells and potent silencing by each individual RNAi mimic within a multi-targeting system 
(Leonard and Schaffer 2005). Finally, the introduction of multiple Pol III promoters has also been 
linked to cellular toxicities as they produce saturating concentrations of shRNAs that compete 
with endogenous pre-miRNAs for access to Exp5, Dicer or RISC [(Grimm, Streetz et al. 2006) 
and section 5.3].  
 
1.14.2 Long-hairpin RNAs 
 
Early work exploring the requirements for Dicer-mediated RNA cleavage revealed that dsRNAs 
with 21 bp duplexes were not processed by recombinant human Dicer in vitro (Provost, Dishart 
et al. 2002). In contrast, Drosphila melanogaster Dicer could cleave dsRNAs of 30 bp (short) to 
130 bp (long) with equal efficiency in vivo (Elbashir, Lendeckel et al. 2001; Zhang, Kolb et al. 
2002). Substrates with 3' overhangs were shown to be more efficiently processed than blunt-
ended dsRNAs by human recombinant Dicer in vitro (Zhang, Kolb et al. 2002; Zhang, Kolb et al. 
2004; Vermeulen, Behlen et al. 2005). Furthermore, human recombinant Dicer was shown to 
preferentially cleave long dsRNAs at their termini as opposed to their loop ends in vitro (Zamore 
2001; Zhang, Kolb et al. 2002). Multiple cleavage products, including ~22 bp siRNAs, were 
detected when purified Dicer was incubated with 130 bp dsRNAs (Zhang, Kolb et al. 2002). 
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While this was suggested to be a result of more than one Dicer molecule binding co-operatively 
to each long dsRNA, no supporting data was provided. An alternative explanation could be that 
a single Dicer molecule may be able to cleave a single long dsRNA multiple times. This 
hypothesis has formed the premise for the development of long-hairpin RNAs as substrates for 
Dicer-mediated cleavage (Akashi, Miyagishi et al. 2005; Nishitsuji, Kohara et al. 2006). 
Theoretically, if Dicer could produce multiple siRNAs from a single expressed lhRNA substrate 
this would provide a powerful combinatorial RNAi-based strategy for inhibiting numerous targets. 
This has been a controversial application as a major concern of working with longer (> 30 bp) 
dsRNAs in mammalian cells involves the potential activation of an innate immune response [(Ui-
Tei, Zenno et al. 2000; Elbashir, Harborth et al. 2001) and section 5.3]. Synthetic siRNAs 
encoding particular sequence motifs induce cellular immune stimulation when delivered naked 
or in lipid vehicles, but the same sequences are non-stimulatory when expressed endogenously 
(Robbins, Li et al. 2006). Similarly, long (800 bp) dsRNAs expressed endogenously as head-to-
head inverted repeats did not induce an immunostimulatory response in various mammalian cell 
lines (Diallo, Arenz et al. 2003). Clearly, long dsRNAs can be processed by Dicer in the absence 
of an unwanted innate immune response. However, prior to the completion of this thesis, limited 
studies exploring the potential for lhRNAs to simultaneously produce multiple effective siRNAs 
had been published. Expressed lhRNAs with duplex stem regions of 50 to 197 bp were shown to 
suppress viral replication of HCV and HIV (Akashi, Miyagishi et al. 2005; Watanabe, Sudoh et al. 
2006). All three studies utilised lhRNAs with G:U mismatches in the duplex regions and 
suggested that these modifications prevented immunostimulation. Notably, these studies used 
lhRNAs targeted to single continuous viral sequences, making it very difficult to identify the 
relative inhibitory contributions of each potential siRNA. In addition, no analyses were completed 
to determine how many functional siRNAs were produced from each of the lhRNAs. While 
promising, more research is required to elucidate how Dicer processes these constructs, what 
sequences can be targeted using lhRNAs and if additional sites within HIV are amenable to 
these RNAi mimics.  
 
1.14.3 Polycistronic pri-miRNA mimics 
 
The polycistronic nature of many endogenous pri-miRNAs provides a naturally-occurring 
combinatorial RNAi-based system that could be readily mimicked for anti-viral purposes. It has 
been shown that the guide strand of endogenous single pri-miRNAs can be successfully 
substituted with an artificial sequence capable of inhibiting its cognate target. In addition, 
individual Pol II promoters were shown to drive expression of up to eight tandem copies of one 
type of pri-miRNA scaffold (Zhou, Xia et al. 2005; Chung, Hart et al. 2006; Sun, Melegari et al. 
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2006). These studies provided important proof-of-concept data showing that single pri-miRNA 
scaffolds could be combined in one system capable of generating multiple exogenous guide 
sequences. Some data has also been published to show that endogenous polycistronic pri-
miRNA clusters could produce exogenous siRNAs although not all of these were functional  
(Aagaard, Zhang et al. 2008; Liu, Haasnoot et al. 2008). These studies offer valuable 
information regarding the potential for polycistronic pri-miRNA mimics as combinatorial RNAi 
effectors but further investigation is needed to address important questions relating to the design 
of these mimics. For example, which endogenous pri-miRNA backbone represents the best 
scaffold for guide sequence substitution? Different endogenous pri-miRNAs vary significantly in 
their overall secondary structures and thus may exhibit discrete abilities to process exogenous 
guide sequences. Furthermore, a recent study has shown that pri-miRNA-like hairpins regulate 
the Microprocessor complex (Drosha/DGC28) suggesting that substrates other than canonical 
pri-miRNAs feed into the RNAi pathway at this level. As pri-miRNAs may produce functional 
guide sequences from either arm of the duplex, this could have an effect on the production of 
artificial guide sequences. Related to this, studies that compare the efficacies of exogenous 
guides produced from the 5' arm versus the 3' arm of the same pri-miRNA scaffold would be 
valuable.  In addition to natural polycistronic pri-miRNAs, discrete scaffolds could be combined 
in a single expression system thereby providing a modular construct capable of targeting a 
combination of genes of interest. Data demonstrating the inhibitory efficacies of various pri-
miRNA backbones in differing combinations is required and presents another interesting avenue 
of research.  Elucidation of all these areas is of particular value in the context of HIV as the 
answers may provide another combinatorial RNAi tool for limiting escape mutants. 
 
1.15 Thesis objectives 
 
Monotherapies against HIV are ineffective, leaving combinatorial approaches as the only viable 
option. The ability of RNAi mimics to be multimerised provides a significant advantage over 
other gene therapy strategies especially when targeted to a highly mutable virus such as HIV. 
Multiply expressed RNAi mimics can be designed in a number of ways although lhRNAs and pri-
miRNA mimics present the best two options due to their modularities, limited promoter 
requirements and abilities to remain highly effective at low doses. Concurrent to the initiation of 
this thesis, only limited data outside of the field of HIV was available and no research had been 
published on co-expressed anti-HIV pri-miRNA mimics thereby leaving many unanswered 
questions. Furthermore, little data was available on the HIV LTR as a target for RNAi.  
Both lhRNAs and pri-miRNA mimics provide a post-transcriptional mechanism of gene 
suppression that can theoretically be targeted to any transcribed portion of the HIV genome. In 
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addition, the use of anti-LTR asRNAs are useful in transcriptional gene silencing. Thus the aims 
of this thesis were to explore two very different combinatorial RNAi strategies, namely lhRNAs 
and pri-miRNA mimics, using HIV as a target, as well as to investigate the possibility of targeting 
the viral LTR promoter with the intention of inducing transcriptional and post-transcriptional 
inhibition. Importantly, while preventing viral escape is a long-term goal of any anti-HIV 
therapeutic strategy, the focus of this thesis was to generate various combinatorial RNAi 
effectors that could produce multiple highly efficacious anti-HIV guide sequences capable of 
specific cognate target silencing. The results generated from this work significantly improved the 
understanding of modular RNAi mimics, provided new information on design approaches that 
yielded compelling suppression of HIV, and uncovered vital considerations for RNAi-based 
targeting of the viral promoter. This thesis encompassed the following aims:   
 
1. The transcribed region of the HIV 5' LTR was investigated as a target for RNAi-mediated 
inhibition using multiple Pol III-expressed long-hairpin RNAs with 63 bp duplex stems. In 
addition, the un-transcribed region of the LTR was assessed as a target for antisense 
mediated inhibition by siRNAs.   
2. The efficacies of siRNAs targeted to the U3 region of the 5' LTR of HIV were assessed 
for their ability to induce transcriptional gene silencing of the viral promoter. Histone 
modifications in the siRNA targeted regions were analysed to uncover the state of 
epigenetic silencing and assess if the silencing effect had migrated up- or downstream of 
the target sites. 
3. The potential of the anti-LTR lhRNAs to inhibit processive and non-processive LTR-
expressed transcripts was analysed using various HIV subtypes. Of particular interest 
was the use of a potent primary isolate of HIV to determine the abilities of anti-HIV 
lhRNAs to suppress varied target sequences present during wild type infection.   
4. The ability of Dicer to process anti-HIV long-hairpins RNAs was investigated to establish 
if multiple functional siRNAs were produced from the duplex stem regions. Furthermore, 
as long dsRNAs had been shown to induce unwanted innate immune-stimulation, cellular 
immune responses following the introduction of anti-HIV lhRNAs were analysed in 
mammalian cells.  
5. The inhibitory efficacies of Pol II-expressed anti-HIV polycistronic pri-miRNA mimics were 
assessed in order to elucidate the potential of these mimics as combinatorial RNAi 
effectors. Each polycistronic pri-miRNA comprised four discrete endogenous scaffolds 
designed to inhibit multiple HIV target mRNAs. A modular approach was used to 
investigate if the different endogenous pri-miRNA backbones affected the efficacies of 
anti-HIV guide sequences targeted to reporter vectors as well as wild type HIV. 
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Chapter two: expressed long hairpin RNAs targeted to the HIV LTR as a combinatorial RNAi 
strategy 
 
 
2.1 Introduction 
 
Traditionally expressed shRNAs have been designed with stem lengths of ~23 bp that are 
processed by Dicer to form a single guide strand capable of targeting one mRNA sequence. The 
use of RNA Pol III promoters to drive expression of shRNAs has been favoured as this allows for 
constructs with defined 5' and 3' ends required for Dicer recognition to be generated (Paul, 
Good, et al., 2002; Tuschl and Borkhardt, 2002; Yu, DeRuiter, et al., 2002; Cheng and Chang, 
2007). RNA Pol III promoters are required in vivo for the constitutive and ubiquitous synthesis of 
ribosomal 5S rRNA, tRNA and other small RNAs in most cell types and therefore modifications 
for translation are not included in Pol III generated transcripts [for more detail on eukaryotic RNA 
polymerases see section 3.1 and (Cramer, Armache, et al., 2008)]. Dicer has been shown to 
cleave longer dsRNAs (> 30 bp) into functional siRNAs capable of inhibiting their cognate 
targets (Elbashir, Lendeckel, et al., 2001; Provost, Dishart, et al., 2002; Zhang, Kolb, et al., 
2002). This paved the way for the development of long-hairpin RNAs (lhRNAs) that function as 
pre-miRNA mimics and thus serve as Dicer substrates. The approach has been used against 
HCV with expressed lhRNAs that contained stem regions of 50 to 197 bp (Akashi, Miyagishi, et 
al., 2005; Watanabe, Sudoh, et al., 2006). Akashi et al utilised U6- or tRNAVAL-expressed 
lhRNAs with 50 or 100 bp stem regions that had been modified to contain G:U wobbles (Akashi, 
Miyagishi, et al., 2005). The shorter of the two lhRNAs showed HCV target-specific inhibition in 
the absence of a cellular immunostimulatory response as assessed by the induction of members 
of the interferon (IFN) suite of genes. In addition, Northern blot analysis detected siRNAs from 
two adjacent positions along the stem of the duplex although the sequences detected nearest 
the loop of the hairpin were at a significantly lower concentration. Watanabe et al obtained 
similar inhibitory data with U6-expressed lhRNAs comprising 197 bp but no work was completed 
to detect processed products from different regions of the lhRNAs (Watanabe, Sudoh, et al., 
2006). The success of targeting HCV using expressed lhRNAs suggested that these mimics 
could be efficacious against other viruses such as Hepatitis B Virus (HBV) or HIV. A single study 
using expressed shRNAs targeted to a conserved region of HIV integrase demonstrated RNAi-
mediated suppression but viral escape occurred within a number of days rendering the shRNAs 
ineffective (Nishitsuji, Kohara, et al., 2006). U6-expressed lhRNAs comprising 50 bp stem 
regions were designed to target the same site. While these constructs effectively inhibited shIN 
resistant HIV, no data was provided on the specific siRNAs generated from these lhRNAs nor 
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was there any analysis of the target sites that were susceptible to such inhibition. Taken 
together, these studies suggest that lhRNAs are recognised by Dicer and cleaved into functional 
siRNAs capable of suppressing viral replication. Importantly, the extended duplex region of 
lhRNAs discriminates these pre-miRNA mimics from shRNAs and theoretically provides Dicer 
with a substrate that could be processed into multiple siRNAs. This would provide a unique 
combinatorial RNAi strategy to be investigated against HIV. However, additional data describing 
Dicer processing of long dsRNAs is required and the choice of HIV-specific target remains 
largely unexplored. This latter point is of particular relevance to HIV where a diverse set of viral 
mRNAs are present during wild-type infection.  
Previous RNAi-mediated suppression of HIV has largely focused on viral transcripts and 
while one study using synthetic siRNAs targeted the primer binding site immediately 
downstream of the 5' LTR (Han, Wind-Rotolo, et al., 2004), little is known about the efficacies of 
expressed RNAi mimics specific to the transcribed region of the LTR. The nature of the 5' LTR 
promoter means it is present within viral genomic RNA as well as sub-genomic RNA species 
implying that knockdown of the LTR would reduce transcripts produced at both early and late 
stages of the viral life cycle. A previous study noted unique LTR enhancer and promoter 
configurations for each HIV subtype and moreover, while all LTR sequences responded equally 
to a subtype B transcriptional transactivator Tat protein, differences were noted in the basal 
levels of transcription that occurred in the absence of Tat (Jeeninga, Hoogenkamp, et al., 2000). 
This suggested that the mechanism of Tat activation was similar for all LTR subtypes, and the 
changes in basal transcription were correlated to the number of NF-κβ sites within each viral 
promoter. A subtype C promoter contains three of these sites while a subtype B sequence has 
only two, and both subtypes each encode three Sp1 binding sites. The implications of these 
variations are unclear but given the significance of Tat in the viral life cycle, assessing RNAi-
mediated inhibition in the presence and absence of Tat provides an interesting avenue for 
exploration. Furthermore, the sequence diversity present between subtype B and C viral isolates 
remains an important consideration for any combinatorial approach and provides a mechanism 
to explore whether or not a combinatorial construct such as a lhRNA would be effective at 
inhibiting diverse targets.  
In this chapter, three distinct RNA Pol III-expressed lhRNAs targeted to the R and U5 
transcribed regions of the 5' LTR of HIV were investigated for the potential to generate functional 
siRNAs along the duplex of the stem that were capable of inhibiting subtype B and C viral 
sequences. Both episomal and integrated forms of the LTR were chosen as targets and 
importantly, a wild type HIV isolate that included a pool of non-isogenic target sequences was 
included in the analysis. 
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2.2 Materials and methods 
 
2.2.1 Cloning of expressed anti-HIV long hairpin RNAs targeted to the 5' LTR 
 
As the anti-HIV lhRNAs used here were designed to be pre-miRNA mimics, they were 
expressed from an RNA Pol III promoter, specifically the mammalian U6 small nuclear RNA 
promoter (GenBank® accession number X59362). The generation of a Pol III U6 shRNA 
cassette has been previously described (Castanotto, Li, et al., 2002; Lee, Dohjima, et al., 2002) 
and a similar approach was used to produce 3 distinct lhRNAs targeted to a 190 bp contiguous 
region of the HIV 5' LTR [co-ordinates 454-512 (lhRNA LTR 1), 507-565 (HIV lhRNA 2) and 566-
624 (HIV lhRNA 3) numbered according to the HXB2 molecular clone sequence, GenBank® 
accession number K03455 and Figure 8].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Long hairpin RNA target sites within the HIV 5' LTR. Diagrammatic representation of a subtype 
C HIV-1 proviral genome depicting all viral ORFs flanked by 5' and 3' LTR sequences (upper panel). A 
more detailed map of the 5' LTR is highlighted, with important cis and trans regulatory elements shown 
(see 2.1.). The conserved target regions for each of the 63 bp lhRNAs are shown within the R and U5 
regions of the LTR (blue lines). The TAR loop corresponds completely with lhRNA LTR 1 (co-ordinates 
454 to 512) while lhRNAs LTR 2 (co-ordinates 507 to 565) and LTR 3 (co-ordinates 566 to 624) are 
immediately downstream (numbers are according to the HXB2 HIV sequence GenBank® accession 
number K03455). Drawing is not to scale.  
 
A two-step PCR approach was used to generate the anti-LTR lhRNAs (Figure 9) with 
oligonucleotide primers obtained from Integrated DNA Technologies, IA, USA.  
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Figure 9. Two-step PCR cloning strategy used to generate anti-HIV lhRNAs. Round 1 PCR amplification 
used universal U6 forward and lhRNA LTR Reverse 1 primers with pTZU6+1 plasmid as template to 
generate a Round 1 PCR product that comprised the U6 promoter, sense strand and loop region of the 
lhRNA. This product was diluted and used as template in the second PCR reaction with universal U6 
forward and lhRNA LTR Reverse 2 primers to generate a lhRNA LTR comprising the U6 promoter, sense, 
loop, antisense and polyT tail. The lhRNA LTR was ligated into the TA vector pTZ57R/T and candidate 
clones were screened using SpeI and HindIII digestion.  
 
 
For lhRNA LTR 1, the first round of PCR amplification was carried out with a universal U6 
forward primer containing a SpeI restriction site (5' CTA ACT AGT GGC GCG CCA AGG TCG 
GGC AGG AAG AGG G 3'; the SpeI site is underlined) and lhRNA LTR 1 Reverse 1 primer (5' 
CCT CTC TTG AAG AGT CCC CTA AAT AAC CAG AGA ACC CCC GGA CTC AGA TCC GGT 
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CCA CCC AGA AAG AAC CGG TGT TTC GTC CTT TCC ACA A 3') with pTZU6+1 plasmid 
DNA as template (Carmona, Ely, et al., 2006). A PCR was carried out using Expand High 
FidelityPLUS PCR System reagents (Roche, Basel, Switzerland) on a Mastercycler® (BioRad, CA, 
USA). The PCR mixture included 0.4 μM each of forward and reverse primers, 10 ng of 
template, 1.5 mM MgCl2, 200 μM dNTP mix, 2.5 U of Expand HiFi
PLUS Taq polymerase and 1 x 
final volume Expand HiFiPLUS Reaction Buffer (proprietary information) in a final volume of 50 μL. 
PCR conditions comprised 3 minutes at 95 oC followed by 35 cycles of 30 seconds each at 95 
oC, 58 oC and 72 oC followed by 10 minutes at 72 oC. The amplified product was excised and 
eluted from a 1 % agarose gel (see Appendices A1.2.3 and 1.2.4). Following extraction, the 
PCR product was diluted to 10 ng/μL in distilled water and 1 μL of the dilution was used as 
template for a second PCR amplification step using the universal U6 forward primer and lhRNA 
LTR 1 Reverse 2 primer containing an XbaI site (5' GAT CTC TAG AAA AAA GGG TCT CTC 
TAG GTA GAC CAG ATC TGA GCC CGG GAG CTC TCT GGC TAT CTA GGG AAC CCT CTC 
TTG AAG AGT CCC C 3'; the XbaI site is underlined). The PCR mixture and cycling conditions 
were the same as those described above. The amplified product was excised and eluted from a 
1 % agarose gel. Following extraction the PCR product was diluted to 100 ng/μL in distilled 
water and ligated into the TA cloning vector pTZ57R/T (Fermentas, WI, USA). A ligation reaction 
containing a 3:1 molar ratio of  insert  to vector (0.09 pmol insert to 0.03 pmol vector) was 
incubated at room temperature for 1 hour in a 20 μL reaction volume containing 20 U T4 DNA 
Ligase (New England Biolabs® Inc, MA, USA). Aliquots (10 μL) of the ligation reaction were 
used to transform competent Escherichia coli DH5α (Invitrogen, CA, USA). Transformed cells 
were plated on Luria Bertani agar plates (see Appendix A1.1.1) containing Ampicillin (Amp, 
Gibco, BRL, UK), X-gal (5-bromo-4-chloro-3-indolyl- -D-galactopyranoside; Sigma-Aldrich, MO, 
USA) and IPTG (Roche, Basel, Switzerland). To identify correctly cloned lhRNA LTR 1-encoding 
plasmids, individual white colonies (  10) were cultured in 3 ml of Ampicillin positive medium 
(see Appendix A1.1.1). Plasmids were prepared using a commercially available kit (three 
methods are described in Appendix A1.2.1) and 10 μL was digested for 60 minutes at 37 oC with 
SpeI and HindIII in a 20 μL final reaction volume using 0.5 U of each enzyme, 33 mM Tris-
acetate (pH 7.9 at 37 oC), 10 mM magnesium acetate, 66 mM potassium acetate, 0.1 mg/ml 
BSA (Tango Buffer, Fermentas, WI, USA). Digested plasmid DNA was electrophoresed on a      
1 % agarose gel and compared to a molecular weight marker (O‘GeneRulerTM Mix, Fermentas, 
WI, USA). Correct candidate clones were sequenced to determine their fidelity (InqabaBiotech, 
Pretoria, South Africa). The same two step PCR cloning strategy was used to generate lhRNA 
LTR 2, lhRNA LTR 3 and a control lhRNA targeted to a site within the Hepatitis B Virus (HBV) 
genome (1581 to 1640 of subgenotype A1, GenBank® accession number J02203) with the 
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following changes: lhRNA LTR 2 was generated using the universal U6 forward primer, lhRNA 
LTR 2 Reverse 1 primer (5' TGC CCT CTC TTG AAA GAC ACA CAC CAC TCA GAA CAC CCA 
AGA CAA ACT TCA TTA AGG CCT AAA CAG TAG GCT CGG TGT TTC GTC CTT TCC ACA A 
3') and lhRNA LTR 2 Reverse 2 primer containing a HindIII site (5' AAA AAA GAA CCC ACT 
GCT TAA GCC TCA ATA AAG CTT GCC TTG AGT GCT CTA AGT AGT GTG TGC CCT CTC 
TTG AAA GAC 3'; the HindIII site is underlined). LhRNA LTR 3 was generated using the 
universal U6 forward primer, lhRNA LTR 3 Reverse 1 primer (5' GGA AAT CTC TTG AAC TCC 
CAC ACC AAC ACA AAG AGT CTA AGA GAC CTC CAG TCA CCA GAA TCA CAC AAC AAA 
CGG TGT TTC GTC CTT TCC ACA A 3') and lhRNA LTR 3 Reverse 2 primer (5' AAA AAA GTC 
TGT TGT ATG ACT CTG GTA ACT AGA GAT CCC TCA GAC CCT TTG TGT TAG TGT GGA 
AAT CTC TTG AAC TCC 3'). LhRNA HBV was generated using the universal U6 forward primer, 
lhRNA HBV Reverse 1 primer (5' ACT CTC TTG AAG CGC AAA GGC GAA GCA AAG TAC 
ACA CGA TCC GAC AGA CGA GAA GAC ACA AAC AGG AAG TCG GTG TTT CGT CCT TTC 
CAC AA 3') and lhRNA HBV Reverse 2 primer containing an XbaI site (5' GAT CTC TAG AAA 
AAA GAC TCC CCG TCT GTG CCT TCT CAT CTG CCG GAC CGT GTG CAC TTC GCT TCA 
CCT CTG CAC TCT CTT GAA GCG CAA AG 3'; the XbaI site is underlined). Candidate 
pTZ57R/T-lhRNA LTR 2 and 3 clones were screened by digestion using SpeI and HindIII and 
sequencing as described above.  
 
2.2.2 Cloning of a subtype C 5' LTR-driven luciferase reporter target vector 
 
To assess target knockdown induced by the three distinct expressed anti-HIV lhRNAs described 
above, two reporter vectors were constructed that utilised either a subtype B or a subtype C 5' 
LTR promoter to drive expression of humanised Firefly luciferase (hFluc) activity. The subtype B 
luciferase vector was previously described (Jeeninga, Hoogenkamp, et al., 2000) and contained 
an LTR promoter sequence from the HIV-1 LAI molecular clone (Peden, Emerman, et al., 1991). 
To generate a subtype C luciferase reporter, a two-step cloning procedure was used. Firstly, the 
5' LTR of the HIV-1 isolate Du151 (GenBank® accession number AY043173) was amplified by 
PCR from proviral samples obtained from M. Papathanasopolous  using Du151 LTR Forward 
primer containing SalI, EcoRV and BglIII sites (5' GAT CGT CGA CGA TAT CAG ATC TGG 
AAG GGT TAA TTT ACT CTA AG 3'; the SalI site is underlined, the EcoRV site is shown by a 
dotted underline and the BglIII site is italicised) and Du151 LTR Reverse primer containing 
EcoRI and HindIII sites (5' ATC GAA TTC AAG CTT GTT CGG GCG CCA CTG CTA GAG ATT 
TTC CA 3'; the EcoRI site is underlined and the HindIII site is shown by a dotted underline). 
PCR was carried out using the same reaction mixture components as described for the 
generation of the anti-HIV lhRNAs (see section 2.2.1) however the cycling conditions differed as 
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follows: 3 minutes at 95 oC followed by 30 cycles of 45 seconds each at 95 oC, 60 oC and 72 oC 
followed by 10 minutes at 72 oC. Agarose gel-purified PCR products were ligated into the TA 
cloning vector pTZ57R/T to generate pTZ-Du151-LTR and candidate clones were screened by 
digestion using EcoRV and HindIII and sequencing. Secondly, the Luc-SV40polyA sequence 
derived from the Firefly luciferase cassette of plasmid pGL3 (Promega, WI, USA) was amplified 
by PCR using Luc-SV40pA Forward primer (5' ATT AGA ATT CAT GGA AGA CGC CAA AAA 
3') and Luc-SV40pA Reverse primer containing ApaI, SpeI and HindIII sites (5' ATT AGG GCC 
CAC TAG TAA GCT TAC CAC ATT TGT AGA GGT TTT AC 3'; the ApaI site is underlined, the 
SpeI site is shown by a dotted underline and the HindIII site is italicised) as described for the 5' 
LTR PCR amplification. Agarose gel-purified PCR products were ligated into the TA cloning 
vector pCR®2.1-TOPO® (Invitrogen, CA, USA) to generate pCR®2.1-Luc-SV40pA and 
candidate clones were screened by digestion using EcoRI and HindIII and sequencing. Positive 
orientation pTZ-Du151-LTR and pCR®2.1-Luc-SV40pA clones were digested using BamHI and 
PstI in a 50 μL final volume reaction. Agarose gel-purified digestion products were ligated as 
described (see section 2.2.1). A 3:1 molar ratio of annealed fragment to vector (0.09 pmol 
annealed fragment to 0.03 pmol vector) was used to generate pLTRc-luc-SV40pA. This 
construct served as an episomal LTR-driven luciferase target reporter. To generate a LTR-
driven luciferase target vector capable of integration, the LTRc-luc-SV40pA region of pLTRc-luc-
SV40pA was amplified by PCR using Du151 LTR Forward primer and Luc-SV40pA Reverse 
primer and the agarose gel-purified PCR product was inserted in the TA vector psiLentGene-
Puro (Invitrogen, CA, USA) using the same ligation molar ratio as described for pLTRc-luc-
SV40pA to generate pLTRc-luc-SV40pA-Puro. Candidate clones were screened by digestion 
using EcoRI and HindIII and sequencing. The pLTRc-luc-SV40pA-Puro vector was used to 
generate a stable HEK293 cell line following Puromycin selection (see section 2.2.5).  
 
2.2.3 Cloning of a tiling array set of target reporter vectors 
 
The HIV tiling array consisted of a set of dual luciferase-based reporter vectors that comprised a 
single target vector complementary to the complete lhRNA LTR 2 target sequence as well as 5 
overlapping target vectors (‗tiles‘) that together spanned the entire lhRNA LTR 2 target 
sequence. The psiCheck2 dual luciferase vector (Promega, WI, USA) provided a convenient 
method of generating a luciferase based target reporter and comprised an HSV TK-driven hFluc 
cassette as well as an SV40-driven humanised Renilla luciferase (hRluc) cassette with a 
multiple cloning site within the 3' UTR. The cloning strategy used here introduced the HIV LTR 
target sequences within the 3' UTR of the hRluc cassette (Figure 10). Inhibition of the target 
sequence was detected as a change in the ratio of hRluc/hFluc. To generate the ‗LTR 2 
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complete target‘, the lhRNA LTR 2 target sequence was amplified from pLTRc-luc-SV40pA by 
PCR using LTR lhRNA 2 Forward primer containing an XhoI site (5' GAT CTC GAG GAA CCC 
ACT GCT TAA GCC TC 3'; the XhoI site is underlined) and LTR lhRNA 2 Reverse primer 
containing a NotI site (5' GAT CGC GGC CGC TTT CCA CAC TAA CAC AAA GG 3'; the NotI 
site is underlined) and the same PCR mixture and thermal cycler conditions as described above 
(see section 2.2.2). The purified PCR product was digested using XhoI and NotI and 
directionally ligated into the similarly restricted psiCheck2 vector (Promega, WI, USA) that had 
been dephosphorylated as follows:  3 μg of psiCheck2 was incubated for 60 minutes at 37 oC 
with 1 x Antarctic Phosphatase Reaction Buffer [50 mM bis-tris-propane-HCl, 1 mM MgCl2, 0.1 
mM ZnCl2 pH 6.0, New England Biolabs® Inc, MA, USA] and 5 U of Antarctic Phosphatase 
(New England Biolabs® Inc, MA, USA) in a final reaction volume of 10 μL followed by 
inactivation of the enzyme for 5 minutes at 65 oC. Dephosphorylated psiCheck2 and the 
digested PCR product were ligated using a 3:1 molar ratio as described for pLTRc-luc-SV40pA 
to generate psi-LTR 2-complete. To generate the first ‗tile‘ in the HIV tiling array (Tile A), 10 μM 
each of complementary oligonucleotides Target A Forward containing XhoI and EcoRV sites (5' 
TCG AGA TAT CGA ACC CAC TGC TTA AGC CTC AAG C 3') and Target A Reverse 
containing a NotI site (5' GGC CGC TTG AGG CTT AAG CAG TGG GTT CGA TAT C 3') were 
treated with T4 Polynucleotide Kinase (T4 PNK, Fermentas, WI, USA) for 30 minutes at 37 oC 
with the following conditions: 1 x Reaction Buffer A (50 mM Tris-HCl (pH 7.6 at 25 oC), 10 mM 
MgCl2, 5 mM DTT, 0.1 mM spermidine and 0.1 mM EDTA) in a final volume of 20 μL. The 
oligonucleotides were annealed after heating to 95 oC for 5 minutes followed by slow cooling to 
room temperature. Double stranded DNA, with 5  XhoI and 3  NotI cohesive ends, was ligated to 
the equivalent restriction sites of dephosphorylated psiCheck2 vector and candidate clones were 
screened by digestion using EcoRV and sequencing. The same cloning strategy was used to 
generate Tile B to E target vectors with the following oligonucleotide pairs: Target B Forward 
containing XhoI and EcoRV sites (5' TCG AGA TAT CCG TCT GTG CCT TCT CAT CTG CCG 
GAG C 3') and Target B Reverse containing an EcoRV site (5' GGC CGC TCC GGC AGA TGA 
GAA GGC ACA GAC GGA TAT C 3') for Tile B, Target C Forward containing XhoI and EcoRV 
sites (5' TCG AGA TAT CTC ATC TGC CGG ACC GTG TGC AGC 3') and Target C Reverse 
containing an EcoRV site (5' GGC CGC TGC ACA CGG TCC GGC AGA TGA GAT ATC 3') for 
Tile C, Target D Forward containing XhoI and EcoRV sites (5' TCG AGA TAT CCC GTG TGC 
ACT TCG CTT CAC CTC TGG C 3') and Target D Reverse containing an EcoRV site (5' GGC 
CGC CAG AGG TGA AGC GAA GTG CAC ACG GGA TAT C 3') for Tile D and Target E 
Forward containing XhoI and EcoRV sites (5' TCG AGA TAT CCT TCG CTT CAC CTC TGC 
ACG TGC 3') and Target E Reverse containing an EcoRV site (5' GGC CGC ACG TGC AGA 
GGT GAA GCG AAG GAT ATC 3') for Tile E.   
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A similar strategy was used to generate a set of dual luciferase-based reporter vectors that 
comprised a single target vector complementary to a HBV-specific target sequence as well as 5 
overlapping target tile vectors that together spanned the entire HBV target sequence (Appendix 
A3.1 contains additional information related to this assay). To generate the ‗HBV complete 
target‘, the HBV target sequence was amplified from a plasmid (pCH-9/3091) that contains a 
greater than genome length HBV sequence similar to the HBV A1 subgenotype (Nassal, 1992) 
using lhRNA HBV Forward primer containing an XhoI site (5' GAT CTC GAG GAC TCC CCG 
TCT GTG CCT TCT 3'; the XhoI site is underlined) and lhRNA HBV Reverse primer containing a 
NotI site (5' GAT CGC GGC CGC ACG TGC AGA GGT GAA GCG AAG TGC ACA CGG 3'; the 
NotI site is underlined) and cloned into psiCheck2 as described above for the ‗LTR 2 complete 
target‘ vector. The same cloning strategy as described above for the HIV tiling array was used to 
generate HBV-specific Tile A to E target vectors with the following oligonucleotide pairs: Target 
A Forward containing XhoI and EcoRV sites (5' TCG AGA TAT CGA CTC CCC GTC TGT GCC 
TTC TGC 3') and Target A Reverse containing an EcoRV site (5' GGC CGC AGA AGG CAC 
AGA CGG GGA GTC GAT ATC 3') for Tile A, Target B Forward containing XhoI and EcoRV 
sites (5' TCG AGA TAT CCG TCT GTG CCT TCT CAT CTG CCG GAG C 3') and Target B 
Reverse containing an EcoRV site (5' GGC CGC TCC GGC AGA TGA GAA GGC ACA GAC 
GGA TAT C 3'; ) for Tile B, Target C Forward containing XhoI and EcoRV sites (5' TCG AGA 
TAT CTC ATC TGC CGG ACC GTG TGC AGC 3') and Target C Reverse containing an EcoRV 
site (5' GGC CGC TGC ACA CGG TCC GGC AGA TGA GAT ATC 3') for Tile C, Target D 
Forward containing XhoI and EcoRV sites (5' TCG AGA TAT CCC GTG TGC ACT TCG CTT 
CAC CTC TGG C 3') and Target D Reverse containing an EcoRV site (5' GGC CGC CAG AGG 
TGA AGC GAA GTG CAC ACG GGA TAT C 3') for Tile D and Target E Forward containing XhoI 
and EcoRV sites (5' TCG AGA TAT CCT TCG CTT CAC CTC TGC ACG TGC 3') and Target E 
Reverse containing an EcoRV site (5' GGC CGC ACG TGC AGA GGT GAA GCG AAG GAT 
ATC 3') for Tile E.  For all forward primers used to generate ‗tile targets‘ in the HIV and HBV 
tiling arrays, the XhoI sites are underlined and the EcoRV sites are shown by a dotted underline. 
For all corresponding reverse primers, the EcoRV sites are underlined. 
 
2.2.4 Mammalian cell culture 
 
The human embryonic kidney (HEK293) cell line was maintained using Dulbecco‘s Modified 
Eagle‘s Medium (DMEM, Lorenza Biosciences, Basel, Switzerland)  supplemented with heat-
inactivated 10 % fetal calf serum (FCS, Invitrogen, CA, USA) at 37 oC and 5 % CO2 in a Forma 
Series II 3110 Water Jacketed CO2 incubator (Thermo Fisher Scientific, Inc, MA, USA). The 
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human astrocyte glioblastoma U87.CD4.CCR5 cell line was maintained and transfected using 
DMEM supplemented with heat-inactivated 15 % FCS, 50 U/mL Penicillin/50 μg/mL 
Streptomycin antibiotic mix (Gibco, BRL, UK), 1 μg/mL Puromycin antibiotic (Merck, Darmstadt, 
Germany), 300 μg/mL G418 antibiotic (Sigma-Aldrich, MO, USA) and 1 % L-glutamine (Sigma-
Aldrich, MO, USA) at 37 oC and 5 % CO2. 
 
2.2.5 Transfection to generate a stable cell line expressing hFluc from a subtype C HIV 5' LTR 
 
To generate a stable cell line that constitutively expressed hFluc from a HIV-1 subtype C 5' LTR 
promoter, HEK293 cells were transfected with pLTRc-luc-SV40pA-Puro and placed under 
Puromycin selection. Prior to the generation of the stable cell line, a minimum inhibitory 
concentration of Puromycin was determined by kill curve analysis using untransfected HEK293 
cells. Twenty four hours prior to the addition of Puromycin, HEK293 cells were seeded at 120 
000 cells per well in a 24 well dish (NuncTM, Thermo Fisher Scientific, Inc, MA, USA).  Cells were 
counted on a haemocytometer using a 1:1 mixture of Trypan Blue stain (Sigma-Aldrich, MO, 
USA) and cells that had been washed in phosphate buffered saline (PBS, Gibco, BRL, UK) and 
resuspended in DMEM. Seeded cells were left to settle overnight and the following day duplicate 
wells were supplemented with 0.25 μg/mL, 0.50 μg/mL, 0.75 μg/mL, 1 μg/mL, 1.25 μg/mL,    
1.50 μg/mL or 1.75 μg/mL Puromycin. Cell viability was monitored for 1 week using light 
microscopy and the minimum Puromycin concentration at which untransfected HEK293 cells 
were viable was 0.50 μg/mL. A concentration of 1 μg/mL Puromycin was selected to generate 
stable cell lines.  
To generate a stable cell line using pLTRc-luc-SV40pA-Puro, 24 hours prior to transfection 
HEK293 cells were counted as described above and seeded at 2.5 million cells per 10 cm dish 
(NuncTM, Thermo Fisher Scientific, Inc, MA, USA). The following day, 10 μg of pLTRc-luc-
SV40pA-Puro was mixed with 500 μL of OptiMem (Gibco, BRL, UK) and left to incubate for 10 
minutes at room temperature. Separately, 10 μL of Lipofectamine 2000 (Invitrogen, CA, USA) 
was mixed with 500 μL OptiMem and incubated concurrently. The DNA/OptiMem mixture was 
added to the Lipofectamine 2000/OptiMem mixture, vortexed briefly and incubated for 20 
minutes at room temperature before being added to the seeded HEK293 cells. Media was 
changed 24 hours post-transfection and supplemented with 1 μg/mL Puromycin for selection of 
stable clones. Single colonies of the LTRc-hFluc HEK293 stable cell line were picked 
approximately four weeks following transfection using Perspex rings and maintained in DMEM 
supplemented with Puromycin until a luciferase assay had been performed (see the following 
paragraph). Thereafter stable cells were maintained in the presence of 1 μg/mL Puromycin. 
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LTRc-driven hFluc activity was measured using the Promega Dual Luciferase Reporter 
Assay® Kit (Promega, WI, USA). Following selection and expansion of LTRc-hFluc HEK293 
stable clones, cells were seeded at 120 000 cells per well as described above and left to settle 
overnight. The following day, cells were washed in PBS and incubated for 20 minutes at room 
temperature in 100 μL of 1 x Passive Lysis Buffer (proprietary information) per well. Fifty μL of   
1 x Luciferase Assay II Reagent (LARII - proprietary information) was prepared per sample by 
transferring the contents of one bottle of LAR II into one vial of Luciferase Assay Substrate. 
Following lysis, 50 μL of each sample was aliquoted per well into a solid white luminometer plate 
(Turner Biosystems, CA, USA) before being loaded into a VeritasTM Dual-Injection Microplate 
Luminometer (Turner Biosystems, CA, USA) along with the pre-prepared LARII solution. 
Following priming of a single injector within the luminometer, samples were automatically 
exposed to LARII and hFluc expression was analysed using VeritasTM software.  
 
2.2.6 Transfection and detection of luciferase activity in cultured mammalian cells 
 
To assess the inhibitory effects of the three anti-LTR lhRNAs against the episomal subtype B 
and C LTR-driven luciferase reporter targets, HEK293 cells were seeded at 120 000 cells per 
well in 24 well dishes and transfected in triplicate as described (see section 2.2.5) with the 
following changes: cells were co-transfected with a combination of 90 ng of pLTRb-luc (LAI) or 
pLTRc-luc-SV40pA and 900 ng of either pTZ-lhRNA LTR 1, 2, 3 or pTZ-lhRNA HBV as well as 
90 ng of either pCMV-Tat (a gift from J. van Harmelen) or pCI-Neo mock (Promega, WI, USA). 
In addition, 5 ng of an RNA Pol II-expressed (CMV) Renilla luciferase plasmid (pRSV-Rluc – a 
gift from J. J. Rossi) was included per sample, as well as 10 ng of a plasmid vector that 
constitutively produced enhanced green fluorescent protein [pCI-eGFP, (Passman, Weinberg, et 
al., 2000)] to monitor transfection efficiency using fluorescence microscopy. The total amount of 
co-transfected DNA per well (1.10 μg) was incubated in 100 μL of OptiMem as described (see 
section 2.2.5). Separately, 1 μL of Lipofectamine 2000 was incubated in 100 μL of OptiMem and 
the transfection was completed as described (see section 2.2.5). Both hFluc (generated from 
pLTRb-luc or pLTRc-luc-SV40pA) and hRluc (generated from pRSV-Rluc) were measured using 
a luciferase assay as described above with the following changes: 48 hours post-transfection 
cells were washed in PBS, incubated with 1 x Lysis Buffer and 50 μL of each sample was 
aliquoted per well into a luminometer plate. Fifty μL each of 1 x LARII and 1 x Stop & Glo® 
solution (proprietary information) were prepared per sample. Both injectors within the 
luminometer were primed and samples were automatically exposed to LARII followed by Stop & 
Glo®. Notably hFluc activity was assayed using the LARII solution and hRluc was assayed using 
the Stop and Glo® solution. 
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To investigate the inhibitory effects of the three anti-LTR lhRNAs against the integrated 
subtype C LTR-driven luciferase reporter target, LTRc-hFluc HEK293 stable cells were seeded 
and co-transfected in triplicate as described above with 90 ng of either pCMV-Tat or pCI-Neo 
mock and 900 ng of either pTZ-lhRNA-LTR 1, 2 or 3 or pTZ-lhRNA HBV or pTZU6+1 mock 
(Carmona, Ely, et al., 2006). The expression of hFluc was assessed by luciferase activity as 
described (see section 2.2.5). 
To evaluate the inhibitory effects of the three anti-LTR lhRNAs against the HIV Tiling Array 
target reporter vectors, HEK293 cells were seeded and co-transfected in triplicate as described 
above with 90 ng of either psi-LTR 2 complete or psi-Tile A, B, C, D or E and 900 ng of pTZ-
lhRNA LTR 2 or pTZ-lhRNA HBV or pTZU6+1 mock. To assess the inhibitory effects of lhRNA 
HBV against the HBV Tiling Array target reporter vectors, HEK293 cells were seeded and co-
transfected in triplicate as described above with 90 ng of either psi-HBV complete or psi-Tile A, 
B, C, D or E and 900 ng of pTZ-lhRNA HBV or pTZU6+1 mock. Dual luciferase activity was 
assessed as described above.  
To investigate the inhibitory effects of the three anti-LTR lhRNAs against a subtype B 
infectious molecular clone of HIV, HEK293 cells were seeded and co-transfected in triplicate as 
described above with 40 ng of pNL4-3.Luc.R-E- (NIH AIDS Research and Reference Reagents 
Program, MD, USA), 20 ng of pRSV-Rluc, 80 ng of  pBluescript SK (as a carrier, Invitrogen, CA, 
USA) and 40 ng of either pTZ-lhRNA LTR 1, 2 or 3 of pTZ-lhRNA HBV or pTZ-shRev (a gift from 
J. J. Rossi). The pNL4-3.Luc.R-E- clone contained a hFluc gene within the nef ORF and two 
frameshift events had rendered the clone Vpr and Env deficient (Connor, Chen, et al., 1995; He, 
Choe, et al., 1995). The clone was capable of a single round of replication and the hFluc gene 
served as a reporter. Dual luciferase activity was assessed as described above. 
 
2.2.7 Northern blot analysis to detect processed guide sequences from anti-LTR lhRNAs 
 
TriReagentTM (Sigma-Aldrich, MO, USA) was used to extract total RNA (see Appendix A1.3.1) 
from HEK293 cells that had been seeded in 10 cm dishes and transfected with 20 μg of either 
pTZ-lhRNA HBV, pTZ-shHBV or pTZU6+1 as described (see section 2.2.5). A radioactively 
labeled RNA molecular weight marker (see following paragraph, Ambion Decade MarkerTM, 
Applied Biosystems, CA, USA) as well as 30 μg of RNA per sample were mixed with an equal 
volume of RNA loading dye (Appendix A1.3.3) and resolved on a 15 % polyacrylamide (Sigma-
Aldrich, MO, USA) denaturing (7 M urea, Sigma-Aldrich, MO, USA) gel using TBE buffer       
(890 mM Tris base, 890 mM Boric acid and 32 mM EDTA, Merck, Darmstadt, Germany) and 
stained with 10 mg/mL ethidium bromide (Sigma-Aldrich, MO, USA) to ensure equivalent 
quantities of RNA were loaded in each lane, prior to being transferred to a nitrocellulose 
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membrane (Hybond, Amersham Biosciences, CT, USA) using a semi-dry blotter (Hybaid, 
Amersham Biosciences, CT, USA) for 60 minutes at 100 volts. RNA was cross-linked to the 
blots with 1000J UV light (Stratalinker, Stratagene, CA, USA) followed by baking for 60 minutes 
at 80 oC (Thermo Fisher Scientific, Inc, MA, USA). 
DNA oligonucleotide probes A (5' GAC TCC CCG TCT GTG CCT TCT CA 3'), B (5' TCA 
TCT GCC GGA CCG TGT GCA CT 3'), C (5' TGC ACT TCG CTT CAC CTC TGC ACT C 3') 
were hybridized to baked blots to detect guide sequence production from lhRNA HBV and 
shHBV while a U6 snRNA probe (5' TAG TAT ATG TGC TGC CGA AGC GAG CA 3') was used 
to detect small nuclear RNA as a marker of equal RNA loading between samples. Probes were 
labeled at the 5' end with γ-32P-ATP (6000 ci/mmol, Perkin Elmer, MA, USA) and T4 PNK for 30 
minutes at 37 oC with the following components: 1 x Reaction Buffer A (50 mM Tris-HCl pH 7.6, 
10 mM MgCl2, 5 mM dithiothreitol (DTT), 0.1 mM spermidine and 0.1 mM EDTA), 20 pmol of 
oligonucleotide probe, 20 pmol of γ p-32 ATP and 10 U of T4 PNK in a final volume of 20 μL. 
The addition of 1 µl of 0.5 M EDTA pH 8.0 followed by 10 minutes of incubation at 75 oC 
terminated the reaction. Probes were purified using Sephadex® G-25 columns (Sigma-Aldrich, 
MO, USA) and centrifugation for 5 minutes at 59.5 x g before being added to the blot that had 
been incubated for 30 minutes with 10 mL pre-warmed hybridization solution (Rapid Hyb, 
Amersham Biosciences, CT, USA) per 100 cm2 of blot in a rotating hybridisation oven (Thermo 
Fisher Scientific, Inc, MA, USA). Hybridisation occurred overnight at 42 oC and the following day, 
blots were washed twice using 1 % SSC (NaCl/Na-citrate) and 0.1 % SDS (sodium 
dodecylsulphate, Sigma-Aldrich, MO, USA) in a total volume of 50 mL per wash before being 
exposed for 2 days to x-ray film at -80 oC. Probed blots were stripped using a high stringency 
wash solution (0.1 % SSC/1 % SDS) for 30 minutes at 50 oC.  
 
2.2.8 Quantitative real-time reverse transcription PCR (qRT-PCR) of interferon-related genes 
in cultured mammalian cells transfected with anti-LTR lhRNAs 
 
To analyse immunostimulation in HEK293 cells following transfection with the anti-LTR lhRNAs, 
interferon-β (IFN-β) mRNA levels were assayed by qRT-PCR. Total RNA was extracted from 
HEK293 cells that had been transfected with 100 ng pCi-eGFP and 20 μg of either pTZ-lhRNA 
LTR 1, 2 or 3 or pTZU6+1 mock or 2 μg of polyinosinic: polycytidylic acid [poly (I:C), Sigma-
Aldrich, MO, USA]. Poly (I:C) is a dsRNA construct that is known to induce an IFN response in 
HEK293 cells (Loseke, Grage-Griebenow, et al., 2006; Reynolds, Anderson, et al., 2006). RNA 
pellets were resuspended at a concentration of 2 μg/μL in RNAse-free water and DNAse treated 
for 30 minutes at 37 oC using 10 mM Tris-HCl pH 7.5, 2.5 mM MgCl2, 0.1 mM CaCl2 and 1 U of 
DNAse I (Fermentas, WI, USA). Two μg of DNAse-treated RNA was reverse-transcribed for 60 
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minutes at 37 oC using Omniscript RT (Qiagen, Hilden, Germany) with the following reaction 
components: 0.5 mM dNTP mix, 0.1 μM Oligo-dT primer (12 nt), 10 U RNAse inhibitor and 4 U 
of Omniscript RT in a total volume of 20 μL. Complementary DNA (cDNA) was amplified by PCR 
with the Quantitect® SYBR® Green PCR Kit (Qiagen, Hilden, Germany) on a Roche Lightcycler 
V.2. (Roche, Basel, Switzerland). To allow for absolute quantification of RNA, two primer sets 
were used, one for IFN-β (Forward: 5' TCC AAA TTG CTC TCC TGT TGT GCT 3' and Reverse: 
5' CCA CAG GAG CTT CTG ACA CTG AAA A 3') and one for the housekeeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH Forward: 5' AGG GGT CAT TGA TGG 
CAA CAA TAT CCA 3' and Reverse: 5' TTT ACC AGA GTT AAA AGC AGC CCT GGT G 3'). 
PCR reaction mixtures included 0.5 μM of each forward and reverse primer set, 1 μg of cDNA, 
and 1 x Quantitect® SYBR® Green PCR Master Mix (HotStar Taq DNA polymerase, Tris-Cl, 
KCl, (NH4)2SO4, dNTP mix, SYBR Green and MgCl2, concentrations not provided) in a final 
volume of 25 μL. PCR cycling conditions included: hot start for 30 seconds at 95 oC followed by 
50 cycles of 95 oC for 10 seconds, 58 oC for 10 seconds and 72 oC for 10 seconds. PCR product 
specificity was determined by melting curve analysis. Controls included water blanks (no 
template added), and RNA template that had not been subjected to reverse transcription.  
 
2.2.9 Viral propagation and challenge assays using p24 ELISA 
 
To investigate the inhibitory efficacies of the three anti-LTR lhRNAs against a wild type strain of 
HIV-1, a viral challenge assay was conducted in U87.CD4.CCR5 cells. A South African R5-
tropic subtype C HIV isolate that had been isolated from an HIV positive AIDS patient admitted 
to the Johannesburg General Hospital in 1998 was used. The strain was designated FV5 
(GenBank® accession number DQ382363) and propagated by standard peripheral blood 
mononuclear cell (PBMC) co-culture techniques (M. Papathanasopolous). The co-receptor 
tropism of FV5 was established genotypically by automated sequencing of the V3 loop of the 
viral env gene (GenBank® accession number 05ZAFV5) and confirmed phenotypically by MT-2 
assay (personal communication with M. Papathanasopolous). 
For the challenge assay U87.CD4.CCR5 cells were seeded at 20 000 cells per well in a 
96 well dish and transfected in triplicate as described (section 2.2.5) using 0.25 μg of either pTZ-
lhRNA LTR 1, 2 or 3 or pTZ-lhRNA HBV or pTZ-U6+1 mock or pTZ-shRev in 25 μL of OptiMem 
and 0.25 μL of Lipofectamine 2000 per well in 25 μL of OptiMem. 24 hours later the cells were 
infected with FV5 using a TCID50 of 1000/mL (tissue culture infectious dose as measured by p24 
ELISA, see Appendix A2.1) and cultured for a further 24 hours. Cells were washed three times 
using PBS and fresh media was added to a final volume of 250 μL per well. On days zero (day 
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of washing), four and seven a maximum of 200 μL of supernatant was collected and stored at -
80 oC for p24 ELISA analysis and 200 μL of fresh media was replaced. 
Stored supernatants collected from the various days of a challenge assay were 
simultaneously thawed at room temperature and analysed by ELISA for p24 antigen production 
(Murex Biotech LTD, Kent, UK). One hundred μL of Conjugate Working Solution I (biotinylated 
murine anti-p24 monoclonal antibodies, Proclin® preservative, bovine albumin, heat inactivated 
mouse serum, aggregated human IgG in phosphate buffer, concentrations not supplied) was 
aliquoted per well into pre-coated ELISA strips. At least one positive and two negative samples 
(supplied in the kit) were included in each assay. One hundred μL per sample of thawed viral 
supernatant was aliquoted per well and aspirated to mix followed by incubation for 60 minutes at 
37 oC. ELISA strips were washed five times with Wash Buffer (phosphate buffer and Proclin® 
preservative, concentrations not supplied) using an automated plate washer (BioRad, CA, USA). 
This was followed by the addition of 200 μL per well of Conjugate Working Solution II 
(peroxidase conjugated streptavidin, phosphate buffer, Proclin® preservative, bovine casein and 
bovine aprotinin, concentrations not supplied) and incubation for 30 minutes at 37 oC. A second 
wash step was completed followed by the addition of 200 μL of Substrate Solution 
(tetramethylbenzidine, dimethyl sulphoxide, Thiomersal preservative, phosphate citrate buffer 
and hydrogen peroxide, concentrations not provided) per well. Following 30 minutes of 
incubation at room temperature, 50 μL of 2M H2SO4 (Merck, Darmstadt, Germany) was added 
per well.  Fluorescence was analysed at 450 and 690 nm using an automated plate reader 
(BioRad, CA, USA). A standard curve of serially diluted positive sample (supplied in the kit) was 
assessed in parallel to the experimental samples and values at 450/690 nm were converted to 
ng/mL using the standard curve.  
 
2.2.10 Statistical analysis 
 
Data are expressed as the mean ± the standard error of the mean (SEM) and where appropriate 
are normalised to a control sample within the experiment. Statistical difference was considered 
to be significant when p < 0.05 and highly significant when p < 0.01. In all cases α = 0.99 and 
data was analysed using a one-way ANOVA followed by a Dunnett‘s Multiple Comparison post-
test calculated using GraphPad Prism (GraphPad Software Inc, CA, USA).  
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2.3 Results 
 
2.3.1 Inhibitory efficacies of anti-HIV lhRNAs targeted to subtype B and C LTR-driven reporters 
 
Three discrete U6-driven lhRNAs (LTR 1 to 3) were expressed as sense-loop-antisense 
constructs with 63 bp stem regions and two bp 3' overhangs required for Dicer recognition. G:U 
mismatches were included in the sense strand approximately every four to eight bp (Figure 10) 
as this had been shown to facilitate the cloning steps required to generate such long constructs 
(Akashi, Miyagishi, et al., 2005). The limitation of these mismatches to the sense strand ensured 
that the antisense (guide) strand was still 100 % complementary to its cognate target. Each 
lhRNA stem region was 63 bp in length as it was hypothesised this may provide Dicer with a 
substrate that could be processed to form three siRNAs of 21 bp each if Dicer cleaved from the 
two bp overhang towards the loop of the pre-miRNA mimic.  
The HIV LTR provided a novel target for RNAi-mediated inhibition and two distinct LTR-
based reporter vectors were used to assess the efficacies of the lhRNAs against a subtype B 
and C target sequence (Figure 11). As both vectors used the LTR promoter to drive expression 
of hFluc, changes in the hFluc activity in the presence of the hairpins was indicative of lhRNA-
mediated LTR suppression. The addition of a separate plasmid driving hRluc expression 
controlled for transfection efficiencies between samples and provided a background luciferase 
reading against which changes in hFluc could be normalised. To explore the possible 
implications of basal vs. Tat-transactivated levels of LTR transcription, the inhibitory efficacies of 
the lhRNAs were determined in the presence and absence of exogenously supplied Tat. 
Moreover, as the wild type HIV-1 provirus only generated processive transcripts following the 
activation of TAR and RNA Pol II by Tat (Ramanathan, Rajpara, et al., 2001; Richter, Cao, et al., 
2002), the presence and absence of exogenous Tat within cell culture assays served to mimic 
active and inactive forms of the LTR target respectively.  
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Figure 10. Design of expressed anti-HIV lhRNA cassettes. Pol III (U6) cassettes were designed to 
express three individual anti-HIV lhRNAs that each folded into a sense-loop-antisense structure with a 63 
bp stem and characteristic 2 bp 3' overhangs. G:U wobble bases (arrows) were included within the sense 
strand of each lhRNA duplex to facilitate cloning. No mismatches were incorporated into the antisense 
strand thereby ensuring the guide sequence remained complementary to its cognate target.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Design of LTR subtype B and C luciferase-based targets. Two separate hFluc reporter 
constructs were generated by cloning the subtype B (LAI) or C (Du151) LTR promoter upstream of a 
hFluc ORF. A CMV cassette expressing hRluc was co-transfected as a background luciferase control.  
 
 
When targeted to a subtype B LTR-driven reporter vector (LAI), all three lhRNAs showed highly 
significant inhibition of the target (α = 0.99; p < 0.01) in the absence and presence of exogenous 
Tat (Figure 12). As previous publications had revealed the TAR loop to be refractory to siRNA-
mediated inhibition (Jacque, Triques, et al., 2002; Yoshinari, Miyagishi, et al., 2004), it was 
surprising to observe knockdown by lhRNA LTR 1 both in the absence (23.57 % ± 3.21 %) and 
presence (33.57 % ± 2.15 %) of Tat. The remaining two lhRNAs exhibited even greater target 
knockdown with lhRNA LTR 2 showing 52.30 % ± 4.81 % (no Tat) and 65.23 % ± 5.03 % (with 
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Tat) inhibition, while lhRNA LTR 3 achieved 30.17 % ± 3.11 % (no Tat) and 40.30 % ± 5.69 % 
(with Tat) target suppression. A slightly different set of data emerged using the subtype C LTR-
driven reporter vector (Du151). In the absence of Tat, all three lhRNAs showed highly significant 
knockdown of the target vector with lhRNA LTR 1 and LTR 2 mediating 19.77 % ± 7.18 % and 
39.43 % ± 8.80 % respectively (α = 0.99; p < 0.01) while lhRNA LTR 3 achieved the greatest 
target suppression with 78.90 % ± 1.57 %. In the presence of exogenous Tat, lhRNA LTR 1 did 
not achieve any significant inhibition (α = 0.99; p > 0.05) with 18.20 % ± 1.50 % knockdown. 
Both lhRNAs LTR 2 and 3 showed highly significant suppression (α = 0.99; p < 0.01) with 49.40 
% ± 6.62 % and 81.57 % ± 1.82 % inhibition respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Inhibitory efficacies of three anti-HIV lhRNAs targeted to LTRb and LTRc luciferase reporter 
vectors. LTR1, 2 and 3 were co-transfected with target reporter plasmids in the presence (blue bars) and 
absence (green bars) of exogenous Tat in HEK293 cells. Data are expressed as a ratio of hFluc to hRluc 
normalised to a non-specific lhRNA control (lhRNA HBV) determined 48 hours post-transfection (n = 3, ± 
SEM). The left hand panel depicts lhRNA-mediated inhibition of a subtype B reporter vector (LTRb LAI) 
and the right hand panel shows inhibition of a subtype C based reporter (LTRc Du151).   
 
 
Taken together, these data suggested that at least two of the three anti-LTR lhRNAs were 
capable of mediating significant inhibition of both subtype B and C target reporter vectors 
regardless of the presence of exogenous Tat. Although lhRNA LTR 1 mediated some inhibition 
of the subtype B target, the degree of suppression (33.57 %) was demonstrated against a 
reporter vector and may not be sufficient in the context of a wild type HIV infection. The inhibition 
mediated by lhRNAs LTR 2 and 3 in the presence of exogenous Tat suggested that these pri-
miRNA mimics were efficacious despite numerous copies of target RNA. This would provide an 
important advantage in the context of wild type HIV infection where high viral loads are present. 
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Of greater interest was the inhibition mediated by lhRNAs LTR 2 and 3 in the absence of 
exogenous Tat as this suggested that non-processive transcripts were suppressed with 
implications for the completion of the viral life cycle (discussed further in section 2.4). The 
observation that lhRNAs LTR 2 and 3 mediated inhibition of both LTRb and LTRc reporter 
vectors suggested that minor sequence variations may be tolerated by lhRNAs. An additional 
indication that sequence variation may have influenced the inhibitory data was the observation 
that  lhRNA LTR 2 mediated greater knockdown of a subtype B target while lhRNA LTR 3 
showed greater inhibition of a subtype C based vector, regardless of the presence of Tat.  
 
2.3.2 Alignment of LTRb and LTRc promoter sequences 
 
The observed variations between lhRNA-mediated inhibition of the LTRb and LTRc-driven 
luciferase reporters may have been as a result of sequence differences between the two 
promoter regions. RNAi is well-known to be negatively influenced by mismatches between the 
guide strand of a siRNA and its target mRNA, particularly within the seed region (Yekta, Shih, et 
al., 2004; Brennecke, Stark, et al., 2005). Alignment of the LTRb and LTRc target sequences 
revealed minor base changes that may have been responsible for the differences in lhRNA 
efficacies (Figure 13). When aligned with lhRNA LTR 1, four mismatches that spanned the 
length of the stem duplex were detected within the subtype B (LAI) target sequence. Specifically 
these were A to G at position 464, G to T at position 466, C to T at position 484 and T to A at 
position 501. However, the significance of these specific mismatches was difficult to interpret 
because lhRNA LTR 1 was targeted to the TAR loop that was known to be refractory to RNAi-
mediated inhibition. Alignment of LTRb and LTRc regions targeted by lhRNA LTR 2 revealed 
two mismatches within the LTRb sequence, both located close to the loop side of the stem 
duplex. These included a C to T followed by a T to C at positions 548 and 549. The mismatches 
could perhaps have affected siRNAs that were produced from the loop side of the stem while the 
remaining sequence of both target subtypes was a perfect match to lhRNA LTR 2. Three 
subtype B mismatches were revealed within the lhRNA LTR 3 target alignments one of which 
was located within the initial 23 bp of the duplex that may have corresponded with the first Dicer 
cleavage product if the lhRNA was processed from the 3' overhang end. This specific base 
change was A to G at position 575, followed by a G to T at position 610 and a T to C at position 
614. Thus while the degree of inhibition varied between the two LTR sequences, knockdown still 
occurred with two of the three lhRNAs and this suggested that minor sequence variations as 
detected by sequence alignments may be tolerated by lhRNAs. This would be favourable if 
these specific types of RNAi mimics were to be used as a combinatorial anti-HIV strategy.  
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Figure 13. Alignment and comparison of LTRb (LAI) and LTRc (Du151) target sequences. All three 
lhRNAs targeted the LTRc sequence (bottom line of sequence in each panel). Mismatches between the 
LTRb and LTRc sequences are highlighted in bold with green boxes. Long hairpins are shown in with 
respect to their cognate target sequence, and G:U mismatches are shown in bold. Numbering is according 
to the molecular clone HXB2. 
 
2.3.3 Inhibitory efficacies of anti-HIV lhRNAs against an integrated LTR target 
 
The data described in sections 2.3.1 and 2.3.2 was generated following transient transfections of 
episomal target plasmids with the anti-LTR lhRNAs shown to be highly effective at post-
transcriptional silencing of the cognate mRNAs. To assess the inhibitory efficacies of the lhRNAs 
against mRNAs expressed from an integrated target, a stable cell line that expressed hFluc from 
a subtype C LTR was generated.   
Similarly to the transient transfections described in section 2.3.1, each of the anti-LTR 
lhRNAs, an empty vector control (mock) as well as a negative control lhRNA targeted to HBV 
were transfected into the LTRc-hFluc HEK293 stable cell line in the presence or absence of 
exogenous Tat. The pattern of inhibition was similar to that observed following transient 
transfection, with all 3 lhRNAs showing highly significant inhibition (α = 0.99; p < 0.01) of the 
target sequence in the presence and absence of Tat (Figure 14). Intriguingly, the non-specific 
lhRNA HBV also mediated significant inhibition (α = 0.99; p < 0.01) with 33.07 % ± 6.07 % (no 
Tat) and 31.37 % ± 4.86 % (with Tat) knockdown observed. In the absence of Tat, lhRNA LTR 1 
mediated less significant suppression of the target (α = 0.99; p < 0.05) with 14.93 % ± 1.19 % 
knockdown, while lhRNAs LTR 2 and 3 mediated 46.77 % ± 1.58 % and 58.83 % ± 1.28 % 
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inhibition respectively. In the presence of Tat, lhRNAs LTR 2 and 3 showed 61.80 % ± 3.29 % 
and 74.57 % ± 2.10 % suppression respectively.  
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 14. Anti-HIV lhRNA inhibition of cognate RNAs expressed from an integrated LTRc (Du151) target. 
Three lhRNAs and controls were transfected in the absence (turquoise bars) and presence (blue bars) of 
exogenous Tat in HEK293 cells that stably expressed subtype C LTR-driven hFluc. Data are expressed 
as the average relative light units (RLU) of hFluc normalised to an empty vector control (mock) determined 
48 hours post-transfection (n = 3, ± SEM). 
 
 
Overall these data supported the previous observation that lhRNA LTR 3 was most effective 
when targeted to a subtype C LTR reporter sequence, and suggested that an integrated target 
was amenable to lhRNA-mediated inhibition. Recent data has shown that HIV integration is a 
highly co-ordinated concert of interactions (Bera, Pandey, et al., 2009) and that the transcription 
factor binding sites located within the enhancer region of the 5' LTR synergise with IN to ensure 
that the pre-integration complex is tethered to transcriptionally active host chromatin (Felice, 
Cattoglio, et al., 2009). This ensures that HIV proviral DNA is preferentially integrated within 
promoters, regulatory sequences or other euchromatin. The number of integrated HIV copies 
per infected cell has an important bearing on the success of any anti-retroviral therapy including 
RNAi-based effectors such as lhRNAs. In one study, integrated HIV was found in > 90 % of the 
active genes in CD4+ memory T cells taken from HAART-suppressed patients (Duverger, 
Jones, et al., 2009). Thus any therapeutic agent targeted to integrated HIV needs to be present 
at concentrations capable of controlling transcription of nascent viral RNA from numerous target 
sites. The lhRNAs used in this study were expressed from U6 (Pol II) promoters that transcribe 
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high quantities of mRNA. While this has been linked to cellular toxicity and even fatality in mice 
(see sections 2.3.6 and 5.3), one advantage may be that U6-expressed lhRNAs are transcribed 
at levels capable of suppressing highly active HIV. 
 
2.3.4 Inhibitory efficacies of guide sequences produced along the duplex stem of lhRNA LTR 2 
 
Dicer recognises a 2 bp 3' overhang within dsRNA and cleaves to form a siRNA that can then be 
loaded into RISC [section 1.8.1 and (Elbashir, Harborth, et al., 2001; Elbashir, Lendeckel, et al., 
2001)]. Should the guide strand be correctly processed and loaded, silencing of the cognate 
mRNA can then occur. However, should Dicer cleave within the intended guide strand, or should 
the correct guide strand be processed by Dicer but incorrectly loaded into RISC, silencing will 
not occur. The data generated from the experiments in sections 2.3.1 and 2.3.3 demonstrated 
that anti-LTR lhRNAs effectively suppressed their target sequences. However the data did not 
reveal which region(s) of the duplex stem was actively inhibiting the targets. To better 
understand this, a ‗tiling array‘ was designed whereby the entire 63 bp target sequence of lhRNA 
LTR 2 was cropped into 5 tiled segments that overlapped each other by 11 bp (Figure 15). Each 
tile was 22 bp in length thereby representing a potential siRNA target along the duplex. These 
were individually cloned into the 3' UTR of hRluc within a dual luciferase vector and assessed in 
transient transfection assays with either an empty vector control (mock), lhRNA LTR 2 or a non-
specific lhRNA targeted to HBV.  
Luciferase activity assessed 48 hours post-transfection revealed highly significant 
suppression (α = 0.99; p < 0.01) only when the complete LTR 2 sequence or the first 22 bp that 
corresponded to target ‗tile A‘ were targeted (Figure 16). None of the remaining target tiles (B to 
E) were significantly inhibited either by lhRNA LTR 2 or the non-specific control lhRNA targeted 
to HBV (p > 0.05). The observation that tile A was the only sequence to be inhibited by lhRNA 
LTR 2 (70.53 % ± 1.69 %) suggested that the suppression of the complete target sequence 
(62.10 % ± 6.14 %) was probably due to inhibition of the initial 22 bp that corresponded to tile A.  
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Figure 15. Tiling sequences used to generate a set of dual luciferase target reporter vectors. In the upper 
panel, the complete lhRNA LTR 2 target sequence, as well as 5 overlapping tiled segments (target Tiles A 
to E), are depicted and the latter are aligned relative to the complete sequence. All 6 sequences were 
cloned into the 3' UTR of hRluc within the dual luciferase psiCheck2 vector that expressed hFluc from a 
separate HSK TK promoter within the same plasmid (bottom panel).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Tiling array to assess the inhibitory efficacies of guide sequences produced along the duplex 
stem of lhRNA LTR 2. A dual luciferase reporter system was used to assess inhibition of the complete 
LTR 2 sequence as well as 5 tiled segments of the same target that had been individually cloned into the 
3' UTR of hRluc. Forty eight hours post-transfection lhRNA LTR 2-mediated target suppression (turquoise 
bars) was determined in HEK293 cells. Data are expressed as a ratio of hRluc to hFluc normalised to an 
empty vector (mock – red bars) control (n = 3, ± SEM). A non-specific lhRNA was included in each 
experiment (lhRNA HBV – yellow bars).  
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The lhRNA LTR 2 tiling array data was interesting as it suggested functional siRNAs may not 
have been produced across the entire stem of the duplex and in the context of lhRNA LTR 2, 
were predominantly processed from the first Dicer cleavage position. To ensure that the pattern 
of functional siRNA production from a lhRNA construct was not specific to anti-LTR lhRNAs, a 
similar dual luciferase-based tiling array was conducted using the lhRNA HBV cassette targeted 
to an HBV-specific set of target tiles (see Appendix A3.1 for a full description). Using HEK293 
cells, each target tile vector as well as the complete target was co-transfected with either an 
empty vector control (mock) or lhRNA HBV and luciferase activity was assessed 48 hours later 
(Figure 17). 
Similarly to the previous tiling array, lhRNA HBV-mediated suppression was highly 
significant (α = 0.99; p < 0.01) when targeted to the complete sequence (89.60 % ± 1.01 %) and 
target tile A (88.80 % ± 1.41 %). However unlike the previous tiling array, highly significant 
suppression of tiles B (32.90 % ± 1.70 %) and C (59.90 % ± 1.33 %) were also observed 
although with lower efficacy than against tile A. The target tile vectors overlapped each other by 
14 bp thus target tile B straddled the putative initial Dicer cleavage site of lhRNA HBV that 
corresponded to tile A. Thus siRNAs processed from the first Dicer reaction would have only 
partial complementarity to tile B and mediate poor silencing efficacy of this sequence. More 
effective lhRNA HBV silencing of tile C compared to tile B may have been due to improved 
hybridisation of a putative second Dicer-generated siRNA from lhRNA HBV. Target tiles D and E 
were both poorly silenced by lhRNA HBV. 
  
 
  
 
  
 
 
 
 
 
 
 
 
Figure 17. Tiling array to assess inhibitory efficacies of guide sequences produced along the duplex stem 
of lhRNA HBV. A dual luciferase reporter system was used to assess inhibition of the complete HBV X 
ORF sequence as well as 5 tiled segments of the same target that had been individually cloned into the 3' 
UTR of hRluc. Forty eight hours post-transfection lhRNA HBV-mediated target suppression (yellow bars) 
was determined in HEK293 cells. Data are expressed as a ratio of hRluc to hFluc normalised to an empty 
vector (mock – red bars) control (n = 3, ± SEM).  
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The data generated from the two tiling arrays led to several working hypotheses that may have 
explained the results. Firstly, Dicer may have recognised the 3' overhang and cleaved to 
generate one siRNA only from the first position (that corresponded to tile A). The HIV tiling array 
data supported this hypothesis (Figure 16). However, as the HBV specific target tiles A, B and C 
were inhibited by lhRNA HBV, this suggested that siRNAs were produced from more than just 
the initial 22 bp of the lhRNA stem. Another hypothesis proposed that Dicer was generating up 
to three siRNAs from the lhRNA stem region but a greater number of functional siRNAs were 
being produced from the first cleavage reaction. Both the HIV and HBV tiling array data 
supported this hypothesis. The observation that lhRNA HBV mediated greater silencing of target 
tile C as compared to tile B led to a third hypothesis that some of the siRNAs being produced 
were mismatched with respect to their target sequences. Alternatively, functional siRNAs that 
corresponded to each of the target tiles within the arrays may have been produced by Dicer but 
the guide strands were being degraded thereby preventing silencing of target mRNAs. A final 
hypothesis related to strand bias within the lhRNA duplex, such that siRNAs corresponding to 
target tiles B or C may have been produced from the sense strand. However, this was unlikely 
as the G:U mismatches within the sense strand of the lhRNAs ensured that siRNAs produced 
from this strand were not complementary to the target tiles. To dissect out more data regarding 
which region(s) of the lhRNAs were generating active siRNAs, a Northern blot assay was 
completed.  
 
2.3.5 Northern blot analysis of lhRNA HBV 
 
The differences observed between the HIV and HBV tiling arrays in section 2.3.4 suggested that 
Dicer processing of lhRNAs was not restricted to the first 22 bp only but that siRNAs produced 
by second and third Dicer-mediated cleavage reactions may have been mismatched with 
respect to their target sequences. As lhRNA HBV had mediated inhibition of tile A as well as 
target tiles that corresponded with sequences located closer to the loop side of the hairpin, 
Northern blot analysis was completed on this construct. In addition, a shRNA that targeted HBV 
tile D had previously been generated within the same research laboratory and was included as a 
control.  
Three separate probes which together spanned the length of lhRNA HBV were used to 
detect guide sequence RNA in HEK293 cells that had been transfected with either an empty 
vector control (mock), lhRNA HBV or the shHBV control. Precursor unprocessed shHBV was 
detected in all 3 blots as a band at ~60 nt and a U6 snRNA probe that was used to detect small 
nuclear RNAs showed equal loading of RNA across the blots (Figure 18). Probe A (23 nt), 
located at the 3' overhang end of the lhRNA and corresponding to tile A, detected a putative 
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guide sequence of ~23 nt only in cells transfected with lhRNA HBV. Probe B (23 nt) detected 
putative ~23 nt guide sequences in lhRNA HBV- and shHBV-transfected cells. Probe C (25 nt) 
detected a ~23 nt guide sequence as expected for cells transfected with shHBV but no guide 
was detected for cells transfected with lhRNA HBV.  
Importantly, previous data had shown shHBV to silence target tile D effectively (Carmona, 
Ely, et al., 2006) suggesting that the target sequence was amenable to RNAi. Probes B and C 
overlapped by six nt and were designed to be complementary to lhRNA HBV and shHBV. 
However, the observation that both probes only detected guide sequences in shHBV-transfected 
cells suggested that no siRNAs corresponding to target tile D (or E) were produced from that 
portion of the lhRNA duplex stem. Alternatively, siRNAs may have been produced from these 
regions but the lack of inhibition noted in the tiling array did not support this.  
Overall these data suggested that Dicer efficiently cleaved functional siRNAs from the 3' 
stem base end of lhRNAs and while subsequent cleavage reactions yielded additional functional 
siRNAs, processing was less efficient as Dicer moved towards the loop of the duplex.  
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Figure 18. Northern blot analysis to detect putative guide sequences produced from lhRNA HBV. The 
upper panel depicts a schematic illustration of lhRNA HBV as well as a shHBV control with 3 ssDNA 
oligonucleotide probes (A, B and C) shown relative to the RNAi mimics. The bottom panel depicts a 
Northern blot following sequential individual hybridisations of all 3 probes as well as U6 snRNA 
oligonucleotides to RNA from HEK293 cells transfected with shRNA HBV, lhRNA HBV or an empty vector 
control (mock). Approximate sizes (nt) of hybridised bands and molecular weight markers (MW) are 
indicated. Repeated hybridisation reactions showed the data to be reproducible.  
 
2.3.6 Assessment of possible cellular toxicity induced by anti-HIV lhRNAs 
 
The introduction of exogenous RNA into mammalian cells, particularly dsRNA > 30 bp in length 
(Caplen, Parrish, et al., 2001), had been linked to the production of an interferon (IFN) response 
that may ultimately lead to mRNA degradation and cell death (see section 5.3). Synthetic 
siRNAs and expressed shRNAs < 30 bp had been shown to evade the IFN response but the 
effect of lhRNAs was largely unknown. As an index of activation of the IFN response, IFN-β 
mRNA concentrations were measured using real-time RT-PCR on RNA extracted from HEK293 
cells that had been transfected with either one of the LTR-specific lhRNAs, an empty vector 
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control (mock) or a dsRNA construct called poly (I:C) that was a known inducer of IFN in this cell 
line (Loseke, Grage-Griebenow, et al., 2006; Reynolds, Anderson, et al., 2006). Absolute 
quantification of the IFN-β mRNA levels within each sample was determined by normalisation to 
the housekeeping gene GAPDH.  
Relative to poly (I:C) none of the lhRNAs or the mock treated samples elicited a statistically 
significant increase in IFN-β mRNA (α = 0.99; p < 0.01), both in the absence of presence of Tat 
(Figure 19). In addition, cell morphology as measured by light field microscopy and transfection 
efficiencies as determined by GFP expression were the same for control treated cultures as well 
as those that received anti-LTR lhRNAs (Figure 20). Taken together, these data showed that the 
anti-LTR lhRNAs could be efficiently transfected and were non-immunostimulatory as measured 
by IFN-β expression when introduced into HEK293 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Quantitative real-time RT-PCR analysis to determine IFN-β levels in HEK293 cells following 
transfection with anti-HIV lhRNAs. IFN-β mRNA expression relative to the housekeeping gene GAPDH 
was determined 48 hours post-transfection in cells treated with one of the anti-LTR lhRNAs, an empty 
vector control (mock) or a positive control [poly (I:C)] in the absence (green bars) or presence (pink bars) 
of exogenous Tat. Data are represented as a ratio of IFN-β and GAPDH mRNA expression (n = 3, ± 
SEM).           
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Figure 20. Anti-HIV lhRNAs do not affect cell morphology or transfection efficiency. HEK293 cells were 
co-transfected with two of the three anti-HIV lhRNAs and a GFP expressing plasmid, to verify equivalent 
transfection efficiencies between samples 48 hours post-transfection. The upper panel shows GFP 
expression under fluorescent light for empty vector control (mock) and lhRNA treated cultures and the 
lower panel represents transmitted light images of the same cultures. Data is represented at 100 x original 
magnification. 
 
2.3.7 Suppression of HIV replication using LTR-specific lhRNAs 
 
Although inhibitory efficacies of the LTR-specific lhRNAs against both episomal and integrated 
target reporter vectors (sections 2.3.1 and 2.3.3) showed these RNAi mimics to be effective 
suppressors, the target sequences used were expressed as single transcripts outside of their 
natural genomic context. To assess the ability of the anti-LTR lhRNAs to inhibit their cognate 
targets expressed from the context of an HIV genome, two separate assays were used. Initially 
the LTR-specific lhRNAs were tested against a subtype B infectious molecular clone of HIV 
(pNL4-3.Luc.R-E-) that expressed hFluc in place of the nef ORF and was capable of a single 
round of infection. HEK293 cells were co-transfected with pNL4-3.Luc.R-E-, a hRluc expressing 
plasmid (that served as a background luciferase control) and either one of the LTR-specific 
lhRNAs or the non-specific lhRNA HBV or a shRNA complementary to HIV Rev that had been 
shown to effective against the molecular clone (Lee, Dohjima, et al., 2002).  
Measurement of luciferase activity 48 hours post-transfection revealed that all three 
lhRNAs mediated highly significant inhibition of pNL4-3.Luc.R-E- (α = 0.99, p < 0.01) as 
compared to lhRNA HBV (Figure 21). Overall, lhRNA LTR 2 showed the most inhibition (80.00 % 
± 2.64 %) although none of the lhRNAs were as effective as the shRev (94.83 % ± 0.08 %). 
Notably, the pattern of inhibition was similar to that previously observed for the episomal subtype 
B LTR target vectors (Figure 12) suggesting that the ability of lhRNAs to suppress their cognate 
targets was not significantly affected by the context from which that target sequence was 
expressed.  
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Figure 21. Anti-HIV lhRNAs inhibit replication of a subtype B HIV molecular clone. All three LTR-specific 
lhRNAs (purple bars), a non-specific lhRNA (HBV – orange bar) as well as a shRNA (Rev – blue bar) 
were co-transfected with the subtype B infectious clone pNL4-3.Luc.R-E- in HEK293 cells. Luciferase 
activity was determined 48 hours post-transfection and data are expressed as a ratio of hFluc to hRluc 
activity normalised to lhRNA HBV (n = 3, ± SEM).  
 
 
 
The second assay used to score the ability of anti-HIV lhRNAs to inhibit their targets in the 
context of a genome utilised a South African R5-tropic subtype C HIV isolate (FV5). As an 
infectious replicating HIV strain, FV5 had continually evolved during the course of infection to 
develop into a pool of similar but probably non-identical subtype C strains. The use of FV5 in a 
challenge assay therefore provided a unique opportunity to assess the inhibitory efficacies of the 
anti-LTR lhRNAs against a non-isogenic population of target sequences expressed from within 
their native genomic context. The fibroblast cell line U87.CD4.CCR5 bearing CD4 and CCR5 
receptors required for HIV infection was transfected with the anti-HIV lhRNAs, the non-specific 
control lhRNA HBV and positive control shRev before being challenged with FV5 using a TCID50 
of 1000/mL. Inhibition of HIV was assessed four days post-infection by determining Gag p24 
antigen concentrations (Figure 22).  
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Figure 22. Challenge assay to assess anti-HIV lhRNAs against a subtype C viral isolate of HIV. All three 
LTR-specific lhRNAs (purple bars), a non-specific lhRNA (HBV – orange bar) as well as a shRNA (Rev – 
blue bar) were transfected into U87.CD4.R5 cells prior to challenge with viral isolate FV5 at a TCID50 of 
1000/mL. Viral Gag p24 antigen levels were determined four days post-infection by ELISA (450 nm). 
Values were converted to ng/mL using a standard curve supplied with the ELISA kit and data are 
expressed as p24 antigen levels in ng/mL (n = 3, ± SEM).  
 
Cells that received only FV5, empty vector (mock) treated cells or those transfected with lhRNA 
HBV prior to FV5 infection showed no significant differences (α = 0.99; p > 0.05) indicating that 
the viral isolate was indeed infectious and the non-specific lhRNA control was unable to inhibit 
wild type HIV replication as expected. All three anti-LTR lhRNAs showed highly significant 
inhibition of FV5 (α = 0.99; p < 0.01) with lhRNA LTR 3 mediating 57.98 % ± 9.28 % 
suppression. One notable observation was that the highest level of inhibition overall was 
mediated by shRev (84.52 % ± 9.54 %). This was significantly greater (p < 0.05) than the 
suppression mediated by lhRNA LTR 3 and the implications of these differences are discussed 
elsewhere (section 2.4). Interestingly, the overall trend in lhRNA-mediated inhibition of FV5 was 
similar to that previously observed for the episomal and integrated subtype C LTR target vectors 
(Figures 12 and 14). This suggested that either the majority of targets within the FV5 pool 
shared the same sequence, or alternatively that slight variations between target sequences 
within the pool did not significantly impair the inhibitory abilities of the lhRNAs. This latter 
argument was more likely given that FV5 had been isolated from a drug-naive AIDS patient who 
had been infected for a number of years thereby providing time for sequence mutations to occur 
and accumulate. Thus these data provided a very promising proof-of-principle result that lhRNAs 
were able to inhibit a wild type infection using a natural HIV isolate.  
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2.4 Discussion and conclusions 
 
The approach used in this study has been to design three separate RNA Pol III-expressed 
lhRNAs targeted to the viral 5' LTR and to assess the inhibitory efficacies of these RNAi mimics 
against three distinct target sequences in both episomal and integrated forms and, importantly, 
against wild type HIV. In addition, Dicer processing of lhRNAs has been investigated as a 
means of understanding how these constructs are cleaved to form functional siRNAs.  
The observation that U6-expressed lhRNAs can target the HIV LTR whether in an 
episomal or integrated context suggests that these RNAi mimics would be effective against 
active and inactive forms of the proviral promoter. However, the suppression levels did not 
exceed 50 % regardless of the type of reporter used and this level would not be acceptable in a 
therapeutic strategy. The inhibition mediated by lhRNA LTR 1 despite being targeted to the TAR 
loop was interesting given that previous studies had shown the secondary structure of the TAR 
loop to interfere with siRNA-mediated inhibition. Notably, the repeated trend of inhibition 
whereby lhRNA LTR 2 was more efficacious against a subtype B target and lhRNA LTR 3 
against a subtype C LTR suggested that sequence variation influenced these mimics in a 
manner similar to shRNAs. Mismatches within the seed region of the guide strand(s) probably 
decreased the overall inhibitory efficacy of the lhRNA and sequence alignment of the LTRb and 
LTRc promoters revealed mismatches that may have been responsible for the differences 
observed. The presence and absence of exogenously supplied Tat generated processive and 
non-processive LTR-driven transcripts respectively and the lhRNAs were efficacious under both 
conditions. Notably though, the lhRNA-mediated inhibition of the LTR in the absence of Tat 
suggested a novel strategy to impair the completion of the HIV life cycle. Following integration of 
the virus and in the absence of Tat, small amounts of truncated viral RNA are transcribed from 
the LTR as RNA Pol II remains de-phosphorylated. This low level transcription is sufficient to 
generate Tat which phosphorylates RNA Pol II and creates a positive feedback resulting in 
increased transcription (see section 1.4.4). As Tat is required to ensure that processive 
transcription occurs and all viral RNAs are transcribed, inhibition of the non-processive 
transcripts as mediated by lhRNAs LTR 2 and 3 may block the virus at a crucial point in the life 
cycle. The inhibition mediated by the non-specific lhRNA HBV was only observed when targeted 
against the integrated subtype C LTR (Du151; Figure 14) both in the presence and absence of 
exogenous Tat. The suppression was observed despite repeated preparation of the lhRNA HBV 
construct and numerous technical and biological replicates of the experiment. Analysis of the 
Du151 LTR sequence and alignment with the seed region of the non-specific lhRNA did not 
reveal any base pairing. Thus the observed suppression was difficult to explain but was most 
likely due to an unintended off-target effect.   
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The design of a tiling array to investigate the activity of siRNAs processed from various 
regions along the duplex stem of a lhRNA was novel and generated an intriguing set of data that 
suggested Dicer efficiently processes the first two putative siRNAs along the lhRNA stem only. 
This has implications for the design of future lhRNAs as modifications may be required to ensure 
that functional and highly potent siRNAs are produced from all potential Dicer cleavage 
reactions and additional data related to this is discussed further below.  
The potential toxicities of the expressed lhRNAs were assessed using poly (I:C) as a 
positive marker of IFN within HEK293 cells. However, poly I:C traverses the endosome and 
induces the IFN response via toll-like receptors (TLRs) whereas expressed RNAi mimics do not 
traverse endosomes and activate the pathway via PKR or OAS1 (see section 5.3). Thus a more 
appropriate positive control would be an expressed construct that activates IFN similarly to 
shRNAs and lhRNAs. This remains to be developed and should be an important consideration 
for future lhRNA studies. In addition, the ability of Dicer to process the lhRNA duplex into 
multiple siRNAs could generate guides capable of targeting unintended sequences such as host 
mRNAs. These are known as off-target effects (OTEs) and have been linked to death in mice 
[(Grimm, Streetz, et al., 2006) and refer to section 5.3 for an account of the mammalian IFN 
response]. While the lhRNA sequences designed here were subjected to a BLAST search to 
minimise the chances of OTEs, the possibility remains. The data presented in Figures 19 and 20 
suggested that OTEs as characterised by the IFN response were not elicited in the presence of 
the lhRNAs although a more exhaustive investigation could include a genome-wide microarray 
assay.  
The use of a wild type HIV isolate provided a unique and extremely important piece of 
data as previous studies to assess RNAi mimics against HIV utilised infectious molecular clones 
such as pNL4-3.Luc.R-E- or LAI. While these assays are reliable, technically undemanding and 
robust, the target sequences are isogenic and thus do not mimic the diversity present in natural 
HIV infections. FV5 was a mixed population of actively replicating HIV and the inhibition 
mediated by the anti-LTR lhRNAs, while only ~ 50%, was a vital proof-of-principle argument for 
the use of lhRNAs as a combinatorial strategy against HIV.  
Concurrent to this work, data was published describing expressed lhRNAs targeted to 
HIV nef, tat and rev that were designed with 300 bp stem and 46 bp loop regions 
(Konstantinova, de Vries, et al., 2006). EF1α-driven lhRNAs displayed poor efficacy against an 
HIV molecular clone (LAI) as well as a luciferase-based reporter target although this was not 
surprising given that EF1α is an RNA Pol II promoter and thus the lhRNAs would not have been 
transcribed with defined 5' and 3' ends required for Dicer recognition. Similarly, LTR-driven 
lhRNAs with a 1000 bp spacer sequence included in the loop showed poor inhibition of LAI and 
substitution of the promoter with a TetO system did not improve lhRNA-mediated inhibition. The 
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inclusion of a leader sequence between the LTR promoter and nef target of one of the lhRNAs 
dramatically increased the suppressive efficacy of this construct against LAI as well as two LAI-
based clones that were previously shown by the same group to be resistant to a nef-specific 
shRNA (Das, Brummelkamp, et al., 2004). While these data showed impressive inhibition of nef-
resistant HIV, the use of the LTR as a promoter (transcribed by RNA Pol II) in conjunction with a 
leader sequence suggests that the observed inhibition was not due to an RNAi-mediated effect. 
Finally, as no data were provided to show how these lhRNAs were processed into functional 
siRNAs or the specific target sequences inhibited, these data do not clearly extend the 
knowledge base regarding anti-HIV lhRNAs. 
The tiling array and Northern blot data described in sections 2.3.4 and 2.3.5 suggested 
that the ‗molecular ruler mechanism‘ inherent to the PAZ domain of Dicer influences the 
processing of lhRNA duplex regions into functional siRNAs (refer to the section entitled ‗Nuclear 
export and cytoplasmic processing‘ in section 1.8.1). Based on these findings, the spacing 
between putative guide sequences in a set of anti-HIV lhRNAs was manipulated and while 
improvements could be made to first and second position siRNAs by adjusting spacing 
arrangements at the junction site, silencing of third position siRNAs (closest to the loop) 
remained largely ineffective (Saayman, Barichievy, et al., 2008). This was supported by data 
from two other groups, one of which showed the positioning of two siRNAs within the lhRNA 
stem was crucial for their functioning (Liu, Haasnoot, et al., 2007) while the other also suggested 
that Dicer seems to process the first two siRNAs from a lhRNA duplex encoding three putative 
guides (Sano, Li, et al., 2008). Taken together, these data suggest that a stem region of ~50 bp 
is long enough to generate two functional siRNAs if the guide sequences are not immediately 
adjacent. Obviously, lhRNAs with less than one guide sequence are simply shRNAs but an 
upper limit to lhRNA stem length has not been clarified. In one set of experiments, a lhRNA of 80 
bp was efficacious against a reporter vector but did not induce long-term suppression of HIV and 
did not produce functional siRNAs from the entire length of the stem (Sano, Li, et al., 2008). 
Indeed, the most effective lhRNA from this work was a 53 bp lhRNA that produced two distinct 
siRNAs in a manner similar to Saayman et al (Saayman, Barichievy, et al., 2008). Recently 
published data suggested that a minimum of 43 bp are needed to obtain 2 functional siRNAs 
(Liu, von Eije, et al., 2009). The authors further suggested that lhRNAs with stem duplex regions 
of 66 bp could produce 3 functional siRNAs but the inhibition mediated by the siRNA generated 
closest to the loop was not as pronounced as the other two. Taken together, these studies have 
revealed conditions required for the design of lhRNAs that generate potent siRNAs from more 
than one position in the duplex. Importantly, only one long-term study to date has been 
conducted to see if a combination of two or more siRNAs generated from a single lhRNA is 
sufficient to inhibit HIV escape mutants. A single lhRNA targeted to nef, pol and the tat/rev 
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overlapping sequence was shown to suppress viral replication for 49 days although escape 
mutants were detected particularly in the presence of high viral load (Liu, von Eije, et al., 2009). 
Additional long-term studies to assess viral escape in the presence of expressed lhRNAs are 
required to support this data. 
In conclusion, the lhRNAs described in this chapter are functional in suppressing LTR-
driven luciferase activity across subtype B (HIV-1LAI) and C (HIV-1Du151) sequences, both in the 
presence and absence of Tat and do not induce a detectable IFN response. Importantly, the 
anti-LTR lhRNAs showed suppression of a primary HIV-1 isolate comprising a varied pool of 
target sequences. New data have been provided on how these mimics may be processed by 
Dicer with implications for the future design of potent lhRNAs. Yet despite these advances, 
modifications and improvements are required as none of the lhRNAs reduced HIV to the same 
levels as an expressed shRNA. Additional data has been published to show how these mimics 
can be designed to ensure their overall potency but long-term studies need to be completed to 
ensure that lhRNAs can indeed function as a combinatorial RNAi mimic capable of suppressing 
viral escape. This suggests that alternative combinatorial RNAi approaches need to be explored 
and pri-miRNA mimics represent a novel strategy to be investigated against HIV. 
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Chapter three: expressed polycistronic pri-miRNAs targeted to discrete HIV mRNAs as a 
combinatorial RNAi strategy 
 
 
3.1 Introduction 
 
The data presented in the previous chapter demonstrated that anti-HIV lhRNAs may be an 
effective combinatorial modality but modifications are required for these constructs to generate 
numerous functional siRNAs. In addition, the HIV 5' LTR was shown to be amenable to inhibition 
using expressed combinatorial RNAi mimics. Other combinatorial RNAi strategies against HIV 
have utilised variations in the number and arrangement of expressed shRNAs that enter the 
RNAi pathway as pre-miRNA mimics at the level of Dicer (see section 1.10.2). An alternative 
approach that has not been attempted against HIV is the use of ‗pri-miRNA mimics‘ 
(endogenous pri-miRNAs encoding exogenous guide strands) that enter the RNAi pathway as 
Drosha substrates (see section 1.10.2). These present an exciting avenue particularly since it 
has been shown that the endogenous guide strand of pri-miRNA 30 (pri-miR30) can be replaced 
with an exogenous guide sequence capable of binding its own cognate target (Zhou, Xia, et al., 
2005; Sun, D, Melegari, et al., 2006). Endogenous pri-miRNAs are generally located within 
protein-coding genes and are thus expressed by RNA Pol II activity (Lagos-Quintana, Rauhut, et 
al., 2003; Lee, Y, Kim, et al., 2004) although some RNA Pol III expression has been described 
(Borchert, Lanier, et al., 2006). The use of RNA Pol II expression would allow for tissue-specific 
production as these promoters are naturally required for the synthesis of protein-coding mRNAs 
(Cramer, Armache, et al., 2008). More importantly, the use of Pol II-driven RNAi mimics would 
dramatically reduce the saturating toxicities observed with Pol III-expressed effectors (see 
section 5.3). U6-expressed shRNAs caused fatalities in mice as a result of Exp5 saturation and 
while the concentrations of shRNAs used in this study were high, over-expression of these RNAi 
mimics was clearly deleterious (Grimm, Streetz, et al., 2006). As RNA Pol II promoters naturally 
transcribe lower levels of transcripts and can function in a tissue-specific manner, they provide 
an enticing option for pri-miRNA mimic transcription.  
For a combinatorial RNAi approach against HIV to be effective, it has been estimated 
that a minimum of four target mRNAs need to be suppressed (ter Brake, Konstantinova, et al., 
2006; ter Brake, Hooft, et al., 2008). Incorporating this into a pri-miRNA-based combinatorial 
strategy would require the expression of four separate guide sequences either from four 
individual pri-miRNA backbones expressed in tandem, or four repeats of the same pri-miRNA 
backbone each expressing one anti-HIV guide sequence. Two studies have been published that 
focused on the latter option. In one instance, two identical Homo sapien (hsa) pri-miR30a-based 
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mimics transcribed in tandem from a single Pol II promoter were modified to express guide 
sequences targeted to Skp2 mRNA [S-phase kinase-associated protein 2; (Sun, D, Melegari, et 
al., 2006)]. Interestingly, two copies of pri-miR30-Skp2 were more efficacious than one when 
targeted against a GFP-based reporter, but the addition of a third similar scaffold only resulted in 
marginal improvement in GFP suppression. In the second study, two, four or eight copies of a 
hsa pri-miR155 backbone that had been modified to express a guide sequence targeted to 
mouse neuroD1 mRNA were expressed from a single RNA Pol II promoter (Chung, Hart, et al., 
2006). Using a luciferase-based reporter assay, progressive enhancement of the guide 
sequence efficacy was observed as the number of pri-miRNA scaffolds increased. This was in 
direct contrast to the data published by Sun et al but the reasons for the discrepancies remain 
unclear. While the use of different pri-miRNA backbones or the lengths of the ss flanking regions 
may have contributed to the inconsistent results, the feasibility of tandemly repeating pri-miRNA 
mimics under the control of a single Pol II promoter was clearly demonstrated in both 
publications. This provided a foundation from which to investigate the use of pri-miRNA scaffolds 
in a combinatorial RNAi system targeted to various HIV mRNAs.  
The design of a combinatorial RNAi system that encompasses multiple, distinct pri-
miRNA scaffolds designed to express discrete exogenous guide sequences had not previously 
been investigated. However, for this approach to be feasible, the efficacies of exogenous guide 
sequences processed from various pri-miRNA backbones needed to be assessed. Based on the 
studies by Sun et al and Chung et al, hsa pri-miRNAs 30a and 155 were included in the current 
body of work and two additional pri-miRNAs (hsa pri-miR122 and hsa pri-miR31) were chosen 
based on data showing that these pri-miRNAs yield functional exogenous guide sequences (Ely, 
Naidoo, et al., 2008). Importantly, as mature miRNAs can be excised from either arm of a pre-
miRNA stem or even from both arms (Khvorova, Reynolds, et al., 2003), the dominant guide 
strand of each of the four pri-miRNAs was designated according to published data downloaded 
from the Sanger miRNA Registry database (http://microrna.sanger.ac.uk/sequences/).  Notably, 
this revealed that 3 of the pri-miRNAs (hsa pri-miRNAs 122, 31 and 155) generated guide 
strands predominantly from their 5' arms while pri-miR30a predominantly generated 3' arm 
guides. This provided the opportunity to explore an additional characteristic that may have 
affected guide sequence production.  
In this chapter, the relationship between pri-miRNA scaffold and guide sequence efficacy 
was investigated using four individual pri-miRNA backbones (hsa pri-miRNAs 122, 30a, 31 and 
155) each modified to produce one of four separate anti-HIV guide sequences. This approach 
was used in order to tease out the most efficacious scaffold/guide pairs with the aim of 
generating a combinatorial system ideally comprised of four different pri-miRNA backbones 
expressing four discrete anti-HIV guides. The requirement for four individual guide sequences 
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was based on the estimation provided by ter Brake et al (ter Brake, Konstantinova, et al., 2006; 
ter Brake, Hooft, et al., 2008) and the use of four discrete pri-miRNA backbones was 
hypothesised to decrease the chances of a recombination event that could excise one or more 
of the scaffolds.  
 
3.2 Materials and methods 
 
3.2.1 Cloning of individual expressed pri-miRNA mimics targeted to four separate HIV mRNAs 
 
To construct different pri-miRNA scaffolds with anti-HIV guide sequences that were expressed 
from an RNA Pol II promoter, each pri-miRNA backbone in a group of four was modified to 
encode each of four separate anti-HIV guide sequences and cloned into the pCi-Neo 
mammalian expression vector (Promega, WI, USA) such that the cassettes were expressed 
from the Cytomegalovirus (CMV) promoter as follows: the sequences of four endogenous pri-
miRNAs (hsa pri-miR122, GenBank® accession number Mi0000442 and co-ordinates 54269286 
to 54269370 on chromosome 18; hsa pri-miR30a, GenBank® accession number Mi0000088 
and co-ordinates 72169975 to 72170045 on chromosome 6; hsa pri-miR31, GenBank® 
accession number Mi0000089 and co-ordinates 21502114 to 21502184 on chromosome 9; hsa 
pri-miR155, GenBank® accession number Mi0000681 and co-ordinates 25868163 to 25868227 
on chromosome 21) were downloaded from the Sanger miRNA Registry database 
(http://microrna.sanger.ac.uk/sequences/). The sequences included the 5' and 3' ss flanking 
regions of each pri-miRNA required for Drosha recognition and processing [refer to ‘Expression 
and nuclear processing’ of section 1.8.1 and (Zeng and Cullen, 2005; Han, Lee, et al., 2006)].  
The endogenous guide strand of each pri-miRNA was substituted with each of four guide 
sequences taken from shRNAs that had been shown to be highly effective against HIV [(Lee, N 
S, Dohjima, et al., 2002; Cave, Weinberg, et al., 2006; Nishitsuji, Kohara, et al., 2006; ter Brake, 
Konstantinova, et al., 2006; Westerhout, Vink, et al., 2006) and see Appendix A3.2]. These 
included shRNAs targeted to int, gag, LTR and tat mRNAs and guide sequence substitution 
generated a panel of sixteen anti-HIV pri-miRNA mimics (four anti-HIV guides in each of four pri-
miRNA backbones).  
The predicted secondary structure of each endogenous pri-miRNA as well as the anti-
HIV mimics was analysed using the RNA folding program Mfold (http://mfold.burnet.edu.au/) as 
previously described (Mathews, Sabina, et al., 1999; Zuker, 2003). Based on a ‗nearest 
neighbour fit‘, Mfold is ideally suited to generating a predicted secondary structure for single 
hairpin sequences. As the ss flanking regions of the pri-miRNAs did not naturally form duplex 
structures, they were omitted from the Mfold analysis. The predicted secondary structure of the 
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pre-miRNA portion of each anti-HIV pri-miRNA mimic was compared to the endogenous 
counterpart to determine the shape and thermodynamic stability of each (Figure 26). Related to 
the former characteristic, the duplex regions, loop arrangements and bulge sequences of each 
mimic were analysed to determine if the guide sequence replacement altered the overall shape 
of each mimic as compared to their endogenous backbone. To determine if the predicted 
secondary structure of each mimic was energetically equivalent to the endogenous backbone, 
the free energy values for each predicted structure were compared to the wild type.  
The entire sequence (~ 235 bp) of each anti-HIV pri-miRNA mimic was divided into four 
overlapping oligonucleotides and a two step approach (Figure 23) was used to generate the 
panel of modified pri-miRNA cassettes as follows: for pri-miR122 targeted to HIV int (pri-miR122 
IN), an extension step was carried out using two oligonucleotide primers (IDT, USA) that 
overlapped by 38 nt called Pri-miR122-IN Forward (5' GAG TTT CCT TAG CAG AGC TGA CTA 
GCC ATT GCT CTC CGG CTT TGT CTA AAC TAT AAG CCG GAG 3') and Pri-miR122-IN 
Reverse (5' GGA TTG CCT AGC AGT AGC TAA AGA ACC ATT TCT CTC CGG CTT ATA GTT 
TAG ACA AAG CCG GA 3'). A PCR was carried out using Expand High FidelityPLUS PCR 
System reagents (Roche, Basel, Switzerland) on a Mastercycler® (BioRad, CA, USA). The PCR 
mixture included 0.5 μM of each primer, 1.5 mM MgCl2, 200 μM dNTP mix, 2.5 U of Expand 
HiFiPLUS Taq polymerase and 1 x final volume Expand HiFiPLUS Reaction Buffer (proprietary 
information) in a final volume of 50 μL. PCR conditions comprised 3 minutes at 95 oC followed 
by 35 cycles of 30 seconds each at 95 oC, 58 oC and 72 oC followed by 10 minutes at 72 oC. The 
product formed the complete ds portion of each pri-miRNA mimic (5' arm, loop and 3' arm, 
Figure 23) and was excised and eluted from a 1 % agarose gel (see Appendices A1.2.3 and 
1.2.4). Following extraction, the product was diluted to 10 ng/μL in distilled water and 2 μL of the 
dilution was used as template for a second PCR step using primers Pri-miR122 Flank Left 
containing XhoI and SpeI sites (5' GAT CCT CGA GAC TAG TCA GGT AAG GTG GAG GTG 
AAG TTA ACA CCT TCG TGG CTA CAG AGT TTC CTT AGC AGA GCT G 3', the XhoI site is 
underlined and the SpeI site is shown with a dotted underline) and Pri-miR122 Flank Right 
containing an NheI site (5' CGC TAG CGG ACA CCT GTG GAG AGA AAG AGC AAA CGA 
TGC CAA GAC ATT TAT CGA GGG AAG GAT TGC CTA GCA GTA GCT A 3', the NheI site is 
underlined). The second round primers overlapped the first round template by 20 nt and 
generated the 5' and 3' flanking regions of the pri-miRNA mimic respectively. The same reaction 
and cycling conditions were used during the second PCR step. The second round PCR product 
was cloned into the TA cloning vector pTZ57R/T (Fermentas, WI, USA) and candidate clones 
were screened using EcoRI and XhoI as described in section 2.2.1.  
The same two step cloning strategy was used to generate the other anti-HIV pri-miRNA 
mimics with the following primer combinations: for pri-miR122 targeted to HIV gag (pri-miR122 
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Gag), the first round extension was completed using Pri-miR122 Gag Forward (5' GAG TTT 
CCT TAG CAG AGC TGA TAT TGA CGC TCT CGC ACC CTT TGT CTA AAC TAT AAG GGT 
GCG 3') and Pri-miR122 Gag Reverse (5' GGA TTG CCT AGC AGT AGC TAA CCT TGA CGC 
CCT CGC ACC CTT ATA GTT TAG ACA AAG GGT GC 3'), and the second round PCR was 
completed using the Pri-miR122 Flank Left and Right primers. For pri-miR122 targeted to HIV 
LTR (pri-miR122 LTR), the first round extension was completed using Pri-miR122 LTR Forward 
(5‘ GAG TTT CCT TAG CAG AGC TGT CTG AGG GAT CTC TAG TTA CTT TGT CTA AAC 
TAT AAG TAA CTA 3') and Pri-miR122 LTR Reverse (5' GGA TTG CCT AGC AGT AGC TAA 
CCT TGA CGC CCT CGC ACC CTT ATA GTT TAG ACA AAG GGT GC 3'), and the second 
round PCR was completed using the Pri-miR122 Flank Left and Right primers. For pri-miR122 
targeted to HIV tat (pri-miR122 Tat), the first round extension was completed using Pri-miR122 
Tat Forward (5' GAG TTT CCT TAG CAG AGC TGC TCT TCG TCG CTG TCT CCG CTT TGT 
CTA AAC TAT AAG CGG AGA 3') and Pri-miR122 Tat Reverse (5' GGA TTG CCT AGC AGT 
AGC TAC GAT TCA TCG GTG TCT CCG CTT ATA GTT TAG ACA AAG CGG AG 3'), and the 
second round PCR was completed using the Pri-miR122 Flank Left and Right primers.  
For pri-miR30a targeted to HIV int (pri-miR30a IN), the first round extension was 
completed using Pri-miR30a IN Forward (5' CTG TTG ACA GTG AGC GCA GCC GGA GAG 
CAT CAT GGT TAG TCT GTG AAG CCA CAG ATG GGA CTA GCC AT 3') and Pri-miR30a IN 
Reverse (5' TCC GAG GCA GTA GGC AAA GCC GGA GAG CAA TGG CTA GTC CCA TCT 
GTG GCT TCA CAG ACT AAC CAT 3'), and the second round PCR was completed using Pri-
miR30a Flank Left containing XhoI and SpeI sites (5' GAT CCT CGA GAC TAG TCA GGT GAG 
AGG TTA ACC CAA CAG AAG GCT AAA GAA GGT ATA TTG CTG TTG ACA GTG AGC G 3', 
the XhoI site is underlined and the SpeI site is shown with a dotted underline) and Pri-miR30a 
Flank Right containing an NheI site (5' CGC TAG CGA GGC CTC TAG AGC CGC CGG AAA 
CAA GAT AAT TGC TCC TAA AGT AGC CCC TTG AAG TCC GAG GCA GTA GGC A 3', the 
NheI site is underlined). For pri-miR30a targeted to HIV gag (pri-miR30a Gag), the first round 
extension was completed using Pri-miR30a Gag Forward (5' CTG TTG ACA GTG AGC GGA 
GGG TGC GAG AGT CCG TCA ATA TCT GTG AAG CCA CAG ATG GGA TAT TGA CG 3') 
and Pri-miR30a Gag Reverse (5' TCC GAG GCA GTA GGC AAA GGG TGC GAG AGC GTC 
AAT ATC CCA TCT GTG GCT TCA CAG ATA TTG ACG 3'), and the second round PCR was 
completed using the Pri-miR30a Flank Left and Right primers. For pri-miR30a targeted to HIV 
LTR (pri-miR30a LTR), the first round extension was completed using Pri-miR30a LTR Forward 
(5' CTG TTG ACA GTG AGC GCA GTA ACT AGA GAT CTC TCT CAG ACT GTG AAG CCA 
CAG ATG GGT CTG AGG GA 3') and Pri-miR30a LTR Reverse (5' TCC GAG GCA GTA GGC 
AAA GTA ACT AGA GAT CCC TCA GAC CCA TCT GTG GCT TCA CAG TCT GAG AGA 3'), 
and the second round PCR was completed using the Pri-miR30a Flank Left and Right primers. 
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For pri-miR30a targeted to HIV tat (pri-miR30a Tat), the first round extension was completed 
using Pri-miR30a Tat Forward (5' CTG TTG ACA GTG AGC GCA GCG GAG ACA GCT CGA 
TGA AGA GCT GTG AAG CCA CAG ATG GGC TCT TCG TC 3') and Pri-miR30a Tat Reverse 
(5' TCC GAG GCA GTA GGC AAA GCG GAG ACA GCG ACG AAG AGC CCA TCT GTG GCT 
TCA CAG CTC TTC ATC 3'), and the second round PCR was completed using the Pri-miR30a 
Flank Left and Right primers.  
For pri-miR31 targeted to HIV int (pri-miR31 IN), the first round extension was completed 
using Pri-miR31 IN Forward (5' TAA CTT GGA ACT GGA GAG GAA CTA GCC ATT GCT CTC 
CGG CTT TGA ACT GGG AAA CTC CGG AG 3') and Pri-miR31 IN Reverse (5' TGC TGT CAG 
ACA GGA AAG ATA CTA ATC ATG GCT CTC CGG AGT TTC CCA GTT CAA AGC CGG AGA 
3'), and the second round PCR was completed using Pri-miR31 Flank Left containing XhoI and 
SpeI sites (5' GAT CCT CGA GAC TAG TAA GGT AAG GTA AAA CAC TGA AGA GTC ATA 
GTA TTC TCC TGT AAC TTG GAA CTG GAG AGG A 3', the XhoI site is underlined and the 
SpeI site is shown with a dotted underline) and Pri-miR31 Flank Right containing an NheI site (5' 
CGC TAG CGC ACA CCT ATG GAG AGA GGA CAC GAA GGA CTG GCA TGC AGG TGG 
CCA TGG CTG CTG TCA GAC AGG AAA GAT 3', the NheI site is underlined). For pri-miR31 
targeted to HIV gag (pri-miR31 Gag), the first round extension was completed using Pri-miR31 
Gag Forward (5' TAA CTT GGA ACT GGA GAG GAA TAT TGA CGC TCT CGC ACC CTT TGA 
ACT GGG AAA CTG GTG CG 3') and Pri-miR31 Gag Reverse (5' TGC TGT CAG ACA GGA 
AAG ATA TAT TTA CGG TCT CGC ACC AGT TTC CCA GTT CAA AGG GTG CGA 3'), and the 
second round PCR was completed using the Pri-miR31 Flank Left and Right primers. For pri-
miR31 targeted to HIV LTR (pri-miR31 LTR), the first round extension was completed using Pri-
miR31 LTR Forward (5' TAA CTT GGA ACT GGA GAG GAT CTG AGG GAT CTC TAG TTA 
CTT TGA ACT GGG AAA CTT AAC TA 3') and Pri-miR31 LTR Reverse (5' TGC TGT CAG ACA 
GGA AAG ATT CTG ATA GAG CTC TAG TTA AGT TTC CCA GTT CAA AGT AAC TAG 3'), 
and the second round PCR was completed using the Pri-miR31 Flank Left and Right primers. 
For pri-miR31 targeted to HIV tat (pri-miR31 Tat), the first round extension was completed using 
Pri-miR31 Tat Forward (5' TAA CTT GGA ACT GGA GAG GAC TCT TCG TCG CTG TCT CCG 
CTT TGA ACT GGG AAA CTC GGA GA 3') and Pri-miR31 Tat Reverse (5' TGC TGT CAG ACA 
GGA AAG ATC TCT TTA TCT CTG TCT CCG AGT TTC CCA GTT CAA AGC GGA GAC 3'), 
and the second round PCR was completed using the Pri-miR31 Flank Left and Right primers.  
For pri-miR155 targeted to HIV int (pri-miR155 IN), the first round extension was 
completed using Pri-miR155 IN Forward (5' TTG CTG TAG GCT GTA TGC TGA CTA GCC ATT 
GCT CTC CGG CTG TTT TTG CCT CCA ACT GAC AGC CGA G 3') and Pri-miR155 IN 
Reverse (5' GTA ACA GGC ATC ATA CAC TGA CTA ACC ATT GTC TCG GCT GTC AGT TGG 
AGG CAA AAA CAG CCG GA 3'), and the second round PCR was completed using Pri-miR155 
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Flank Left containing XhoI and SpeI sites (5' GAT CCT CGA GAC TAG TAA GGT GAG TCT 
TTA TGC CTC ATC CTC TGA GTG CTG AAG GCT TGC TGT AGG CTG TAT GCT G 3', the 
XhoI site is underlined and the SpeI site is shown with a dotted underline) and Pri-miR155 Flank 
Right containing an NheI site (5' CGC TAG CGA GGC CTC TGG AGC CGC GCG CCA CGG 
CAG CAA TTT GTT CCA TGT GAA TGC TAG TAA CAG GCA TCA TAC ACT G 3', the NheI 
site is underlined). For pri-miR155 targeted to HIV gag (pri-miR155 Gag), the first round 
extension was completed using Pri-miR155 Gag Forward (5' TTG CTG TAG GCT GTA TGC 
TGA TAT TGA CGC TCT CGC ACC CTT TTT TTG CCT CCA ACT GAA AGG GTC G 3') and 
Pri-miR155 Gag Reverse (5' GTA ACA GGC ATC ATA CAC TGA TAT TGA CGC TTC GAC 
CCT TTC AGT TGG AGG CAA AAA AAG GGT GC 3'), and the second round PCR was 
completed using the Pri-miR155 Flank Left and Right primers. For pri-miR155 targeted to HIV 
LTR (pri-miR155 LTR), the first round extension was completed using Pri-miR155 LTR Forward 
(5' TTG CTG TAG GCT GTA TGC TGT CTG AGG GAT CTC TAG TTA CTG TTT TTG CCT 
CCA ACT GAC AGT AAT A 3') and Pri-miR155 LTR Reverse (5' GTA ACA GGC ATC ATA CAC 
TGT CTG AGA GAT CCT ATT ACT GTC AGT TGG AGG CAA AAA CAG TAA CT 3'), and the 
second round PCR was completed using the Pri-miR155 Flank Left and Right primers. For pri-
miR155 targeted to HIV tat (pri-miR155 Tat), the first round extension was completed using Pri-
miR155 Tat Forward (5' TTG CTG TAG GCT GTA TGC TGC TCT TCG TCG CTG TCT CCG 
CTG TTT TTG CCT CCA ACT GAC AGC GGG A 3') and Pri-miR155 Tat Reverse (5' GTA ACA 
GGC ATC ATA CAC TGC TCT TCA TCG CGT CCC GCT GTC AGT TGG AGG CAA AAA CAG 
CGG AG 3'), and the second round PCR was completed using the Pri-miR155 Flank Left and 
Right primers.  
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Figure 23. Two-step cloning strategy used to generate anti-HIV pri-miRNA mimics. Round 1 extension 
used internal forward and reverse primers to generate a Round 1 (R1) product comprising a ~16 bp region 
of each ss pri-miRNA flank (grey boxes), two regions common to all pri-miRNA mimics (CR, green boxes), 
the anti-HIV guide (G, purple box), loop (L, blue box) and anti-guide (AG, pink box) sequences. This 
product was diluted and used as template in the second PCR reaction with flank forward and reverse 
primers to generate a Round 2 (R2) PCR product that included XhoI, SpeI and NheI sites within the 
flanking regions. The entire pri-miRNA mimic was ligated into the TA vector pTZ57R/T and candidate 
clones were screened using EcoRI and XhoI digestion.  
 
Positive orientation pri-miR122 IN clones were digested using XhoI and XbaI, 
electrophoresed and agarose-gel purified digestion product was directionally ligated into the 
similarly restricted pCi-Neo vector [(Promega, WI, USA) and Figure 24) that had been 
dephosphorylated as follows:  3 μg of pCi-Neo was incubated for 60 minutes at 37 oC with 1 x 
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Antarctic Phosphatase Reaction Buffer [50 mM bis-tris-propane-HCl, 1 mM MgCl2, 0.1 mM ZnCl2 
pH 6.0, New England Biolabs® Inc, MA, USA] and 5 U of Antarctic Phosphatase (New England 
Biolabs® Inc, MA, USA) in a final reaction volume of 10 μL followed by inactivation of the 
enzyme for 5 minutes at 65 oC. Dephosphorylated pCi-Neo and the digested PCR product were 
ligated using a 3:1 molar ratio as described for the psiCheck2-based tiling array vectors (see 
section 2.2.3). The same cloning strategy was used to generate pCi-pri-miR122 Gag, pCi-pri-
miR122 LTR, pCi-pri-miR122 Tat, pCi-pri-miR31 IN, pCi-pri-miR31 Gag, pCi-pri-miR31 LTR, 
pCi-pri-miR31 Tat, pCi-pri-miR155 IN, pCi-pri-miR155 Gag, pCi-pri-miR155 LTR and pCi-pri-
miR155 Tat. An XbaI site was present within the 5' flanking sequence of pri-miR30a, thus 
positive orientation pri-miR30a IN clones were digested using XhoI and EcoRI, electrophoresed 
and the agarose-gel purified digestion product was directionally ligated into the similarly 
restricted pCi-Neo vector (Promega, WI, USA) to generate pCi-pri-miR30a IN as described 
above. The same cloning strategy was used to generate pCi-pri-miR30a Gag, pCi-pri-miR30a 
LTR, pCi-pri-miR30a Tat and candidate pCi-Neo based clones were screened by digestion using 
SpeI and NotI and sequencing.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Cloning steps used to generate RNA Pol II-driven anti-HIV pri-miRNA mimics. Following the 
2
nd
 round of PCR amplification, anti-HIV pri-miRNA mimics were cloned into the TA vector pTZ57R/T. 
Positive orientation clones were digested using XbaI and XhoI and directionally ligated into the similarly 
digested pCiNeo vector containing a CMV promoter (red arrow). Common region (CR), G (guide), L 
(loop), AG (anti-guide).  
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3.2.2 Cloning of HIV target reporter vectors 
 
To assess the inhibitory efficacies of the anti-HIV pri-miRNA mimics, a set of psiCheck2 based 
target vectors were generated as described in section 2.2.3 although the oligonucleotides used 
here were digested with XhoI and SpeI as opposed to XhoI and NotI. Candidate clones were 
screened by digestion using EcoRV and sequencing as described for the psiCheck2-based tiling 
array vectors (see section 2.2.1). To generate the psi-IN (HIV int) target vector, IN Forward 
containing a XhoI and EcoRV sites (5' TCG AGA TAT CAG CCG GAG AGC AAT GGC TAG TA 
3', the XhoI site is underlined and the EcoRV site is shown with a dotted underline) and IN 
Reverse containing a SpeI site (5' CTA GTA CTA GCC ATT GCT CTC CGG CTG ATA TC 3', 
the SpeI site is underlined) were used. To generate the psi-Gag (HIV gag) target vector, Gag 
Forward containing a XhoI and EcoRV sites (5' TCG AGA TAT CGG TGC GAG AGC GTC AAT 
ATT AA 3', the XhoI site is underlined and the EcoRV site is shown with a dotted underline) and 
Gag Reverse containing a SpeI site (5' CTA GTT AAT ATT GAC GCT CTC GCA CCG ATA TC 
3', the SpeI site is underlined) were used. To generate the psi-LTR (HIV LTR) target vector, LTR 
Forward containing a XhoI and EcoRV sites (5' TCG AGA TAT CAG TAA CTA GAG ATC CCT 
CAG CAC 3', the XhoI site is underlined and the EcoRV site is shown with a dotted underline) 
and LTR Reverse containing a SpeI site (5' CTA GTG TCT GAG GGA TCT CTA GTT ACT GAT 
ATC 3', the SpeI site is underlined) were used. To generate the psi-Tat (HIV tat) target vector, 
Tat Forward containing a XhoI and EcoRV sites (5' TCG AGA TAT CAG CGG AGA CAG CGA 
CGA AGA GA 3', the XhoI site is underlined and the EcoRV site is shown with a dotted 
underline) and Tat Reverse containing a SpeI site (5' CTA GTC TCT TCG TCG CTG TCT CCG 
CTG ATA TC 3', the SpeI site is underlined) were used. To generate the psi-Complete targets 
vector that comprised targets sites for int, gag, LTR and tat, Complete Forward containing a 
XhoI and EcoRV sites (5' TCG AGA TAT CAG TAA CTA GAG ATC CCT CAG ACG AAG AGC 
CGG AGA GCA ATG GCT AGT AGG CAG CGG AGA CAG CGA CGA AGA TGA CGG GTG 
CGA GAG CGT CAA TAT TAA 3', the XhoI site is underlined and the EcoRV site is shown with 
a dotted underline) and Complete Reverse containing a SpeI site (5' CTA GTT AAT ATT GAC 
GCT CTC GCA CCC GTC ATC TTC GTC GCT GTC TCC GCT GCC TAC TAG CCA TTG CTC 
TCC GGC CTC TTC GTC TGA GGG ATC TCT AGT TAC TGA TAT C 3', the SpeI site is 
underlined) were used.  
 
3.2.3 Cloning of multimeric polycistonic anti-HIV pri-miRNA mimics 
 
The generation of the multimeric polycistronic anti-HIV pri-miRNA mimic vectors was based on a 
cloning strategy that had been previously described (Sun, D, Melegari, et al., 2006), whereby 
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single pri-miRNA mimics were amplified by PCR using primers that contained XbaI (5' primer) 
and SpeI sites (3' primer). To multimerise two (or more) single pri-miRNA mimics, each construct 
was digested using XbaI and SpeI and ligated using the 3' SpeI cohesive end of the first mimic 
and the 5' XbaI cohesive end of the second thereby joining the two and destroying both sites. A 
similar strategy was used in the current body of work as follows: from the panel of 16 individual 
pCi-pri-miRNA mimics, four were selected and cloned as multimeric vectors. These included 
pCi-pri-miR31 IN, pCi-pri-miR155 Gag, pCi-pri-miR30a LTR and pCi-pri-miR122 Tat. To 
generate multimeric vectors such that each pri-miRNA mimic was cloned within each possible 
position in the combination (one to four), four sets of ‗2mers‘ were cloned (IN-Gag, Gag-LTR, 
LTR-Tat and Tat-IN) and these were then used to generate four sets of ‗4mers‘ (IN-Gag-LTR-
Tat, Gag-LTR-Tat-IN, LTR-Tat-IN-Gag and Tat-IN-Gag-LTR).  
To generate IN-Gag, pTZ-pri-miR31 IN was digested using ScaI and NheI while pTZ-pri-
miR155 Gag was digested using ScaI and SpeI as described in section 2.2.1. The two gel-
purified pri-miRNA fragments were ligated such that the NheI cohesive end of pri-miR31 IN 
recombined with the SpeI cohesive end of pri-miR155 Gag destroying both sites to generate 
pTZ-IN-Gag (Figure 25). Positive orientation clones were digested using XhoI and EcoRI, 
electrophoresed and the agarose-gel purified digestion product was directionally ligated using a 
1:1 ratio into the similarly restricted pCi-Neo vector (Promega, WI, USA) to generate pCi-pri-miR 
IN Gag as described in sections 2.2.1 and 2.2.2. The same strategy was used to clone the 
remaining 2mers and all four 4mers. 
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Figure 25. Cloning strategy used to generate multimeric polycistronic anti-HIV pri-miRNA constructs. The 
cloning of pTZ IN-Gag is depicted as an example of the steps used to generate all 2mer and 4mer 
multimeric constructs. Initially, pTZ-pri-miR31 IN (green arrow) was ScaI/NheI digested and pTZ-pri-
miR155 Gag (orange arrow) was ScaI/SpeI digested. The two pri-miRNA fragments were ligated such that 
the NheI/SpeI sticky ends recombined but destroyed both sites to generate the 2mer pTZ-IN-Gag.   
 
3.2.4 Transfection and detection of luciferase activity in cultured mammalian cells 
 
To assess the inhibitory effects of the panel of sixteen individual anti-HIV pri-miRNA mimics 
against their cognate dual luciferase-based targets, HEK293 cells (maintained as described in 
section 2.2.4) were seeded at 120 000 cells per well in 24 well dishes and transfected as in 
triplicate as described in section 2.2.5 with the following changes: cells were co-transfected with 
a combination of 90 ng of psi-Complete or psi-IN, psi-Gag, psi-LTR, psi-Tat and 900 ng of either 
pCI-Neo mock (Promega, WI, USA) or one of the 16 individual pCi-based anti-HIV pri-miRNA 
mimics or one of the pCi-based anti-HIV pri-miRNA 2mer constructs or one of the pCi-based 
anti-HIV pri-miRNA 4mer constructs. In addition, 10 ng of pCI-eGFP (Passman, Weinberg, et al., 
2000) was added per well to monitor transfection efficiency by fluorescence microscopy. As a 
positive control to measure psiCheck2-based target inhibition, triplicate wells were co-
transfected with a combination of 90 ng of psi-Complete or psi-IN, psi-Gag, psi-LTR, psi-Tat and 
900 ng of either pTZU6+1 mock (Carmona, Ely, et al., 2006), shIN, shGag, shLTR, shTat or 
shHBV [negative control, (Carmona, Ely, et al., 2006)]. In addition 10 ng of pCi-eGFP was added 
per well. Dual luciferase activity was measured using the Promega Dual Luciferase Reporter 
Assay® Kit (Promega, WI, USA) as described in section 2.2.6. 
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3.2.5 Northern blot analysis to detect processed guide sequences from anti-HIV pri-miRNA 
mimics 
 
Total RNA was extracted from HEK293 cells that had been seeded in 10 cm dishes and 
transfected with 20 μg of either one of the sixteen individual pCi-based anti-HIV pri-miRNA 
mimic constructs or one of the four pCi-based anti-HIV pri-miRNA 4mer constructs (see section 
2.2.5). Northern Blot analysis was completed as previously described (see section 2.2.7) with 
the following changes: to detect guide sequences complementary to HIV int, gag, LTR and tat 
DNA oligonucleotide probes IN (5' AAG CCG GAG AGC AAT GGC TAG T 3'), Gag (5' AAG 
GGT GCG AGA GCG TCA ATA T 3'), LTR (5' AAG TAA CTA GAG ATC CCT CAG A 3') or Tat 
(5' GCG GAG ACA GCG ACG AAG AGC TT 3') were used respectively. Hybridised blots were 
exposed for 14 days to x-ray film at -80 oC. 
  
3.2.6 Challenge assay using p24 ELISA to determine the inhibitory efficacies of multimeric 
polycistronic anti-HIV pri-miRNA mimics 
 
To investigate the inhibitory efficacies of the multimeric polycistronic anti-HIV pri-miRNA mimics 
against a wild type strain of HIV-1, a viral challenge assay was conducted in U87.CD4.CCR5 
cells using the South African R5-tropic subtype C HIV isolate FV5 as described in section 2.2.9 
with the following changes: U87.CD4.CCR5 cells were seeded at 20 000 cells per well in a 96 
well dish and transfected in triplicate using 0.25 μg of either pCi-pri-miR31 IN, pCi-pri-miR155 
Gag, pCi-pri-miR30a LTR, pCi-pri-miR122 Tat or one of the four pCi-based anti-HIV pri-miRNA 
4mer constructs or pCi-Neo mock.  
 
3.2.7 Computational and statistical analysis 
  
Computational analysis 
Sequences of endogenous pri-miRNA mimics used in this chapter were downloaded from the 
Sanger miRNA Registry database (http://microrna.sanger.ac.uk/sequences/) using the ‗miRNA 
name search‘ function with the prefix ‗hsa‘ to denote Homo sapien. For example, a search for 
the pri-miR30a sequence was completed using ‗hsa-miR30a‘ as a search keyword.  
Predicted secondary structures of anti-HIV pri-miRNA mimics were analysed using the 
RNA folding program Mfold [http://mfold.burnet.edu.au/ and (Mathews, Sabina, et al., 1999; 
Zuker, 2003)]. Sequences were uploaded in FASTA format as linear RNA with a folding 
temperature of 37 oC, 1 M NaCl ionic conditions with no divalent ions, 5 % suboptimality, an 
upper bound of 50 computed foldings, a maximum interior bulge size of 30 bp, a maximum 
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asymmetry of an interior bulge of 30 bp and no limit to the maximum distance between paired 
bases.  
 
Statistical analysis 
Data are expressed as the mean ± the standard error of the mean (SEM) and where appropriate 
are normalised to a control sample within the experiment. Statistical difference was considered 
to be significant when p < 0.05 and highly significant when p < 0.01. In all cases α = 0.99 and 
data was analysed using a one-way ANOVA followed by a Dunnett‘s Multiple Comparison post-
test calculated using GraphPad Prism (GraphPad Software Inc, USA).  
 
3.3 Results 
 
3.3.1 Analysis of the predicted secondary structures of anti-HIV pri-miRNA mimics 
 
The sequences and predicted secondary structures of four endogenous pri-miRNAs were used 
as scaffolds for the introduction of exogenous anti-HIV guide sequences with the aim of 
developing a combinatorial construct capable of simultaneously inhibiting multiple HIV mRNAs. 
The pri-miRNAs included pri-miR122, pri-miR30a, pri-miR31 and pri-miR155 while the anti-HIV 
guide sequences included those targeted against int, gag, LTR and tat. Endogenous pri-miR122 
is hepatocyte-specific  and involved in hepatic circadian rhythms (Gatfield, Le Martelot, et al., 
2009) while pri-miR31 is expressed in mesenchymal cells and controls cellular proliferation and 
adipogenesis (Sun, F, Wang, et al., 2009). Pri-miR155 is vital during haemostasis for the 
regulation of immune cell development and function (O'Connell, Chaudhuri, et al., 2009). To 
date, no specific function had been ascribed to pri-miR30a but this endogenous regulator has 
been found to occur ubiquitously in vertebrate cells (Lagos-Quintana, Rauhut, et al., 2001). 
Notably, as these pri-miRNAs function in a variety of different cells, it is unlikely that they require 
cell-specific post-transcriptional modifications to function. The sequence of each endogenous 
pri-miRNA as well as each of the sixteen anti-HIV pri-miRNA mimics was subjected to 
computational analysis using Mfold to generate their predicted secondary structures. In addition, 
as a measure of the thermodynamic stability of each predicted structure, the Gibbs free energy 
value (δG measured in kcal/mol) was recorded (Figure 26).  
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Figure 26. Predicted secondary structures and Gibbs free energy values (δG) for pri-miRNA mimics. The 
predicted secondary structure of each endogenous pri-miRNA, excluding the ss flanking regions, is 
depicted at the top of each column with guide sequences shown in red. Each endogenous guide 
sequence has been substituted with an anti-HIV guide (IN in green, Gag in orange, LTR in purple and Tat 
in pink) and the predicted secondary structures and δG values for each pri-miRNA mimic is displayed in 
columns based on the pri-miRNA backbone used. 
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The endogenous pri-miR122 backbone was predicted to form a stem-loop structure comprised 
of a 35 bp duplex with one unmatched base (position nine) but no bulges and a 13 bp loop. The 
endogenous guide sequence was predicted to span bases 15 to 37 from the 5' end of the duplex 
(Figure 26 top panel, far left column). Substitution of the endogenous guide strand with any of 
the four anti-HIV guides int, gag, LTR or tat, did not result in any changes to the predicted 
secondary structure of the pri-miR122 backbone. The duplex stem regions and loops of all four 
anti-HIV pri-miR122-based mimics closely resembled that of the endogenous backbone and the 
anti-HIV guide sequences were predicted to span the same bases as the endogenous guide. 
The δG values for two of the pri-miRNA122-based mimics (pri-miRNAs 122 IN and LTR) were 
slightly higher than that of the endogenous backbone (-45.90 kcal/mol and -42.90 kcal/mol 
respectively vs. -48.60 kcal/mol) suggesting that the predicted secondary structures of these two 
mimics were energetically less favourable than the endogenous scaffold.  
 A similar set of results was obtained for pri-miR155-based mimics. The endogenous pri-
miR155 backbone was predicted to form a 30 bp duplex structure with two unmatched bases 
(positions 15 and 19), one bulge (positions 27 to 29) and a six bp loop. The endogenous guide 
sequence was predicted to span bases 4 to 26 from the 5' end of the duplex (Figure 26 top 
panel, second column from the left). Substitution of the endogenous guide strand with any of the 
four anti-HIV guides int, gag, LTR or tat, resulted in minor changes to the predicted secondary 
structure of the pri-miR155 backbone. The duplex stem regions and loops of all four anti-HIV pri-
miR155-based mimics closely resembled that of the endogenous backbone and the anti-HIV 
guide sequences were predicted to span the same bases as the endogenous guide. However, 
the predicted structures of pri-miRNAs 155 IN and Gag showed a second unmatched base at 
position 20 as opposed to 19. Overall, the δG values for all four anti-HIV mimics were lower than 
that of the endogenous backbone suggesting that the predicted secondary structures of the 
mimics were energetically more favourable than the endogenous scaffold.  
 The endogenous pri-miR30a backbone was predicted to form a 30 bp duplex structure 
with two unmatched bases (positions 18 and 19) and an unusual loop-stem-loop structure 
(positions 31 to 47). Unlike the other three pri-miRNAs, the endogenous guide sequence of pri-
miR30a was predicted to span bases 48 to 69 from the 5' end of the duplex such that the guide 
was produced from the 3' arm of the structure (Figure 26 top panel, third column from the left). 
Substitution of the endogenous guide strand with anti-HIV guides int or tat, did not result in any 
changes to the predicted secondary structure of the pri-miR30a backbone and the δG values for 
these two mimics were lower than that of the endogenous scaffold (-44.70 kcal/mol and -45.50 
kcal/mol respectively vs. -38.30 kcal/mol). Substitution of the endogenous guide strand with the 
anti-HIV gag guide resulted in an unmatched base at position 30 that shifted the guide sequence 
into the loop. Interestingly, the δG value for this mimic was the lowest for all pri-miR30a-based 
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mimics (-46.80 kcal/mol) suggesting it was the most thermodynamically stable secondary 
structure for this set of scaffolds. Substitution of the endogenous guide strand with the anti-HIV 
LTR guide resulted in a δG value almost exactly the same as the endogenous scaffold (-38.90 
kcal/mol vs. -38.30 kcal/mol respectively) but the overall predicted shape of pri-miR30a LTR 
resembled the predicted endogenous structure the least. The duplex region of pri-miR30a LTR 
contained no unmatched bases and the stem-loop-stem structure spanned bases 24 to 50 with 
an additional bulge present at bases 27 and 28. Furthermore, while the LTR guide was predicted 
to span the same bases as the endogenous sequence (positions 48 to 69) the rearranged stem-
loop-stem structure caused the LTR guide to be present within the loop region.   
 The endogenous pri-miR31 backbone was predicted to form a 31 bp duplex structure 
with one bulge at position 28 and a nine bp loop (positions 31 to 40). The endogenous guide 
sequence was predicted to span bases 9 to 29 from the 5' end of the duplex (Figure 26 top 
panel, far right column). Substitution of the endogenous guide strand with any of the anti-HIV int, 
gag, LTR or tat, resulted in significant changes to the predicted secondary structure of the pri-
miR31 backbone such that the mimics closely resembled each other in shape but not the 
endogenous scaffold. All four pri-miR31-based mimics were predicted to form a 27 bp duplex 
with no bulges and a loop-loop structure at positions 28 to 45. In addition, while the anti-HIV 
guides were predicted to span the same bases as the endogenous sequence (positions 9 to 29) 
the rearranged loop-loop structure caused the guides to be present within the loop region. 
Overall, the δG values for all four pri-miR31-based mimics were higher than that of the 
endogenous backbone suggesting that the predicted secondary structures of the mimics were 
energetically less favourable than the endogenous scaffold. 
Importantly, as programs such as Mfold provide predicted secondary structures for RNA 
sequences, no functional data could be extrapolated. The data described in Figure 26 suggested 
that substitution of the endogenous guide sequences of four discrete pri-miRNA backbones with 
anti-HIV guides resulted in mimics whose predicted structures were generally a close fit to their 
endogenous counterparts. However, to assess the functional consequences of substituting the 
endogenous guide sequence of the various pri-miRNA backbones and the abilities of the 
different scaffolds to generate efficacious anti-HIV siRNAs, a luciferase-based assay was 
completed.  
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3.3.2 Inhibitory efficacies of individual anti-HIV pri-miRNA mimics targeted to a luciferase 
reporter to assess the ability of different pri-miRNA backbones to generate functional guide 
sequences 
 
To determine the ability of each pri-miRNA scaffold to generate functional anti-HIV guide 
sequences, each of the anti-HIV pri-miRNA mimics was cloned into a mammalian expression 
vector under the control of a CMV promoter. The transcribed cassettes folded into pri-miRNAs 
with ds duplex regions comprising 5' and 3' arms connected by a loop and two ss flanking 
regions (Figure 27). To investigate the inhibitory efficacies of anti-HIV guide sequences when 
expressed from discrete pri-miRNA backbones, a dual luciferase-based target vector that 
encoded a complementary target sequence for each anti-HIV guide (int, gag, LTR and tat) was 
co-transfected with each of the individual modified pCi-pri-miRNA mimics. In addition, each of 
the shRNAs (IN, Gag, LTR and Tat), a non-specific shRNA targeted to HBV, as well as an empty 
vector were included as controls.  
 
 
 
 
 
 
 
 
 
 
Figure 27. Design of expressed anti-HIV pri-miRNA cassettes. Pol II (CMV) cassettes were generated 
using a two step PCR approach such that transcribed pri-miRNA mimics folded to form a ds duplex 
structure comprising 5' and 3' arms connected by a loop and two ss flanking regions. The entire folded pri-
miRNA was ~118 bp.  
 
 
Luciferase data analysed 48 hours post-transfection revealed an interesting pattern of inhibition 
(Figure 28). Overall, all 16 individual anti-HIV pri-miRNA mimics showed highly significant 
inhibition of the target vector as compared to the mock (α = 0.99; p < 0.01) although the total 
percentage suppression varied between the different pri-miRNA backbones. Interestingly, three 
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of the four sets of mimics (pri-miRNAs 122, 30a and 155) showed similar levels of target 
inhibition regardless of the guide sequence present. Pri-miR122-based mimics consistently 
showed the least overall target inhibition with an average suppression level of 45.00 % ± 2.18 %. 
In contrast, pri-miR30a yielded highly potent anti-HIV guide sequences from all 4 scaffolds with 
inhibitory levels comparable to the shRNA controls that had been chosen based on their potent 
suppressive efficacies. From the entire panel of 16 mimics, pCi-pri-miR30a LTR mediated the 
greatest overall inhibition of psi-Complete with 94.00 % ± 0.01 % suppression. Similarly to the 
pri-miR30a-based scaffolds, potent inhibition of psi-Complete was mediated by all 4 anti-HIV pri-
miR155-based scaffolds with pCi-pri-miR155 IN and Gag suppressing their targets to the same 
degree as the corresponding pri-miR30a mimics. pCi-pri-miR155 LTR mediated the poorest 
suppression for this set but the level was highly significant at 73.33 % ± 1.16 %. In contrast, 
target inhibition mediated by the pri-miR31 scaffolds varied depending on the guide sequence 
present with pCi-pri-miR31 IN showing the most (64.33 % ± 0.01 %) and pCi-pri-miR31 Tat 
showing the least (16.67 % ± 3.51 %) suppression for this set of backbones. This latter construct 
mediated the worst target suppression out of the entire panel of 16 mimics.  
Intriguingly, the suppression data seemed to correlate with the predicted secondary 
structures for three out of the four sets of mimics (refer to Figure 26). The anti-HIV pri-miR122 
and 155-based mimics showed the ‗closest fit‘ overall to their relative endogenous scaffolds and 
both sets of mimics generated comparable target inhibition levels regardless of the guide 
sequence present. Similarly, pri-miR30-based mimics mediated highly significant inhibition with 
all four guide sequences and were predicted to fold into secondary conformations that closely 
resembled the endogenous scaffold with the exception of pri-miR30a LTR. The predicted shape 
of this mimic was the ‗least likely fit‘ as compared to the endogenous backbone and yet this 
mimic mediated the greatest percentage of luciferase inhibition out of the entire panel of 16 
mimics. Pri-miR31-based mimics showed a different trend for both their predicted secondary 
structures and inhibitory levels. None of the four anti-HIV pri-miR31-based mimics were 
predicted to fold into a structure that closely resembled the endogenous scaffold and the 
inhibition mediated by each of the mimics differed depending on the guide sequence present.  
Taken together, these data suggested that the pattern of inhibition was the same for 
each scaffold regardless of the guide sequence present if the folding parameters were as close 
to the endogenous backbone as possible. Pri-miR31 was the exception and the data for this 
scaffold suggested that the guide sequence itself was the main predictor of inhibitory efficacy.   
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Figure 28. Inhibitory efficacies of individual anti-HIV pri-miRNA 
mimics targeted to a reporter vector containing each of 4 HIV 
targets. Target sequences for HIV int, gag, LTR and tat were 
cloned into a dual luciferase-based vector to generate psi-
Complete that was co-transfected with each of the individual 
anti-HIV pri-miRNA mimics (blue bars) in HEK293 cells. 
Luciferase data measured 48 hours post-transfection revealed 
that anti-HIV guide sequence efficacy depended on the pri-
miRNA scaffold used. Data are expressed as a ratio of hRluc to 
hFluc normalised to an empty vector control (mock – red bars; 
n = 3, ± SEM). A), B), C) and D) depict knockdown mediated by 
pri-miR122, pri-miR30a, pri-miR31 and pri-miR155-based 
mimics respectively. E) depicts knockdown mediated by shRNAs 
controls. 
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3.3.3 The design and construction of multimeric polycistronic anti-HIV pri-miRNA mimics  
 
To develop a combinatorial RNAi system based on anti-HIV pri-miRNAs, the relationship 
between pri-miRNA scaffold and guide sequence efficacy was investigated. The data described 
in section 3.3.2 revealed that the same anti-HIV guide sequence could mediate varying levels of 
target inhibition depending on the pri-miRNA scaffold it was processed from. To avoid possible 
recombination events that could excise one or more of the pri-miRNA members within a 
combinatorial system, a representative scaffold from each of the four backbones was included. 
However, as there was no obvious trend for which guide sequence/pri-miRNA scaffold ‗pair‘ 
induced the greatest target suppression, the following mimics were chosen to generate a Pol II-
expressed multimeric system: pri-miR122 Tat, pri-miR30a LTR, pri-miR31 IN and pri-miR155 
Gag.  
To investigate if the position of an individual anti-HIV pri-miRNA mimic within the 
multimeric system affected the guide sequence efficacy, each individual pri-miRNA mimic was 
cloned such that it occupied either the first, second, third or fourth position within the multimer 
relative to the Pol II (CMV) promoter. To achieve this, each of the individual anti-HIV pri-miRNA 
mimics were cloned in tandem to generate a set of 2mers with each mimic cloned in both the 
first and second position within each vector (Figure 29A). The 2mers were then directionally 
cloned in tandem to generate a set of 4mers with each 2mer pair cloned in both the first and 
second position within each vector. This generated a total of four 2mers and four 4mers each 
expressed off a single CMV promoter (Figure 29B). 
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Figure 29. Generation of a panel of multimeric anti-HIV pri-miRNA mimics using pri-miR122 Tat, pri-
miR30a LTR, pri-miR31 IN and pri-miR155 Gag. A) Single pri-miRNA mimics were directionally cloned in 
tandem to generate a set of 2mers with each mimic cloned in the 1
st
 and 2
nd
 position relative to the CMV 
promoter within each vector. B) The 2mers were directionally cloned in tandem to generate a set of 4mers 
with each 2mer pair cloned in the 1
st
 and 2
nd
 position relative to the CMV promoter within each vector. 
This generated a set of four 2mers and four 4mers each expressed off a single CMV promoter (red 
arrows).  
 
3.3.4 Inhibitory efficacies of multimeric polycistronic anti-HIV pri-miRNA mimics targeted to 
individual luciferase-based HIV target reporter vectors 
 
To assess target knockdown induced by each of the multimeric polycistronic anti-HIV pri-miRNA 
mimics, a set of dual luciferase target vectors was generated. The sequence for each of the HIV 
targets (int, gag, LTR and tat) was individually cloned within the 3‘ UTR of hRluc of psiCheck2 to 
generate psi-IN, psi-Gag, psi-LTR and psi-Tat. Each target vector was co-transfected with one of 
the multimeric pri-miRNA constructs or an empty vector control (mock) and luciferase data was 
collected 48 hours post-transfection.  
When co-transfected with psi-IN, psi-Gag or psi-Tat, all four pri-miRNA mimic constructs 
mediated highly significant inhibition of each target vector (α = 0.99; p < 0.01) with an average 
percentage inhibition of 91.33 % ± 0.03 % which was comparable to that of the shRNA controls 
(95.25 % ± 0.01 % and Figure 30). Furthermore, there was no significant difference between 
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each of the 4mers regardless of the target construct (p > 0.05) suggesting that the position of the 
individual pri-miRNA mimic within the multimer did not affect guide sequence efficacy.  
The 2mer constructs that contained target-specific guide sequences mediated highly 
significant suppression (α = 0.99; p < 0.01) with the exception of pCi-LTR-Tat. Sequencing 
analysis of this construct revealed 10 mismatches within the LTR guide sequence of this mimic 
that had been introduced during the cloning process (see Appendix A3.3). These data reinforced 
the need for complementarity between the guide sequence and its cognate target. Notably this 
clone had not been used to generate the 4mer constructs and so the mismatches were limited to 
the 2mer. In contrast to the other HIV targets, inhibition of psi-Tat was poor regardless of the pri-
miRNA mimic used. One of the 2mers (pCi-Tat-IN) and three of the 4mers mediated highly 
significant inhibition of psi-Tat (α = 0.99; p < 0.01) although the greatest suppression was only 
55.33 % ± 1.53 % (pCi-LTR-Tat-IN-Gag). Sequence analysis revealed 11 mismatches within the 
Tat guide sequence of pCi-LTR-Tat that had been introduced during the cloning process (see 
Appendix A3.3) but this clone had not been used to generate the 4mers and thus the reasons for 
the poor knockdown mediated by the latter mimics were unclear.  
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Figure 30. Multimeric anti-HIV pri-miRNA mimics targeted to individual HIV targets. Four HIV target sites, 
int, gag, LTR and tat were individually cloned within the 3' UTR of hRluc in the psiCheck2 dual luciferase 
vector to generate psi-IN, psi-Gag, psi-LTR and psi-Tat respectively. The target vectors were co-
transfected into HEK293 cells with an empty vector control (mock – red bars), one of the 2mer (purple 
bars) or 4mer (green bars) multimeric anti-HIV pri-miRNA mimics. In addition, target-specific shRNAs 
(blue bars) were co-transfected along with a shRNA-specific mock (dark red bars). Data are expressed as 
a ratio of hRluc to hFluc normalised to the mock (n = 3, ± SEM). A), B), C) and D) depict knockdown of 
psi-IN, psi-Gag, psi-LTR and psi-Tat respectively.   
 
 
3.3.5 Northern blot analysis of anti-HIV pri-miRNA mimics to determine guide sequence  
 
The luciferase-based reporter assays described in sections 3.3.2 and 3.3.4 demonstrated that 
the inhibitory efficacies of four separate anti-HIV guide sequences depended on the pri-miRNA 
scaffold from which they were expressed. To determine if this variation was linked to guide 
sequence production, Northern blot analysis was completed on all single and polycistronic 
(4mer) pri-miRNA mimics. An empty vector control (mock) as well as a target-specific shRNA 
was included in each of four blots that were probed using radio-labelled oligonucleotides specific 
to the IN, Gag, LTR and Tat guide sequences.  
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In each blot, the shRNA controls (last lane of each blot) were detected indicating that the 
guide-specific probes were able to bind their target sequences and that the Northern blots had 
been successful (Figure 31). In addition, the mock-treated samples were not detected (first lane 
of each blot) suggesting that the probe sequences were specific to their complementary targets 
and not non-specific miRNAs or other small RNAs. When using the IN probe, a precursor and 
guide sequence was detected for the single pCi-pri-miR30a IN construct only (Figure 31A, 3rd 
lane). In addition, the guide sequence was very faint despite 14 days of exposure suggesting 
that a lower concentration of functional guide was produced as compared to the precursor. No 
other sequences were detected for any of the remaining IN-based single pri-miRNA mimics or 
the 4mer constructs. A similar pattern was observed for blots probed with LTR and Tat-specific 
oligonucleotides (Figure 31C and D, 3rd lanes). Precursor and guide sequences were detected 
for single pri-miR30a-based mimics only, with less guide sequence detected as compared to the 
precursors. In contrast, the Gag-specific probe detected processed precursor and guide 
sequences for pCi-pri-miR30a Gag as well as guide sequence only for pCi-pri-miR155 Gag 
(Figure 31B, 3rd and 5th lanes respectively). This latter construct showed a higher concentration 
of guide as compared to pCi-pri-miR30a Gag although no precursor was detected. Furthermore, 
precursor and guide sequences were observed for all four 4mers using the Gag probe.  
Intriguingly, the Northern blot data seemed to correlate with the luciferase-based 
suppression data (refer back to Figures 28 and 30). All 4 individual pri-miR30a-based mimics 
showed the greatest luciferase reporter suppression regardless of the guide sequence present 
(Figure 28B) and both precursor and guide strands were detected for all 4 of these constructs 
using radio-labelled probes (3rd lane of all 4 Northern blots in Figure 31). Similarly, pCi-pri-
miR155 Gag mediated the greatest percentage inhibition of psi-Complete for this set of mimics 
(Figure 28D) and a strong guide sequence signal was detected by Northern blot (5th lane of 
Figure 31B). No precursor or guide sequences were detected for any of the remaining individual 
anti-HIV pri-miRNA mimics and, with the exception of the pri-miR155-based mimic set, none of 
the others mediated highly suppressive target inhibition. This strongly suggests that the amount 
of guide produced by the pri-miR122- and pri-miR31-based mimics was below the limit of 
detection of the Northern blot assay. The reasons for the absence of detectable guide sequence 
from pCi-pri-miRNAs 155 IN, LTR and Tat was unclear as these three constructs had mediated 
highly significant target inhibition albeit at lower levels as compared to pCi-pri-miR155 Gag. This 
latter construct was a component of the 4mer constructs and interestingly, only the Gag-specific 
radio-labelled probe was able to detect guide sequences for any the 4mers (Figure 31B right 
hand panel). This observation did not correlate with the luciferase data (Figure 30) as all four 
4mer constructs mediated highly significant inhibition of all four HIV target reporter vectors. 
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Figure 31. Northern blot analysis to detect putative guide sequences produced from expressed anti-HIV 
pri-miRNA mimics. Four ssDNA oligonucleotide probes targeted to HIV int (A), gag (B), LTR (C) and tat 
(D) as well as a U6 snRNA probe were hybridised to RNA extracted from HEK293 cells transfected with 
either single or combinatorial (4mer) pri-miRNA mimics.  
 
 
3.3.6 Suppression of HIV replication using combinatorial anti-HIV pri-miRNA mimics 
 
The main aim of testing numerous pri-miRNA scaffolds for the ability to produce highly 
efficacious exogenous guide sequences was to generate a combinatorial polycistronic pri-
miRNA system with the capability of simultaneously and potently inhibiting four different HIV 
mRNAs. While all four polycistronic pri-miRNA constructs were highly effective suppressors of 
luciferase-based targets, an important and biologically relevant assay required the use of a fully 
replicative wild type HIV genome. Thus the HIV subtype C isolate FV5 provided a unique 
opportunity to evaluate the antiviral efficacies of all four combinatorial pri-miRNA mimics against 
a pool of target sequences akin to the conditions in a natural HIV infection. U87.CD4.R5 
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fibroblasts were transfected with either an empty vector control (mock) or one of the four 
polycistronic anti-HIV pri-miRNA mimics (4mers) before being challenged with FV5 using a 
TCID50 of 1000/mL . For comparison, the single anti-HIV pri-miRNA mimics that had been used 
to generate the multimeric units were included and inhibition of HIV was assessed seven days 
post-infection by determining p24 antigen levels.  
Cells that received pCi-pri-miR31 IN or pCi-pri-miR122 Tat showed significant differences 
when compared to mock-treated samples (α = 0.99; p < 0.05) but the levels of suppression were 
poor at 29.37 % ± 1.44 % and 29.70 % ± 0.27 % respectively (Figure 32). Cells transfected with 
pCi-pri-miR155 Gag or pCi-pri-miR30a LTR showed highly significant inhibition (α = 0.99;           
p < 0.01) with 98.03 % ± 0.11 % and 98.50 % ± 0.01 % knockdown respectively. As previously 
noted, these two mimics were the only single anti-HIV pri-miRNAs for which guide sequences 
had been detected via Northern blot analysis (see section 3.3.4). Three of the four 4mers 
mediated highly significant suppression of FV5 (α = 0.99; p < 0.01) with only one 4mer, pCi-IN-
Gag-LTR-Tat showing no target inhibition (p > 0.05). The average percentage inhibition for the 
efficacious 4mers was 91.91 % ± 1.39 % with pCi-Tat-LTR-IN-Gag mediating the greatest 
suppression at 98.37 % ± 0.01 %. Although the use of single mimics is not recommended long-
term, these data provided very promising proof-of-principle results that both single and 
multimeric pri-miRNA mimics were able to inhibit multiple replication cycles of a subtype C HIV 
isolate up to seven days post-transfection.   
 
 
 
 
 
 
 
 
 
 
Figure 32. Challenge assay to assess combinatorial anti-HIV pri-miRNA mimics against a subtype C viral 
isolate of HIV. All 4 polycistronic pri-miRNA mimics (blue bars), the single anti-HIV pri-miRNA mimics used 
to generate the combinatorial constructs as well as an empty vector control (mock – red bar) were 
transfected into U87.CD4.R5 cells prior to challenge with viral isolate FV5 at a TCID50 of 1000/mL. Viral 
Gag p24 antigen levels were determined 4 days post-infection by ELISA (450 nm). Values were converted 
to ng/mL using a standard curve supplied with the ELISA kit and data are expressed as p24 antigen levels 
in ng/mL (n = 3, ± SEM).  
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3.4 Discussion and conclusions 
 
The generation of a combinatorial pri-miRNA mimic construct relies on the use of different 
backbones to ensure that the overall potency of the system is not lessened through 
recombination events that delete one or more of the scaffolds. However, the choice of which pri-
miRNA backbones to include in such a system has been confined by the limited data available 
describing the abilities of pri-miRNA scaffolds to produce exogenous guides. In addition, once 
highly efficacious single pri-miRNA scaffolds have been chosen, the order in which to combine 
them to ensure that potent guides are produced from each mimic had not been thoroughly 
investigated. To address these issues, 16 individual pri-miRNAs encoding one of four 
exogenous guide sequences known to be highly efficacious against HIV were designed and their 
abilities to generate discrete, potent anti-HIV guides were compared. Furthermore, various 
combinations of the most efficacious scaffolds were examined thereby providing valuable data 
relating to the generation of expressed combinatorial pri-miRNA systems.  
Replacement of the endogenous guide strand within pri-miR31 resulted in a set of 
mimics that differed significantly in both shape and thermodynamic stability as compared to the 
endogenous scaffold (Figure 26) and this set of constructs mediated varying levels of inhibition 
depending on the guide sequence present (Figure 28). In contrast, the remaining scaffolds (pri-
miRNAs 122, 30a and 155) resulted in mimics that resembled the endogenous backbone both in 
shape and thermodynamic stability (Figure 26) and these constructs mediated similar levels of 
inhibition with all four anti-HIV guides (Figure 28). These data strongly suggested that the 
pattern of target inhibition was the same for each pri-miRNA mimic regardless of the guide 
sequence present as long as the folding parameters of the mimic closely resembled those of the 
endogenous scaffold. Of particular note, pri-miR30a-based mimics mediated the greatest levels 
of target suppression with all four anti-HIV guides at levels comparable to the shRNA controls 
(Figure 28B). The notable difference between this scaffold and the remaining three was that 
guide sequences were predominantly expressed from the 3' arm of pri-miR30a backbones 
(Figure 26 second panel from left). Drosha defines the 5' end of the mature miRNA by cleaving 
11 bp from the ss/ds junction of a pri-miRNA (Zeng and Cullen, 2005; Han, Lee, et al., 2006). 
Should the cleavage site be altered by even a few bases, 5' dominant guide sequences would 
be negatively affected as the cleavage point may occur within the seed region. However, 3' 
dominant guides would be less affected as Drosha cleavage defines the 3' end of these miRNAs 
(see Figure 10). As different anti-HIV guide strands mediated varying levels of inhibition 
depending on the pri-miRNA backbone from which they were processed (Figure 28), guide 
sequence efficacy seems to be partly dependent on the pri-miRNA scaffold. All 4 anti-HIV 
guides had been selected based on their potencies when expressed from shRNA backgrounds 
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yet comparable levels of target suppression were only mediated when the guides were 
expressed from pri-miRNA 30a and 155 backbones (Figure 28). This was intriguing as pri-
miRNAs 122 and 31 had been selected based on previous data that showed potent exogenous 
guides were produced from these 2 scaffolds  (Ely, Naidoo, et al., 2008). Dosage may have 
played a role but increased concentrations of the latter two mimics did not improve their 
inhibitory efficacies or the ability to detect putative guide sequences by Northern blot (data no 
shown). This suggested that certain pri-miRNA backbones may be poor mimic scaffolds 
although the reasons for the discrepancies between the current body of work and that of Ely et 
al remain unclear.  
The position of each individual pri-miRNA mimic within the polycistronic system did not 
affect the guide sequence efficacy when targeted to luciferase-based target vectors (Figure 30) 
suggesting that all four pri-miRNA components were effectively processed by Drosha and Dicer. 
The spacing between each component in the multimeric constructs had not been altered 
although the complete ~100 bases of ss flanking regions for each individual scaffold were 
included (~50 bases in the 5' flank and ~50 bases in the 3' flank). This was similar to the ~102 
bases of flanking region incorporated in combinatorial HBV-specific pri-miRNA mimics that were 
shown to be highly efficacious against all three HBV target mRNAs (Ely, Naidoo, et al., 2009). 
However, Drosha recognises a 33 bp stem as well as the ss/ds junction (Zeng and Cullen, 2005; 
Han, Lee, et al., 2006) suggesting that the flanking regions could be altered. The reasons for the 
lack of inhibition mediated by all four polycistronic systems against the psi-Tat target vector was 
unclear as sequence analysis did not reveal mutations within these constructs (data not shown). 
Furthermore, sequence analysis and the observation that the shTat control mediated highly 
significant target suppression suggested that the psi-Tat construct did not contain any mutations. 
Despite these data, the inhibition by all four polycistronic systems against the remaining three 
targets provided proof-of-concept data that the multimeric pri-miRNA constructs were effective.  
Importantly, the inhibitory efficacies of the individual pri-miRNA mimics could be 
dramatically enhanced when cloned as part of a combinatorial system suggesting that the 
suppressive effect was additive. This has implications for the treatment of wild type HIV as 
ideally each component of the system should present a formidable resistance barrier to the virus 
and if one mimic is producing sub-optimal concentrations of guide sequence, this may provide 
an escape route. Indeed, the Northern blot analysis described in section 3.3.5 suggested that 
pri-miRNA backbones produced more guide sequence when expressed from individual mimics 
as the concentration of guides produced from combinatorial mimics was undetectable. 
Interestingly, very faint or no guide sequence signals were detected using radio-labelled probes 
for either of these mimics (Ely, Naidoo, et al., 2008) lending support to the data described in 
section 3.3.5 of this chapter. However, while the majority of multimeric pri-miRNA mimics 
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described here mediated highly significant inhibition of a wild type HIV isolate (see section 
3.3.6), more work is needed to understand the role and contribution of each processed siRNA 
within the combinatorial scaffold. 
The data presented in this chapter were supported by two studies published concurrently 
to this work that described the manipulation of innate polycistronic pri-miRNAs to express 
multiple guide sequences targeted to HIV (Aagaard, Zhang, et al., 2008; Liu, Haasnoot, et al., 
2008). The first study replaced four guides within a CMV-expressed polycistonic cluster of 6 pri-
miRNAs (pri-miR17-92) and targeted separate sites (int, gag, pol and tat/rev) within HIV (Liu, 
Haasnoot, et al., 2008). To generate an effective anti-HIV polycistonic pri-miRNA construct, the 
authors initially developed an optimal pri-miRNA construct by varying the length (19 to 23 bp) 
and position (5' arm vs. 3' arm) of an anti-HIV guide sequence within two separate pre-miRNA 
backbones based on pri-miRNAs from the polycistron. The inhibition mediated by the different 
pre-miRNA mimics showed that guide sequences of 19 bp processed from the 5' arm of the pre-
miRNA were the most efficacious and these were constructed into multimers of two, four or six 
anti-HIV pri-miRNAs. Similarly to the results described in section 3.3.4, the position of the single 
pri-miRNA mimic within the polycistronic unit did not affect guide sequence efficacy. Furthermore 
the inhibitory efficacies of single pri-miRNA mimics could be dramatically enhanced when cloned 
as part of a combinatorial system. Interestingly, when targeted to a molecular infectious clone of 
HIV (pLAI), the majority of the single pri-miRNA mimics and one of the 2mer constructs were 
poorly efficacious. The remaining 2mers, 3mer and 4mer constructs were all significantly active 
but in contrast to the data described in section 3.3.5 using FV5, the inhibition was measured two 
days post-infection and the assay was not completed on a wild type isolate of HIV. In a separate 
assay, stable cells that expressed single anti-HIV pri-miRNA constructs showed resistance 
mutants six days post-infection while cells that expressed a 4mer maintained suppression levels 
similar to the mock although not as great as that of a shRNA control. In the second study all 
three guides within an endogenous tri-cistronic pri-miRNA cluster (pri-miR106b, pri-miR-93 and 
pri-miR-25) were substituted with anti-HIV sequences targeted to the tat/rev overlapping ORF 
(Aagaard, Zhang, et al., 2008). Initially, two versions of the endogenous pri-miRNA cluster were 
assessed – one that included the exonic sequences and one that did not, but no differences 
were observed in the inhibitory efficacies between these two suggesting that the exonic 
sequences did not enhance activity. To substitute in anti-HIV guide sequences, each entire 
endogenous pri-miRNA within the cluster was replaced with stem-loop structures specific to HIV. 
While this provided a modular system that could be readily manipulated to introduce any stem-
loop sequence of choice, the hybrid construct was not a pri-miRNA multimer. Inhibition data 
using a luciferase target reporter showed that two of the three guide sequences were highly 
efficacious while the third was poorly processed and thus did not mediate significant 
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suppression. This could be marginally improved if the ss/ds junctions of the pri-miRNA 
backbones were re-introduced and the guide sequence was substituted for the natural guide 
within the endogenous backbone. Despite these changes, when targeted to two HIV infectious 
molecular clones (pHIV-IIIB and pLAI), repression was poor and significant inhibition was only 
achieved when a TAR RNA decoy was included in the combinatorial strategy. Thus this study 
represented a combinatorial RNAi approach comprising pre-miRNA mimics and a TAR decoy 
and not a combinatorial pri-miRNA study as suggested.  
In conclusion, the pri-miRNA mimics described in this chapter were capable of 
expressing potent anti-HIV guide sequences although subsequent inhibition depended on the 
endogenous pri-miRNA scaffold used. New data has been provided regarding the construction 
of a modular combinatorial pri-miRNA-based system that can mediate highly significant 
suppression of a wild type isolate of HIV at four different target sites. Taken together, these data 
have provided a foundation for future investigation into combinatorial RNAi using an expressed 
system that can be linked to a tissue-specific promoter to provide stable, long-term gene 
suppression. Additional data is required to further understand how these mimics can be 
designed to ensure consistent and potent guide sequence production such that viral escape no 
longer causes treatment failure. Studies that explore different pri-miRNA backbones to those 
described in this chapter may provide additional examples of scaffolds that could be included in 
modular combinatorial systems. Investigations into the role of splicing in combinatorial pri-
miRNA mimics may shed light on design criteria that could improve pri-miRNA mimic 
processing. For example, would the incorporation of splice donor/acceptor sites within the 
flanking regions of adjacent pri-miRNA mimics affect the overall processivity of the combinatorial 
system? In addition, data that describes the use of inducible or tissue-specific Pol II-driven pri-
miRNA mimics would be valued. Finally, the delivery of combinatorial pri-miRNA mimics to target 
cells of interest remains to be elucidated and needs to be thoroughly tested before these 
constructs can be introduced into patients.  
An additional mechanism that could be employed to enhance the overall post-
transcriptional silencing effect of a combinatorial pri-miRNA system is the use of small RNAs 
such as siRNAs to induce a transcriptional silencing effect. Although highly experimental, ideally 
this would result in permanent silencing of the viral LTR promoter thereby limiting the chance for 
viral escape through spikes in transcription of proviral DNA. As the possibility of silencing the 
LTR of HIV has only briefly been investigated, data that explores numerous sites within the LTR 
for siRNA susceptibility would be of great value. 
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Chapter four: promoter targeted RNAs can modulate indiscriminate off-target gene activation 
 
 
4.1 Introduction 
 
The data in the previous two chapters described novel combinatorial RNAi based strategies 
designed to inhibit sequences within the HIV LTR specifically at the post-transcriptional level. 
Transcriptional gene silencing of promoters has also been described although the majority of 
work to date has been conducted in yeast (Schizosaccharomyces pombe), worms 
(Caenorhabditis elegans) and plants (Arabidopsis thaliana) [reviewed in (Hawkins and Morris 
2008; Morris 2009)]. The mechanism of TGS in mammalian cells is a result of RNA directed 
methylation of histones and DNA at the targeted promoter although the latter observation is not 
a conserved feature in all cases (Morris, Chan et al. 2004; Castanotto, Tommasi et al. 2005; 
Kim, Villeneuve et al. 2006; Han, Kim et al. 2007). In an effort to prolong RNAi-mediated 
silencing of HIV, Suzuki et al targeted siRNAs to conserved tandem NF-κβ sites within the viral 
LTR (Suzuki, Shijuuku et al. 2005; Suzuki, Juelich et al. 2008). Significant long-term (30 days) 
inhibition of HIV that correlated with the extent of de novo methylation of the LTR was observed 
and similar TGS data was described for siRNAs targeted to the 5' LTR of SIV (Lim, Suzuki et al. 
2008). While these studies demonstrated that HIV was susceptible to TGS, little data was 
available describing the regions within the LTR that could be targeted. One site within the HIV 
promoter, designated ‗247‘ (located at positions 249–267 of the HXB2 molecular clone 
sequence, GenBank® accession number K03455) was susceptible to TGS but the silencing 
effect was shown to be directed by the antisense (as) strand alone (Weinberg, Villeneuve et al. 
2006). Specifically, 21 nt asRNAs mediated a 2.8 fold greater suppression of target site 247 as 
compared to a double stranded (siRNA) counterpart. Additional data revealed that the effect was 
as a result of low-copy promoter-associated RNAs that are recognised by the antisense strand 
and function as a binding site for epigenetic silencing complexes (Han, Kim et al. 2007).  
In this chapter, to further investigate the effects of 21 nt asRNAs in TGS, and to define 
additional asRNAs that target the HIV-1 LTR promoter, RNA Pol III (U6)-expressed asRNA 
constructs were generated that span ~ 50 bp up- and downstream of target site 247 (Weinberg, 
Villeneuve et al. 2006). A total of ten asRNAs (including as247) were assessed for their abilities 
to induce TGS when targeted to subtype B luciferase-based reporter constructs.  Interestingly, 
one of the asRNAs that targeted seven bp downstream of site 247 seemed to induce a gene 
activation effect. The site correlated with a gene of unknown function (C10orf76) and microarray 
as well as chromatin immunoprecipitation (ChIP) analysis was conducted to investigate the 
observed activation effect.   
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4.2 Materials and methods 
 
4.2.1 Cloning of expressed asRNAs targeted to site 247 and its flanking regions within the U3 
region of a subtype B HIV LTR 
 
To generate asRNAs targeted to site 247 in the HIV LTR as well as regions that span 50 bp up 
and downstream, PCR was carried out using a universal U6 Forward primer containing a SpeI 
restriction site (5' CTA ACT AGT GGC GCG CCA AGG TCG GGC AGG AAG AGG G 3', the 
SpeI site is underlined) and the following reverse oligonucleotide primers: LTR-247s+7 (5' AAA 
AAA GAG TGG AGG TTT GAC AGC CCG GTG TTT CGT CCT TTC CAC AA 3'), LTR-247s+13 
(5' AAA AAA GGT TTG ACA GCC GCC TAG CGG TGT TTC GTC CTT TCC ACA A 3'), LTR-
247s+19 (5' AAA AAA GAC AGC CGC CTA GCA TTT CCG GTG TTT CGT CCT TTC CAC AA 
3'), LTR-247s-7 (5' AAA AAA GAG AGA AGT GTT AGA GTG GCG GTG TTT CGT CCT TTC 
CAC AA 3'), LTR-247s-14 (5' AAA AAA ACC CTG AGA GAG AAG TGT TCG GTG TTT CGT 
CCT TTC CAC AA 3'), LTR-247s-21 (5' AAA AAA ATG GAT GAC CCT GAG AGA GCG GTG 
TTT CGT CCT TTC CAC AA 3'),LTR-247s-1/+19 (5' AAA AAA ATG GAT GAC CCT GAG AGA 
GAA GTG TTA GAG TGG AGG TTT GAC AGC CGC CTA GCA TTT CCG GTG TTT CGT CCT 
TTC CAC AA 3'), and LTR-247s-12/+10 (5' AAA AAA CCT GAG AGA GAA GTG TTA GAG TGG 
AGG TTT GAC AGC CGC CCG GTG TTT CGT CCT TTC CAC AA 3'). The asRNAs were 
labelled according to their relative positions from site 247 with ‗+‘ denoting upstream and ‗-‗ 
denoting downstream. To generate a sense-strand version of LTR-247as+7 as well as mutant 
versions of LTR-247as+7 (mA and mB), the following reverse oligonucleotide primers were 
used: LTR-247s+7 Reverse (5' AAA AAA GGG CTG TCA AAC CTC CAC TCG GTG TTT CGT 
CCT TTC CAC AA 3'), LTR-247as+7 mA Reverse (5' AAA AAA GAG TGG AGG TTT GAC AGC 
GCG GTG TTT CGT CCT TTC CAC AA 3') and LTR-247as+7 mB Reverse (5' AAA AAA GAG 
TTG AGG TTT GAC AGC CCG GTG TTT CGT CCT TTC CAC AA 3'). PCR was carried out 
using Expand High FidelityPLUS PCR System reagents (Roche, Basel, Switzerland) on a 
Mastercycler® (BioRad, CA, USA). The PCR mixture included 0.4 μM each of forward and 
reverse primers, 10 ng of template, 1.5 mM MgCl2, 200 μM dNTP mix, 2.5 U of Expand HiFi
PLUS 
Taq polymerase and 1 x final volume Expand HiFiPLUS Reaction Buffer (proprietary information) 
in a final volume of 50 μL. PCR conditions comprised 3 minutes at 95 oC followed by 35 cycles 
of 30 seconds each at 95 oC, 58 oC and 72 oC followed by 10 minutes at 72 oC. The amplified 
products were excised and eluted from a 1 % agarose gel (see Appendices A1.2.3 and A1.2.4) 
and cloned into the TA cloning vector pTZ57R/T as described in section 2.2.1. Candidate clones 
were screened using SpeI and EcoRI.  
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 The construction of pCR2.1-LTR-247as -50/+50 required the same two step PCR 
approach that had been used to generate anti-LTR lhRNAs (see section 2.2.1) using a universal 
U6 Forward primer with the following reverse oligonucleotide primers: LTR-247s-50/+50 
Reverse 1 (5' AGT GGA GGT TTG ACA GCC GCC TAG CAT TTC ATC ACG TGG CCC GAG 
AGC TGC ATC CGG AGT ACG GTG TTT CGT CCT TTC CAC AA 3') and LTR-247s-50/+50 
Reverse 2 (5' AAA AAA CAG CTT GTT ACA CCC TGT GAG CCT GCA TGG AAT GGA TGA 
CCC TGA GAG AGA AGT GTT AGA GTG GAG GTT TGA CAG CCG 3'). PCR fragments were 
cloned into the TA vector pCR2.1-TOPO (Invitrogen, CA, USA) and candidate clones were 
screened using sequencing as previously described for the anti-LTR lhRNAs (see section 2.2.1).  
 
4.2.2 Cloning of HIV LTR site 247 target vectors 
 
To generate luciferase reporter constructs containing putative LTR-247as+7 target sequences 
within C10orf76, a set of psiCheck2 based target vectors were generated using the same 
method for generating an HIV tiling array as described in section 2.2.3 with the following 
oligonucleotides: LTR-247as+7 Forward containing XhoI and EcoRV sites (5' TCG AGA TAT 
CGA GTG GAG GTT TGA CAG CCC GC 3'), LTR-247as+7 Reverse containing a NotI site (5' 
GGC CGC GGG CTG TCA AAC CTC CAC TCG ATA TC 3'), C10orf76 1049 Forward containing 
XhoI and EcoRV sites (5' TCG AGA TAT CCA GAG TGG GCT CCC TAA ACA GCC CCG C 3'), 
C10orf76 1049 Reverse containing a NotI site (5' GGC CGC GGG GCT GTT TAG GGA GCC 
CAC TCT GGA TAT C 3'), C10orf76 2230 Forward containing XhoI and EcoRV sites (5' TCG 
AGA TAT CGG GGA GTT GGC TTG TGG TTC CTC CCT TGG ATA GCC TCG C 3'), C10orf76 
2230 Reverse containing a NotI site (5' GGC CGC GAG GCT ATC CAA GGG AGG AAC CAC 
AAG CCA ACT CCC CGA TAT C 3'), C10orf76 463 Forward containing XhoI and EcoRV sites 
(5' TCG AGA TAT CCA GTG GAA GGA AGC AGC TAG C 3'), C10orf76 463 Reverse 
containing a NotI site (5' GGC CGC TAG CTG CTT CCT TCC ACT GGA TAT C 3'), C10orf76 
1534 Forward containing XhoI and EcoRV sites (5' TCG AGA TAT CTA GAG ATG GAG TTT 
TTC ACC ATG TTA CCC AGG ATG GTC TCG C 3'), C10orf76 1534 Reverse containing a NotI 
site (5' GGC CGC GAG ACC ATC CTG GGT AAC ATG GTG AAA AAC TCC ATC TCT AGA 
TAT C 3'), C10orf76 210 Forward containing XhoI and EcoRV sites (5' TCG AGA TAT CGG 
CAC AGU GGG GAG AGG CCU GC 3') and C10orf76 210 Reverse containing a NotI site (5' 
GGC CGC AGG CCT CTC CCC ACT GTG CCG ATA TC 3'). For the above ‗Forward‘ 
oligonucleotide sequences, solid underlined regions correspond to XhoI and dotted underlined 
regions correspond to EcoRV restriction sites. For the ‗Reverse‘ oligonucleotide sequences, 
solid underlined regions correspond to NotI restriction sites.   
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4.2.3 Mammalian cell culture 
 
Both the HEK293 and HEK293-derived cell lines (HEK293-CCR5-GFP) were maintained and 
transfected using FCS-supplemented DMEM as described in section 2.2.4. Jurkat-derived 1G5 
cells (NIH AIDS Research and Reference Reagents Program, MD, USA) were maintained in 
complete Roswell Park Memorial Institute 1640 medium (RPMI 1640, Lorenza Biosciences, 
Basel, Switzerland) supplemented with heat-inactivated 10 % FCS (Invitrogen, CA, USA).  
 
4.2.4 Transfection and detection of asRNA activity in cultured mammalian cells 
   
To assess the inhibitory efficacies of U6-expressed asRNAs targeted to a subtype B HIV-1 LTR 
promoter, 1G5 cells were electroporated and quantitative RT-PCR of luciferase mRNA was 
performed as follows: 1G5s are a Jurkat-derived suspension cell line that express hFluc followed 
by a SV40 poly A strong stop signal from an HIV-1 subtype B LTR (Aguilar-Cordova, Chinen et 
al. 1994; Platt, Wehrly et al. 1998). Three million cells per asRNA-expressing construct were 
washed once in PBS by centrifugation at 215.74 x g followed by a similar wash step using 
ViaspanTM (DuPont Pharmaceuticals, DE, USA) before being resuspended in 800 μL of ice-cold 
ViaspanTM. Cells were transferred to a 0.4 cm gap 5 cuvette (BioRad, CA, USA), and a 
combination of 2.5 μg of pTat-dsRed (Unwalla, Li et al. 2004) and 2.5 μg of pTZ-LTR-247s+7 or 
pTZ-LTR-247s+13 or pTZ-LTR-247s+19 or pTZ-LTR-247s-7 or pTZ-LTR-247s-14 or pTZ-LTR-
247s-21 or pTZ-LTR-247s-21/+19 or pTZ-LTR-247s-12/+10 or pTZ-LTR-247s-50/+50 or pTZ-
LTR-247s+7 mA or pTZ-LTR-247s+7 mB was added. Samples were electroporated in a BioRad 
GenePulser (BioRad, CA, USA) using 0.3 kV, 960 µF, a time constant of 11 milliseconds and a 
field strength of 0.95 kV/cm, before being transferred to 4 ml of warm RPMI 1640 media. 
Twenty-four hours later total cellular RNA was isolated (see Appendix A1.3.2), DNAse treated 
(Ambion Turbo DNA-freeTM, Applied Biosystems, CA, USA), and 1 µg of RNA was converted to 
cDNA (BioRad iScriptTM, BioRad, CA, USA) using the same method described in section 2.2.8. 
Complementary DNA (cDNA) was amplified by PCR with the Quantitect® SYBR® Green PCR 
Kit (Qiagen, Hilden, Germany) on a Roche Lightcycler V.2. (Roche, Basel, Switzerland). To 
allow for absolute quantification of RNA, two primer sets were used, one for hFluc mRNA 
(Forward: 5´ CCT GGA ACA ATT GCT TTT AC 3´ and Reverse: 5´ GTT TCA TAG CTT CTG 
CCA AC 3´) and one for the GAPDH housekeeping gene (GAPDH Forward: 5´ CCA CCC ATG 
GCA AAT TCC 3´ and Reverse: 5´ TGG GAT TTC CAT TGA TGA CAA G 3´).  
 To determine the ability of LTR-247+7as to modulate episomal transcription, HEK293 
cells were transiently co-transfected with 100 ng of pLTRb-luc (LAI) or pLTRc-luc-SV40pA and 
800 ng of pLTR-247as+7 and 100 ng of either pCMV-Tat or pBluescript (Stratagene, CA, USA) 
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as described for the episomal transfection of LTR-driven luciferase vectors described in section 
2.2.6.  
 To determine the ability of the various U6-expressed HIV-1 subtype B LTR specific 
asRNAs to induce off-target enhanced transcription, a CCR5 promoter-expressing GFP 
construct was used to develop the reporter cell line HEK293-CCR5-GFP. The vector pR5-
GFPsg143 contains ~3kb of CCR5 promoter, intron, exons 1 and 2 (Moriuchi, Moriuchi et al. 
1997; Mummidi, Ahuja et al. 1997; Guignard, Combadiere et al. 1998) and drives the expression 
of red-shifted GFP [a gift from Dr. G.N. Pavlakis (Rosati, Valentin et al. 2001; Kim, Villeneuve et 
al. 2006)]. A total of four million HEK293 cells were seeded into a 10 cm dish and transfected 
with 5 μg of pR5-GFPsg143 using 5 μL of Lipofectamine 2000 (Invitrogen, CA,  USA) in 1 mL of 
OptiMem (Gibco, BRL, UK) as described for the stable cell line in section 2.2.5. Transfected 
cells were positively selected over four weeks using 800 μg/mL of Neomycin antibiotic (Merck, 
Darmstadt, Germany) and fluorescence microscopy. Stable HEK293-CCR5-GFP cells were 
maintained as described in section 4.2.3. To assess the off-target effects induced by the various 
U6-expressed HIV-1 subtype B LTR specific asRNAs, HEK293-CCR5-GFP stable cells were 
seeded and transfected as described above using 50 nM of either siRNA-C10-si1 (5´ GCU GUG 
AAU CAC AUA UCC CAA 3´) or siRNA-C10-si2 (5´ CCA GAG CTT TGA CAA CCT CAA 3´) or 
siRNA-C10-si3 (5´ CCT ACT TTG CTG GTT CCC TAA 3´) or control siRNA-AKT-19 (5´ AAC 
ACC ATG GAC AGG GAG AGC 3´). Twenty-four hours later, total mRNA was extracted (see 
Appendix A1.3.2) and quantitative RT-PCR was completed to assess mRNA levels of C10or76, 
GFP, NFYB, and NSBP1 relative to GAPDH using the following primer sets: C10orf76 Forward 
(5´ ATG GCC TGG ACC AGT ATG AG 3´), C10orf76 Reverse (5´CCT TGA GCA GGA CTT CTT 
GG 3‘), GFP (Weinberg, Villeneuve et al. 2006), NFYB Forward (5´ GGA ATT GGT GGA GCA 
GTC AC 3´), NFYB  Reverse (5´ TGT TGT TGA CCG TCT GTG GT 3´), NSBP1 Forward (5´ 
AGG CAC CAG CTT CTG AAA AA 3´) and NSBP1 Reverse (5´ GCT GCC ACT GCT TCT TTC 
TT 3´).  
To determine if the predicted LTR-247as+7 target sites within C10orf76 were susceptible 
to LTR-247as+7-mediated inhibition, HEK293 cells were seeded and transfected as described 
for the luciferase assays in section 2.2.6 with the following changes: cells were co-transfected in 
triplicate with 150 ng of either psi-LTR-247as+7 or psi-C10orf76-1049 or psi-C10orf76-2230 or 
psi-C10orf76-463 of psi-C10orf76-1534 or psi-C10orf76-210 and 100 ng of pCi-eGFP and 750 
ng of pCR2.1-LTR-247as or pTZ-U6+1. Luciferase data were analysed 48 hours post-
transfection as described in section 2.2.6. 
 Total RNA was also used to determine whether or not LTR247as+7 could directly interact 
with C10orf76 as follows: siRNA-247as+7 (5' CAA ACC UCC ACU CUA ACA C 3') or siRNA-
C10-si1 or negative control siRNA-AKT-19 were incubated with total DNAse-treated cellular 
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RNA for 5 minutes at 95°C followed by cooling to room temperature and conversion to cDNA as 
described in section 2.2.8 although no polyA primer was added. PCR using C10orf76 Forward 
and Reverse primers was completed on the cDNA samples as described for IFN-related genes 
in section 2.2.8.  
 
4.2.5 Chromatin immunoprecipitation (ChIP) 
 
Previous work had shown that siRNA-mediated TGS in human cells involves histone methylation 
at the siRNA-targeted promoter, specifically di-methylation at histone 3 lysine 9 (H3K9me2) or 
tri-methylation at histone 3 lysine 27 [H3K27me3,(Kim, Villeneuve et al. 2006; Weinberg, 
Villeneuve et al. 2006; Han, Kim et al. 2007)]. To determine whether the observed increase in 
transcription was the result of the asRNA-directed histone modifications associated with 
increased gene expression, a ChIP assay was performed specifically for H3K4me2. 
Electroporation (see section 4.2.4) was used to co-transfect 1G5 cells with a combination of 2.5 
µg pTat-dsRed and 2.5 μg of pTZ-LTR-247as or pTZ-LTR-247as+7 or pTZ-LTR-247as-7 or pTZ-
LTR-247as+13. The following day cells were cross-linked for ten minutes at room temperature 
using 1 % formaldehyde (Merck, Darmstadt, Germany) and the reaction was stopped by the 
addition of 0.125 M glycine (Merck, Darmstadt, Germany) and incubation for ten minutes at 
room temperature. Cells were washed twice in PBS (Gibco, BRL, UK) supplemented with 5 μM 
PMSF (phenylmethanesulphonylfluoride protease inhibitor, Merck, Darmstadt, Germany), 
resuspended in 600 μL of ChIP lysis buffer (50 mM HEPES pH 7.5, 140 mM NaCl, 10 % Triton 
X-100, 0.1 % NaDeoxycholate, 5 μM PMSF, Merck, Darmstadt, Germany) and incubated for ten 
minutes on ice. Samples were centrifuged for five minutes in a refrigerated centrifuge 
(Eppendorf 5415D/R, Eppendorf, Hamburg, Germany) at 238 x g and 4 oC followed by 
resuspension in 600 μL of ChIP lysis buffer and incubation for ten minutes on ice. Samples were 
sonicated using a Branson Sonifier® 450 (Emerson Industrial Automation, MO, USA) with six 
intervals of 20 second pulses and two minute rests. Sonicated samples were centrifuged for ten 
minutes at 16 000 x g and 4 oC, supernatants were removed and pre-cleared for 15 minutes 
using 30 μL of protein A/ salmon sperm DNA mix (Upstate Biotechnology Inc, NY, USA) on a 
NutatorTM (TCS Scientific, PA, USA). Pre-cleared supernatants were centrifuged for five minutes 
at 16 000 x g and 4 oC. Five hundred μL aliquots of each sample were incubated overnight at 4 
oC on a NutatorTM with 1 μg of either anti-H3K9 antibody (Upstate Biotechnology Inc, NY, USA) 
or anti-H3K27 antibody (Upstate Biotechnology Inc, NY, USA) or no antibody (no-antibody 
control). The following day samples were incubated for 15 minutes with 10 μL of protein 
A/salmon sperm DNA at room temperature on a NutatorTM followed by centrifugation for one 
minute at 16 000 x g and 4oC. The ‗no-antibody control‘ supernatants were stored at -20 oC and 
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used as ‗total chromatin input‘ control samples. The remaining pellets were washed as follows: 
two washes with 1 mL of ChIP lysis buffer, two washes with 1 mL of ChIP lysis buffer with high 
salt (50 mM HEPES pH 7.5, 500 mM NaCl, 1 % Triton X-100, 0.1 % NaDeoxycholate, 0.5 μM 
PMSF) and two washes with 1 mL of ChIP wash buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 
0.5 % NP-40, 0.5 % NaDeoxycholate, 1 mM EDTA, Merck, Darmstadt, Germany). Per wash, 
samples were incubated for three minutes at room temperature on a NutatorTM followed by 
centrifugation for three minutes at 16 000 x g. After the final wash, DNA/protein complexes were 
resuspended in 100 μL of elution buffer (50 mM Tris-HCl pH 8.0, 1 % SDS, 10 mM EDTA, 
Merck, Darmstadt, Germany), incubated for 10 minutes at 65 oC followed by room temperature 
centrifugation for three minutes at 16 000 x g. The eluted complexes as well as 200 μL of the ‗no 
antibody control‘ were incubated for six hours at 65 oC with 1 μL of RNAse A (10 mg/mL, 
Invitrogen, CA, USA) and 20 μL of 5 M NaCl (Merck, Darmstadt, Germany) to reverse cross-link 
the complexes. Reverse cross-linked samples were incubated for one hour at 45 oC with 10 μL 
of 0.5 M EDTA, 20 μL of 1 M Tris-HCl pH 6.5 and 2 μL of 10 mg/mL Proteinase K (Invitrogen, 
CA, USA) and the DNA was recovered by phenol/chloroform extraction (see Appendix A1.2.2). 
Samples were diluted 300 fold in nuclease-free water (Qiagen, Hilden, Germany) and 2 μL per 
sample was amplified by PCR using Quantitect® SYBR® Green (Qiagen, Hilden, Germany) on 
a Roche Lightcycler V.2. (Roche, Basel, Switzerland) as described in section 2.2.8 with the 
following HIV-1 LTR specific oligonucleotide primers: LTR Forward (5´CAC ACA AGG CTA CTT 
CCC TGA 3´) and LTR Reverse (5´ GGC CAT GTG ATG AAA TGC TA 3´). 
 
4.2.6 Microarray analysis  
 
Microarray analysis was used to specifically determine the genes involved in the pTZ-LTR-
247as+7 mediated increase in gene expression. 1G5 cells were co-transfected in triplicate with 
either 2.5 µg of pTZ-LTR-247as and 2.5 µg of pTat-dsRed or 2.5 µg of pTZ-GFPas (Weinberg, 
Villeneuve et al. 2006) and 2.5 µg pTat-dsRed. Twenty-four hours later total RNA was isolated 
(see Appendix A1.3.1) and 1 µg of RNA per sample was labelled and hybridised to the 
Affymetrix Human HG-U133 Plus 2.0 array (Affymetrix Inc, CA, USA) at the Scripps Research 
Institute Core Microarray facility. The HG-U133 Plus 2.0 array includes probes for ~52,000 
human probe-IDs.  The Affymetrix chips were scanned using an Affymetrix GeneChip Scanner 
3000 (Affymetrix Inc, CA, USA).  Chips have a background of less than 50 intensity units and a 
GAPDH 3´/5´ ratio of less than three. Robust Multichip Average (RMA) was used to convert the 
intensity values to expression values (Bolstad, Irizarry et al. 2003; Irizarry, Hobbs et al. 2003).  
RMA consists of a three-step approach which uses a background correction on the Perfect 
Match (PM) probes, a quantile normalisation and summarisation of the probe set information 
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using Tukey‘s median polish algorithm. Present and absent calls were calculated in the R 
software package as implemented in the Affymetrix Microarray Suite version 5. This algorithm 
uses a Wilcoxon signed rank-based calculation to assign presence or absence of probe sets. 
Probe sets were filtered out if they were assigned absent for all the samples, which left ~30,000 
probes for further analysis. ANOVA was performed using BRB Array Tools, developed by Dr. 
Richard Simon and Amy Peng Lam.  BRB utilises multivariate permutation tests to ensure that 
the number or proportion of false discoveries is controlled and is effective when the number of 
samples is at least three per treatment. The ANOVA analysis identified 185 human genes on the 
chip that were significantly altered at a P-value of 0.05, which were considered as false 
positives.  Heat-maps were generated with Cluster and TreeView programs written by Michael 
Eisen (Eisen and Lucchesi 1998).  Based on multiple positive matches using miRNA target-site 
online search algorithms ‗RNA22‘ (Miranda, Huynh et al. 2006) and ‗RNAhybrid 2.2‘ 
(Rehmsmeier, Steffen et al. 2004), three genes were chosen for microarray analysis validation 
by RT-PCR using the same RNA samples and primer sets specific to C10or76, NFYB, and 
NSBP1 as described for off-target determination in section 4.2.4. 
 
4.2.7 Statistical analysis 
 
Data are expressed as the mean ± the standard error of the mean (SEM) and where appropriate 
are normalised to a control sample within the experiment. Statistical difference was considered 
to be significant when p < 0.05 and highly significant when p < 0.01. In all cases α = 0.99 and 
data was analysed using a one-way ANOVA followed by a Dunnett‘s Multiple Comparison post-
test or a Student‘s t-test calculated using GraphPad Prism (GraphPad Software Inc, CA, USA).  
 
4.3 Results 
 
4.3.1 Selection of HIV-1 subtype B LTR-targeted asRNAs 
 
Data had been published showing that only the antisense strand of a promoter-directed siRNA is 
required to initiate transcriptional silencing in human cells (Weinberg, Villeneuve et al. 2006). 
Specifically, a U6-expressed 21 nt asRNA targeted to site 247 (denoted as LTR-247as), which 
lies 205 bp upstream of the HIV-1 transcription start site, was capable of suppressing Tat-
mediated transcription of HIV-1 LTR-luciferase expression in 1G5 cells (Weinberg, Villeneuve et 
al. 2006). 1G5 cells possess an integrated LTR-driven luciferase reporter gene construct, which 
is responsive to the HIV transactivating protein Tat (Aguilar-Cordova, Chinen et al. 1994). In 
order to comprehensively characterise the suppressive efficacy of LTR-247as to the 247 target 
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site, a series of U6-expressed asRNAs were generated to target the region surrounding site 247 
including sequences that spanned 50 bp up- and downstream of this site (Figure 33). It was 
hypothesised that site 247 is intrinsically unique with regards to siRNA and/or asRNA targeted 
TGS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Region within the HIV LTR targeted by U6-expressed asRNAs. A set of nine asRNAs were 
selected that targeted either site 247, or regions which span upstream (+) and/or downstream (-) of 247. 
The respective asRNAs are shown aligned with the HIV-1 subtype B LTR and site 247 (targeted by LTR-
247as). 
 
4.3.2 Screening of HIV-1 LTR targeted U6-expressed asRNAs 
 
To determine asRNA-mediated promoter suppression, the U6-expressed asRNA plasmids were 
transiently co-transfected into 1G5 cells with a Tat expression plasmid, pTat-dsRed (Platt, 
Wehrly et al. 1998). Total RNA was extracted 24 hours later and hFluc mRNA relative to GAPDH 
mRNA was assessed (Figure 34). Interestingly, one of the U6-expressed asRNA constructs, 
LTR-247as+7, which is shifted 7 bases downstream relative to LTR-247as (Figure 33), produced 
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a significant increase in luciferase mRNA expression when compared to an asRNA targeted to 
GFP (α = 0.99, p < 0.01). LTR-247as (Figure 34 dark blue bar) and LTRc-247as [targeted to the 
same sequence on HIV subtype C, isolate Du151 (GenBank® accession number DQ411851), 
Figure 34 turquoise bar], suppressed Tat-mediated activation of the LTR similarly to the subtype 
B-specific LTR-247as.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Effects of various U6-expressed antisense RNAs on luciferase expression. A) Design of 
expressed antisense RNA cassettes. Pol III (U6) cassettes were designed to express a single asRNA with 
characteristic 2 bp 3' overhangs. B) 1G5 cells containing an integrated HIV-1 subtype B LTR driving hFluc 
were co-electroporated with pTat-dsRed and each of the LTR-247as vectors (blue bars). Luciferase 
expression was assessed 24 hours post-transfection relative to GAPDH expression by real-time RT-PCR. 
Data are normalised to control-treated cultures (pU6-GFPas, n = 3, ± SEM). 
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To determine if the increased gene activation was independent of the activity of HIV-1 Tat, 1G5 
cells were co-transfected with either LTR-247as+7 and the HIV-1 Tat expression plasmid, pTat-
dsRed, or LTR-247as+7 and an irrelevant plasmid, pBluescript (pBSK). There was a ~1.5 fold 
enhancement of LTR-mediated luciferase expression in the absence of HIV-1 Tat (Figure 35), 
suggesting that the previously observed increase in LTR activity (Figure 34) was specifically 
mediated by LTR-247as+7.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. LTR-247as activation is independent of HIV-1 Tat. 1G5 cells were co-transfected with either 
pBSK (light blue bars) or pTat-dsRed (dark blue bars) and either pU6-LTR-247as, pU6-LTR-247as+7 or 
pU6-GFPas control. Twenty-four hours later quantitative RT-PCR was performed. Data are expressed as 
hFluc/GAPDH mRNA levels normalised to U6-GFPas control (n = 3, ± SEM). 
 
  
The activation mediated by LTR-247as shown in Figures 34 and 35 was determined using an 
integrated LTR target. To assess if these observations were related to the integrated nature of 
the reporter, transient co-transfections of LTR-247as with episomal subtype B and C LTR-
reporter vectors were completed in HEK293 cells. Luciferase expression was assessed 24 hours 
post-transfection by real-time RT-PCR. Treatment with U6-expressed LTR-247as+7 plasmids 
resulted in a significant increase (α = 0.99, p < 0.01) in episomal LTR-driven expression in a Tat-
independent manner (Figure 36). While significant, this increase was far less than that mediated 
against the integrated target vector (compare Figures 35 and 36). 
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 Taken together, the data in Figures 34 to 36 suggested that the U3 region of the LTR 
spanning 50 bp up-and downstream of site 247as was susceptible to antisense mediated 
inhibition. However, the stark contrast mediated by 247as+7 showed that Tat-independent target 
transactivation could occur. This activation was further shown to be independent of the 
integrated chromatic state of the target. To assess if the 247as+7-mediated activation induced 
chromatin changes at the target site, ChIP analysis was completed to determine the histone 
modifications present. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. LTR-247as+7 modulates episomal gene expression. A) Either a subtype B or C LTR-driven 
hFluc expression plasmid was co-transfected in triplicate with the LTR targeted pU6-LTR-247as+7, pU6-
LTR-247as-7, or control pU6+1 plasmids with or without HIV-1 Tat and a hRluc-expressing plasmid in 
HEK293 cells. B) Twenty-four hours post-transfection, luciferase expression was determined. Data are 
expressed as a ratio of hFluc to hRluc luciferase activity normalised to a pU6-GFPas control (n = 3, ± 
SEM). A Student´s t-test was used to determine statistical significance.  
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4.3.3 The role of histone modifications in LTR-247+7as-mediated increase in LTR-driven 
luciferase expression 
 
Methylation of histone 3 at lysines 9 and 27 (H3K9me2 or H3K27me3) is observed in genes 
silenced by siRNAs targeted to their respective promoter regions in human cells (Morris, Chan et 
al. 2004; Janowski, Huffman et al. 2005; Suzuki, Shijuuku et al. 2005; Janowski, Huffman et al. 
2006; Kim, Villeneuve et al. 2006), Schizosaccharomyces pombe and plants [reviewed in 
(Matzke and Birchler 2005; Morris 2005)]. While H3K9me2 and H3K27me3 correlates with 
transcriptionally silent genes (Jenuwein and Allis 2001), H3K4me2 associates with 
transcriptionally active genes (Krogan, Kim et al. 2003). Furthermore, siRNAs have been shown 
to participate in the activation of genes via epigenetic modifications that include the acetylation 
and/or methylation of histone N-terminal residues (Li, Okino et al. 2006; Janowski, Younger et 
al. 2007). In light of this observation, it was hypothesized that the increase in LTR-luciferase 
reporter gene expression observed with asRNA LTR-247as+7 may be mediated by asRNA-
directed H3K4me2.  
Levels of enrichment of H3K4me2 at the targeted LTR-247 promoter site with asRNAs 
LTR-247as, LTR-247as+7, LTR-247as-7 and LTR-247as+13 was assessed by ChIP. Relative to 
the suppressive effects of asRNA LTR-247as which did not enrich for H3K4me2, LTR-247as+7, 
LTR-247as-7 and LTR-247as+13 were enriched for H3K4me2 in 1G5 cells (Figure 37).  
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Figure 37. H3K4me2+
 
in various asRNA-treated cells. 1G5 cells were co-transfected with pTat-dsRed and 
pTZ-LTR-247as or pTZ-LTR-247as+7 or pTZ-LTR-247as-7 or pTZ-LTR-247as+13 or pTZ-GFPas. The 
following day, ChIP analysis was performed using anti-H3K4me2+ antibodies and LTR-specific 
oligonucleotides. Data represent relative enrichment normalised to a ‗no antibody‘ control (n = 3, ± SEM).   
 
 
Although LTR-247as-7 and LTR-247as+13 showed a six fold increased enrichment of 
H3K4me2 (relative to a two fold enrichment by LTR-247as+7), these asRNAs were only capable 
of marginal gene activation when compared to LTR-247as+7 (Figure 34B). The presence of 
activating H3K4me2 marks may have been a contributing factor in LTR-247as+7-mediated gene 
activation. However, this alone was not sufficient to explain the marked activation observed 
relative to LTR-247as-7 and LTR-247as+13.  
 
4.3.4 Single changes in the LTR-247as+7 sequence can abrogate LTR-targeted activation 
 
To determine whether LTR-247as+7 activation was sequence-specific, two U6-expressed LTR-
247as+7 RNAs containing single mutations aimed at disrupting sequence-specific interactions 
between the asRNA and the target were generated (LTR-247as+7mA and mB). In addition, a 
sense sequence construct (LTR-247s+7) was also included. Construct LTR-247as+7mA 
included a nucleotide change within the first 7 bases that corresponded to the seed region 
typically required for microRNA target specificity (Watanabe, Yachie et al. 2006). Furthermore, 
the nucleotide change discriminated the mA construct from its suppressive LTR-247as 
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counterpart. Construct LTR-247as+7mB included a nucleotide change within the 3' region of the 
asRNA that should not have affected seed region binding (Figure 38A).  
Co-transfection of 1G5 cells with a plasmid containing the LTR-257as+7 target site, the 
mutated constructs and HIV-1 Tat showed that the single base change in LTR-247as+7mA (G to 
C at position 2) was sufficient to partially reverse the activation potential of LTR-247as+7 
whereas LTR-247as+7mB did not mediate such a reversal (Figure 38B). This suggested that the 
activation mediated by LTR-247as+7 was sequence specific and required seed sequence 
pairing to induce the effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. A single point mutation in LTR-247as+7 at nucleotide 7 abrogates off-target gene activation in 
1G5 cells. A) Two U6-expressed LTR-247as+7 RNAs containing single mutations aimed at disrupting 
sequence-specific interactions between the asRNA and the LTR-247as+7 target site were generated 
(LTR-247as+7mA and mB). A sense sequence construct, LTR-247s+7 was also included. All sequences 
are aligned relative to the HIV LTRb region corresponding to the LTR-247as+7 target site. Single point 
mutations are highlighted in red with arrows. B) 1G5 cells were co-transfected in triplicate with a 
combination of psi-LTR-257as+7 and pCMV-Tat and either one of the mutated constructs or LTR-247as+7 
or LTR-247s+7. The following day quantitative RT-PCR was performed. Data are presented as a ratio of 
hRluc to GAPDH mRNA expression normalised to LTR-247as+7 (n = 3, ± SEM). A Student´s t-test was 
used to determine statistical significance.  
 
 
4.3.5 Microarray analysis of LTR-247as+7-treated cells 
 
The data from sections 4.3.2 to 4.3.4 showed that LTR247as+7 mediated Tat-independent gene 
activation from episomal and integrated targets that correlated with a H3K9me2+ marker of 
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transcriptional activation. To determine if the observed increase in gene expression by LTR-
247as+7 was unique to the LTR-luciferase target system present in 1G5 cells, co-transfections 
with LTR-247as+7 were performed in a cell line that contains an integrated CCR5 promoter 
constitutively driving GFP expression (Kim, Villeneuve et al. 2006). 
Similar to the observations in 1G5 cells, the addition of LTR-247as+7 resulted in an 
increase in CCR5-expressed GFP mRNA (Figure 39).  
 
 
 
 
 
 
 
 
 
 
Figure 39. CCR5-expressed GFP shows increased expression in the presence of LTR-247as+7 relative 
to the control LTR-247as. HEK293 CCR5 GFP cells were co-transfected in triplicate with LTR-247as+7 or 
LTR-247as as a control and quantitative RT-PCR was performed 24 hours later. Data are expressed as a 
ratio of GFP to GAPDH mRNA expression normalised to LTR-247as (n = 3, ± SEM). A Student´s t-test 
was used to determine statistical significance.  
 
 
Importantly, no corresponding homologous target site for LTR-247as+7 existed within the CCR5 
promoter, indicating a possible off-target effect induced by LTR-247as+7. To determine which 
genes may have been involved in LTR-247as+7-mediated activation, microarray analysis was 
performed on 1G5 cells treated with LTR-247as+7 or GFPas control.  
A total of 185 genes showed significant alterations in their expression profile when 
compared to control treated cultures, with RNA-associated proteins such as La, DEAD box 
proteins (polypeptide 50 and 26B), and a cold inducible RNA binding protein, being of interest 
(see Table A3.4.1 in Appendix A3.4). Of the 185 deregulated genes, 23 genes could have been 
involved in producing the observed off-target effect based on their annotation (Figure 40A). The 
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microarray analysis was further validated by RT-PCR for 3 of the 23 genes which confirmed the 
corresponding trend of increased expression in the presence of LTR-247as+7 (Figure 40B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. Microarray analysis of 23 deregulated genes. A) A heat-map was produced depicting the 
variation in gene expression for 1G5 cells treated with LTR-247as+7 or GFPas. Data represent triplicate 
samples (labelled at the top of the heat-map as 0223B, 0303B and 0309B) with the names of all 23 
deregulated genes on the right hand side of the heat-map. B) Microarray analysis was further validated for 
3 of the 23 genes that had shown an increase in fold expression relative to GFPas. Real-time quantitative 
RT-PCR was performed using PCR primers specific to NSBP1, NFYB and C10orf76 and GAPDH. Data 
are expressed as a fold change in mRNA expression relative to GAPDH (n = 3, ± SEM).  
 
 
To determine which of the 23 deregulated genes were interacting with LTR-247+7as, the 
potential miRNA binding characteristics of each gene were assessed using RNA22 (Miranda, 
Huynh et al. 2006) and RNAhybrid 2.2 (Rehmsmeier, Steffen et al. 2004) software analysis. 
Both programs find the energetically most favourable hybridisations of small RNAs within large 
RNAs, thus predicting potential binding sites of miRNAs within large target mRNAs. A suspected 
non-coding gene expressing a ~2730 nt transcript from chromosome 10 of unknown function 
(C10orf76, GenBank® accession number NM_024541) was shown to have multiple pairings to 
LTR-247as+7 (Figure 41).  
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Figure 41. Screening the miRNA binding potential of LTR-247as+7 and C10orf76. Complementary 
miRNA for LTR-247as+7 and mRNA target sites for C10orf76 were predicted using RNAhybrid 2.2 and 
RNA22 software analysis. The predicted miRNA-mRNA duplexes required a total free energy value of less 
than -20.0 kcal/mol.  In addition the first 8 nucleotides of the miRNA in the predicted duplexes required a 
total free energy value less than -10.0 kcal/mol.  
 
4.3.6 The effect of C10orf76 on LTR-247as+7-mediated gene activation 
 
To assess if C10orf76 functioned to modulate the suppression of genes that were deregulated in 
the microarray study, C10orf76 was targeted with three different siRNAs and the expression of 
NSBP1, NFYB and CCR5-expressed GFP was simultaneously observed (Figure 42). 
Interestingly, when C10orf76 was suppressed, increased expression of NSBP1, NFYB and 
CCR5-expressed GFP was observed that was inversely proportional to the suppression of 
C10orf76 by the siRNAs. These results matched the increase seen in the microarray data for 
NSBP1, NFYB and CCR5-expressed GFP following treatment with LTR-247as+7 (compare 
Figures 40B and 42B).  
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Figure 42. The effect of C10orf76 on 247as+7-mediated gene activation. A) HEK293 CCR5 GFP cells 
were transfected with siRNAs specific to C10orf76 and quantitative RT-PCR was performed 24 hours 
later. Data are presented as a ratio of C10orf76 to GAPDH mRNA expression normalised to control 
siRNA-AKT19 (n = 3, ± SEM). B) Suppression of C10orf76 is inversely proportional to the activation of 
GFP, NSBP1 and NFYB as measured by quantitative RT-PCR 24 hours post-transfection with C10orf76-
specific siRNAs in HEK293 CCR5 GFP cells. Data are presented as a ratio of each gene relative to 
C10orf76 mRNA expression normalised to control siRNA-AKT19 (n = 3, ± SEM).  
 
 
 
The target site search algorithms described in section 4.3.5 showed putative matches between 
LTR-247as+7 and C10orf76 (Figure 41). To determine if the putative LTR-247as+7 target sites 
within C10orf76 were susceptible to LTR-247as+7-mediated inhibition, HEK293 cells were co-
transfected with LTR-247as+7 and various psiCheck2-based dual-luciferase reporter constructs, 
each containing individual putative C10orf76 target sequences for LTR-247as+7 (Figure 43A). 
Relative to a complete LTR-247as+7 target as a control, two of the five putative C10orf76 target 
sites tested were susceptible to LTR-247as+7 (C10orf76-1049 and C10orf76-463), suggesting 
that C10orf76 was being directly suppressed via LTR-247as+7 (Figure 43B). Moreover, the 
C10orf76 transcript could be selectively reverse-transcribed using the LTR-247as+7-siRNA as a 
primer (Figure 43C). Taken together these data suggested that off-target inhibition of C10orf76 
expression was predominantly responsible for the observed gene activation mediated by LTR-
247as+7.   
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Figure 43. Select putative LTR-247as+7 target sites within C10orf76 are susceptible to LTR247as+7-
mediated suppression. A) The complete LTR-247as+7 target site and putative LTR-247as+7 target sites 
within C10orf76 were inserted downstream of hRluc within the psiCheck2 vector. B) Knockdown efficiency 
of LTR-247as+7 was determined against each of the C10orf76 targets following transient co-transfections 
with LTR-247as+7 or a mock (pTZU6+1). Data are expressed as a ratio of hRluc to hFluc normalised to 
the mock (n = 3, ± SEM). A single-tailed Student‘s t-test was used to determine statistical significance. C) 
C10orf76 RNA can be reverse-transcribed using LTR-247as+7-siRNA as a primer. PCR was completed 
using C10orf76-specific primers on cDNA that had been converted using siRNAs specific to C10orf76 
(C10-siRNA-1), LTR-247as+7 or a control (siRNA-AKT19). Additional PCR controls included RNA that 
had not been reverse transcribed (RNA -RT) and RNA in the presence of RT (RNA +RT) but without 
primers. The expected PCR product was ~136 bp as compared to a molecular weight ladder (MW). 
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4.4 Discussion and conclusions 
 
Previous work had identified a TGS-susceptible region, site 247, which when targeted by an 
asRNA (LTR-247as), was capable of suppressing a HIV-1 subtype B LTR promoter in the 
presence of Tat (Weinberg, Villeneuve et al. 2006). Indeed, long-term TGS of HIV was induced 
using HIV-2 delivered asRNAs targeted to site 247 (Turner, De La Cruz et al. 2009). The 
observed silencing correlated with an increase in silent-state epigenetic marks (including histone 
and DNA methylation), a loss of NF-κβ recruitment to the viral promoter, and required AGO1, 
HDAC1 and DNMT3a localisation to the targeted region. Thus it was unexpected that a 22 nt 
asRNA sequence targeted only seven bases downstream of site 247 (LTR-247as+7), and still 
largely overlapping with the suppressor LTR-247as, showed the opposite effect of increased 
gene activation. Intriguingly, transcriptional activation of genes (TGA) in response to synthetic 
siRNAs or short dsRNAs targeted to the promoters has been described for E-cadherin, 
p21WAF1/CIP1 (p21), VEGF, and progesterone (Li, Okino et al. 2006; Janowski, Younger et al. 
2007).  
TGA (also referred to as RNA activation or RNAa) appears to be a robust sequence-
specific phenomenon supported by the observation that asRNAs are also involved in human 
genetic diseases (Tufarelli, Stanley et al. 2003) and point to a biological role for short RNAs in 
the epigenetic control of gene expression in human cells (Han, Kim et al. 2007; Kapranov, 
Cheng et al. 2007). However, since a mechanistic explanation for RNA activation remains to be 
elucidated, it was unclear whether the phenomenon observed with asRNA LTR247as+7 
represented a unique pathway, or formed part of an existing framework of post-transcriptional 
inhibitory effects caused by antisense RNAs or RNAi effector sequences. A number of 
mechanisms exist whereby RNAs can modulate gene activity. For example, gene activation has 
been observed for 20 bp dsRNAs containing neuron restrictive silencer element (NRSE/RE1) 
sequences. NRSE dsRNA activates expression of NRSE/RE1-containing genes by recognising 
the NRSF/REST transcriptional regulator to stimulate neural stem cells differentiation 
(Kuwabara, Hsieh et al. 2004).  
The gene activation observed for LTR-247as+7 was probably as a result of a sequence-
specific off-target effect. This has been ubiquitously observed when using RNAi and antisense 
effector sequences to induce post-transcriptional inhibition (Jackson, Bartz et al. 2003). The data 
presented here suggested that a complex cascade exists which possibly includes several of the 
genes which have been shown to be deregulated by LTR-247as+7. However, in this chapter 
attention was focused on a gene of unknown function, C10orf76, which was down-regulated by 
LTR-247as+7. The link between C10orf76 and LTR247as+7 was determined via an in silico 
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analysis of putative microRNA-like binding sites, two of which were established to be susceptible 
to post-transcriptional inhibition by LTR-247as+7 (Figures 41 and 42).  
Some of the experimental criteria used by Li (Li, Okino et al. 2006) and Janowski 
(Janowski, Younger et al. 2007) in establishing the validity of RNA-mediated gene activation 
may also be true for off-target effects. These include the sequence specificity and length 
characteristics of the targeting asRNA or dsRNA. Firstly, no notable increase in gene expression 
was observed with LTR-247as-50/+50, which includes the LTR-247as+7 sequence, indicating 
that the LTR-247as+7 sequence motif alone was not a determinant for off-target gene activation. 
Moreover, a mutant version of LTR-247as+7, with seed region mismatches, could abrogate 
activation, similarly to what was observed by others (Li, Okino et al. 2006). Since sequence 
specificity may not be a determinant for ruling out off-target or RNA-protein interactions, more 
stringent criteria may be necessary for determining sequence-dependent effects induced by 
RNA when targeted to promoter sequences. As was shown for antisense RNAs that induce TGS 
(Weinberg, Villeneuve et al. 2006), direct association of effector RNAs at the targeted promoter 
would be of value, although this was attempted without success by Janowski et al for AGO1 and 
AGO2 (Janowski, Younger et al. 2007). 
Secondly, RNA activation has been associated with the removal of silencing histone 
methylation marks and/or the addition of activating acetylation and methylation marks (Li, Okino 
et al. 2006; Janowski, Younger et al. 2007). While some increase in H3K4me2+ elicited by LTR-
247as+7 was shown (Figure 37), even greater enrichment was elicited by upstream and 
downstream overlapping asRNAs, which did not show potent gene activation. It is possible that 
the off-target inhibition of a repressor may function to induce active chromatin. The data in this 
chapter suggested that showing active or suppressive chromatin marks was largely correlative, 
and did not provide a mechanistic basis for the underlying result. 
 Lastly, both Li and Janowski used siRNAs and not asRNAs to induce gene activation. Li 
et al (Li, Okino et al. 2006) showed that the inhibition of AGO2 negatively affected the ability of 
siRNAs to inhibit RNA activation. Taken together with the inability to localise AGO2 to the 
activating promoter (Janowski, Younger et al. 2007), the data are consistent with the possibility 
that siRNAs were inadvertently inhibiting a transcriptional regulator. In addition, most studies 
utilising siRNAs to induce TGS made use of very high concentrations of siRNAs in order to 
direct their nuclear localisation (> 30 nM). However to date, much lower concentrations have 
been used to elicit RNA-mediated gene activation [1 nM for (Li, Okino et al. 2006) and 12 nM for 
(Janowski, Younger et al. 2007)].  
The mechanism of TGS has been fairly well described [reviewed in (Hawkins and Morris 
2008; Morris 2009)] and involves AGO1 (Janowski, Huffman et al. 2006; Kim, Villeneuve et al. 
2006) as well as RNA Pol II-expressed promoter-associated RNAs that act as target binding 
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sites for siRNAs (Han, Kim et al. 2007). Less data is available regarding TGA although 
promoter-associated RNAs as well as AGO proteins were required to induce TGA at the human 
progesterone receptor and E-cadherin promoters (Place, Li et al. 2008; Schwartz, Younger et al. 
2008). Interestingly, a mechanism for TGA has been proposed involving deregulation of 
endogenous bidirectional transcription (Morris, Santoso et al. 2008; Morris 2009). The binding of 
asRNAs to bidirectionally transcribed human gene promoters directs epigenetic silencing protein 
complexes to the region resulting in TGS. However, if the asRNA is suppressed or prevented 
from binding to the target promoter, deregulation occurs resulting in a TGA effect. This was 
suggested as a reason for tumour suppressor gene p21 activation (Morris, Santoso et al. 2008) 
and may also be true of previously observed TGA effects (Place, Li et al. 2008; Schwartz, 
Younger et al. 2008).  
Overall, the findings of this chapter indicated that targeting promoter regions with short 
RNAs may have unintended effects, especially if partial homology to transcripts within the 
treated cells exists. Here it was shown that indiscriminate cell-wide gene activation could be 
elicited by off-target down-regulation of a suppressor gene in a manner similar to that proposed 
by Morris et al (Morris, Santoso et al. 2008). Just as off-target effects mask the efficacy of 
siRNAs for post-transcriptional gene knockdown, caution should be taken when RNAs (either 
siRNAs or asRNAs) are generated to target promoter regions with the intention of inducing 
specific RNA-mediated transcriptional modulation.   
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Chapter five: general discussion and conclusions 
 
 
Just over ten years have passed since RNAi was discovered and already RNAi-based gene 
expression systems are being tested in a clinical setting. Although much has been achieved, the 
manipulation of the mammalian RNAi pathway for therapeutic purposes requires a more 
complete understanding of the intricate networks involved to ensure robust, reliable and safe 
clinical outcomes. The emerging field of combinatorial RNAi has been given a lot of recent 
attention because it represents a powerful tool for use against highly mutable viruses such as 
HIV. The main aim of such a combinatorial approach is to prevent viral escape through the 
simultaneous and constitutive application of numerous guide sequences. The majority of 
combinatorial RNAi-based systems tried to date have relied on the co-expression of more than 
one shRNA and a major drawback has been the production of saturating levels of these mimics 
in mammalian cells (Grimm, Streetz et al. 2006). In addition, HIV rapidly generates resistance in 
the presence of low levels or too few unique siRNAs rendering the guide sequences ineffective 
(ter Brake, Konstantinova et al. 2006). The studies presented in this thesis add significantly to 
the newly emerging body of research on combinatorial RNAi strategies by focusing on two novel 
technological approaches for expressed combinatorial RNAi mimic systems. Both long-hairpin 
RNAs and combinatorial polycistronic pri-miRNA systems were generated and shown to produce 
multiple siRNAs capable of simultaneously targeting several HIV sites. Importantly, as a prelude 
toward further studies that prove that these combinatorial RNAi modalities provide robust long-
term inhibition of HIV, the focus of this thesis was to explore the functional attributes of different 
mimics to effectively express and produce multiple anti-HIV guides. Solving the problem of viral 
escape remains a crucial future objective, and while not the immediate focus of this thesis, 
further discussion is warranted. Furthermore, as HIV is highly mutable it has developed counter-
strategies against RNAi that may require the use of additional RNAi target sites and/or RNA-
based inhibitory strategies such as TGS to ensure maximum efficacy. Related to this, the data 
described in Chapter 4 showed the unintended development of significant OTEs following TGS-
inducing RNAs and this topic is discussed further in this chapter. Finally, improvements in 
delivery strategies used to introduce RNAi mimics to HIV-infected cells have enabled rigorous 
clinical testing but the wide-spread application of some of these strategies remains contentious. 
Although it is currently unclear how AIDS may be cured by harnessing RNAi, the potential of this 
gene therapy for countering HIV infection is exciting and the role of combinatorial RNAi is central 
to this.  
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5.1 Combinatorial RNAi and viral escape 
 
The combined expression of numerous anti-HIV siRNAs is effective at reducing HIV replication 
over short periods of time. However, as HIV causes a chronic infection, constitutive long-term 
inhibition of HIV is required. Importantly, as HIV resistance develops over time, monitoring of 
RNAi-resistant strains is crucial to the success of these strategies. Early studies by Westerhout 
et al using single anti-HIV siRNAs revealed that there is an inverse correlation between the level 
of HIV resistance and the stability of the siRNA/target RNA interaction (Westerhout, Ooms et al. 
2005). Nine different HIV escape mutants were detected between 27 and 80 days following the 
introduction of anti-nef siRNAs. The majority of the resistance mutations were present in the 
centre portion of the siRNA guide sequence and included base substitutions or deletions. Two 
escape mutants that showed particularly high levels of siRNA-nef resistance had developed 
mutations that induced alternative RNA folding of the target mRNA thus negatively affecting 
siRNA binding. This result showed that the efficacy of RNAi-mediated inhibition depends on 
siRNA/target RNA binding. While the study by Westerhout et al revealed vital information 
regarding HIV resistance mutations, only single siRNAs targeted to an accessory gene were 
used. In a subsequent study by ter Brake et al, the simultaneous application of four expressed 
anti-HIV shRNAs prevented viral escape for 40 days (ter Brake, Hooft et al. 2008). However, 
viral escape mutants were detected following prolonged culturing and sequence analysis 
revealed point mutations within the central portion of the target sites. Notably, the study by ter 
Brake et al used siRNAs targeted to gag, pol and the tat/rev overlap and no deletion mutations 
were detected. This observation alluded to the notion that the types of HIV resistance mutations 
are restricted when conserved mRNAs are targeted. This was clearly demonstrated in a 
thorough investigation by von Eije et al. When highly conserved HIV sequences were targeted, 
escape mutants only showed point mutations and no deletions were detected (von Eije, ter 
Brake et al. 2008). Similarly to the other studies, the point mutations were all located within the 
central portions of the target sites and intriguingly, G:U mismatches were frequently selected. 
These observations were also in line with previous data showing that mutations in the central 
region of target mRNAs have the greatest effect on RNAi efficacy in vitro (Amarzguioui, Holen et 
al. 2003; Pusch, Boden et al. 2003). Notably, positions 15 and 16 can display discriminatory 
effects such that a single mismatch in either of these two positions is sufficient to cause 
mutation-specific target selectivity of mutant alleles only (Schwarz, Ding et al. 2006; Scholefield, 
Greenberg et al. 2009). Taken together, these observations have important ramifications for the 
combinatorial RNAi systems described in this thesis as a key element to their overall success 
lies in target choice. The combinatorial expressed pri-miRNA mimics described in Chapter 3 
encoded siRNAs against int, gag, LTR and tat mRNAs. The int, gag and tat target sites were 
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chosen based on previously published data that was generated using molecular clones of HIV. 
This latter point is important because HIV molecular clones comprise isogenic sequences that 
do not reflect the diversity of target sequences present in wild type HIV infection. A better option 
would have been to select target sites based on multiple HIV sequence alignments as this may 
have provided more robust siRNAs capable of inhibiting a broader range of cognate mRNAs. 
This is particularly important if long-term suppression in the absence of viral escape is desired. 
The abilities of the pri-miRNA mimics to suppress non-isogenic target sequences was assessed 
using the primary HIV isolate FV5 (Figure 32). However, while potent suppression was noted 
following transient transfection, data was only collected for seven days following infection and 
thus potential escape mutants were not detected. The LTR target sites encoded in the lhRNAs 
described in Chapter 2 were chosen as together they comprised the initial ~180 bp of HIV 
transcripts. LhRNA LTR 1 overlapped completely with TAR loop and despite mediating 
significant (albeit low) target inhibition, the strong secondary structure of this site renders it 
refractory to potent RNAi. As the stability of the siRNA/target RNA interaction has an inverse 
correlation to the level of HIV resistance (Westerhout, Ooms et al. 2005), long-term suppression 
mediated by lhRNA LTR 1 would be unlikely. However, understanding the rules of lhRNA 
processing can lead to improvements in the design and subsequent siRNA/target interactions of 
these mimics (see section 2.4).   
 Transcriptional gene silencing provides an alternative mechanism to induce long-term 
proviral silencing. TGS can be mediated by asRNAs targeted to promoter elements and various 
sequences, including site 247, within the HIV LTR are susceptible to this (Weinberg, Villeneuve 
et al. 2006; Suzuki, Juelich et al. 2008; Turner, De La Cruz et al. 2009; Yamagishi, Ishida et al. 
2009). As the LTR is highly conserved, selective pressure mediated by silencing RNAs may 
result in escape mutants with decreased fitness. However, as TGS of the LTR induces changes 
consistent with latent HIV infection (Williams, Chen et al. 2006) (i.e. basal levels of LTR-
mediated transcription), the detection of potential escape mutants and analysis of the types of 
resistance mutations present remains to be completed. Data on the ability to control the 
evolution of wild type HIV using an RNA-based strategy would be highly valuable. Furthermore, 
targeting of the LTR using a combination of TGS and traditional post-transcriptional RNAi, may 
present a resistance barrier that is too high for HIV to escape and is discussed further in section 
5.4.1.   
 RNAi-mediated inhibition of host cell targets required for HIV infection poses an 
additional set of sequences that can be incorporated into combinatorial RNAi systems (see 
section 1.11.3). The number of novel host proteins available for targeting has been boosted by 
the recent discovery of 200 to 300 new host dependency factors required for HIV replication 
(Brass, Dykxhoorn et al. 2008; Konig, Zhou et al. 2008; Zhou, Xu et al. 2008; Yeung, Houzet et 
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al. 2009). Surprisingly little concordance of specific genes was found between the different 
studies and no single gene was common to all four data sets. The Zhou and Brass papers for 
example had an overlap of only seventeen genes, while the Brass and König papers had five 
overlapping genes (Brass, Dykxhoorn et al. 2008; Zhou, Xu et al. 2008). All three of these data 
sets were generated with different HIV strains, various siRNA design algorithms and unequal 
efficacy criteria. Should the same stringent criteria as used in the König study be used on the 
genes identified in the Brass paper, the level of overlapping genes rises to 60 (Konig, Zhou et al. 
2008). The Yeung study utilised shRNAs delivered by lentiviral vectors to T cell clones which 
was a completely different method as compared to the other three studies. Taken together, 
these discrepancies highlight the importance of thorough experimental design, multi-faceted 
data validation and the fact that variations in these can account for significant differences 
between similar experiments.  
 The impact of these discrepancies is on target choice which ties back to viral escape 
once again. Assessment of the effect(s) each new HDF has on wild type HIV replication will 
require large-scale screening and independent validations that may not reach agreement. Thus 
it was suggested that attention should be paid to the modestly concordant genes only (Konig, 
Zhou et al. 2008). These include genes coding for nuclear pore complex scaffolds, transcription 
factors, Golgi-associated proteins and trans-membrane transporters. As these genes are 
involved in generic cytoplasmic and nuclear transport as well as global gene expression, RNAi-
mediated targeting may be detrimental to the host cell as well. However, HIV is less likely to 
evolve an entirely new set of cellular associations to bypass the requirement for an important 
host factor. Clearly, the incorporation of HDFs into combinatorial systems would place significant 
selective pressure on HIV and escape mutations would most likely occur. This remains to be 
elucidated and should receive ample attention. 
 
5.2 HIV-mediated modulation of the RNAi pathway 
 
HIV-1 is able to escape the RNAi pathway via a number of routes (see section 1.11.2) but the 
virus also demonstrates the capacity to modulate RNAi through specific protein suppressors 
[reviewed in (Corbeau 2008)]. Understanding these interactions may shed light on how 
combinatorial RNAi effectors can be used to reduce or even prevent HIV‘s modulation of the 
pathway. Viral Tat can directly inhibit Dicer processing of siRNAs in vitro via the interaction of 
Tat and TRBP (Bennasser, Le et al. 2005; Bennasser, Yeung et al. 2006). Functional Dicer 
requires TRBP to provide a stable link between itself and AGO2 from RISC (Chendrimada, 
Gregory et al. 2005) but TRBP also specifically binds the HIV-1 TAR loop in order to increase 
Tat-mediated viral expression [(Gatignol, Lainé et al. 2005) and see section 1.4.4]. Recent data 
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indicated that sequestration of TRBP by interactions with the HIV-1 TAR loop, inhibits the action 
of Dicer thereby reducing the overall effectiveness of RNAi (Bennasser, Yeung et al. 2006). 
Moreover, TRBP shares a similar domain (dsRBD3) with the dsRNA binding protein PACT that 
forms part of the Dicer/TRBP/AGO2 complex (Lee, Hur et al. 2006). This means the HIV-1 TAR 
loop could bind both PACT and TRBP, either of which action would negatively impact Dicer 
(Bennasser, Yeung et al. 2006; Lee, Hur et al. 2006). Inhibition of the HIV TAR loop and/or Tat 
would dramatically reduce these interactions thereby ensuring Dicer functioning. As the TAR 
loop was previously been shown to be refractive to siRNA-mediated inhibition, it was surprising 
to see significant (albeit low) levels of suppression mediated by lhRNA LTR 1 (Figure 12). 
However, low level inhibition of TAR may be sufficient to hinder TRBP sequestration, especially 
if combined with additional potent siRNAs. Alternatively, HIV transcription could be inhibited 
before threshold levels of Tat have been produced. The ability of lhRNAs LTR 2 and 3 to inhibit 
non-processive LTR-driven transcription provides an exciting observation that RNAi-based tools 
can reduce early-stage HIV replication and this area should be fully explored.  
Another RNAi suppressor mechanism exhibited by HIV-1 has been linked to viral latency 
and miRNA regulatory loops. Both Drosha and Dicer inhibit early stage HIV-1 replication in 
PBMCs and latently infected cells taken from HIV-1 positive donors [(Triboulet, Mari et al. 2007) 
and see section 1.5]. The mechanism is incomplete but a miRNA cluster that affects a Tat 
cofactor, P300/CBP-associated factor (PCAF) is involved. Two members of the cluster, miR17-
5p and miR20a, down-regulate PCAF mRNAs causing a negative impact on HIV replication 
although the virus can suppress miR17-5p/miR20a expression to complete the feedback loop. 
HIV nef encodes a miRNA (miR-N367) that down-regulates transcription of viral mRNAs through 
the negative response element (NRE) of the LTR U3 region (Omoto, Ito et al. 2004; Omoto and 
Fujii 2005). Two human-encoded miRNAs (hsa-miR29a and hsa-miR29b) detected in PBMCs 
were shown to inhibit Nef expression and HIV replication in vitro (Ahluwalia, Khan et al. 2008) 
thereby completing another loop. Although the exact mechanism is unclear, HIV further 
manipulates RNAi to induce proviral latency by generating a TAR-derived miRNA that degrades 
viral transcripts in HIV infected cells and primary T cell precursors (Klase, Kale et al. 2007). 
Conventional drugs such as histone deacetylase (HDAC) inhibitors have been used to prevent 
HIV latency but the generic action of these compounds causes global HDAC inhibition which is 
toxic to the host cells. Recent data revealed that Class II HDAC inhibitors can selectively repress 
histones located in the LTR of integrated HIV but further development is required before these 
drugs become part of a treatment strategy (Archin, Keedy et al. 2009). The use of gene therapy-
based alternatives such as the siRNAs targeted to site 247 in the HIV LTR (see Chapter 4) 
provide a ready approach to limit the viral/host interactions described above as well as prevent 
HIV replication.  
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The ability to modulate RNAi is not exclusive to HIV and many examples exist of 
pathogenic viruses that encode modulators of the pathway (Manjunath, Kumar et al. 2006; 
Haasnoot, de Vries et al. 2007). An interesting question is why these strategies evolved. Plants 
use the RNAi pathway as an antiviral mechanism and the presence of countless RNAi 
suppressor proteins encoded in plant viruses is evidence of this (Haasnoot, Westerhout et al. 
2007). Due to the increased complexity of vertebrates, antiviral mechanisms here are the 
responsibility of immune systems. Why then are there consistent examples of rapidly evolving 
vertebrate viruses that conserve specific anti-RNAi mechanisms if the pathway is not primarily 
antiviral in nature? An interesting suggestion, put forward in the context of HCV infection, is that 
viruses manipulate the RNAi pathway as a means to ensure viral persistence in the face of 
elimination (Mahajan, Drake et al. 2008). HCV uses a low fidelity polymerase for replication 
thereby generating heterogenous virions during infection, yet two host miRNA target sequences 
within its genome are maintained across all six genotypes. Upon infection HCV induces a potent 
IFN response that leads to sterilising immunity. To avoid immediate annihilation, HCV seems to 
have evolved a mechanism whereby host anti-HCV miRNAs suppress viral expression (at the 
two conserved sites) to levels that do not induce IFN but allow for persistent low level infection 
(Mahajan, Drake et al. 2008). This strategy may also be true of HIV and adds another hurdle to 
anti-HIV RNAi.  
 
5.3 Unintended off-target effects related to RNAi 
 
Although RNAi mimics, both synthetic and expressed, are highly effective inducers of RNAi, 
toxicities related to their sequences, structures or processing as well as possible OTEs remain a 
problem. The Pol III-expressed lhRNAs presented in this thesis did not induce cellular 
immunostimulation and there are several explanations for this. Firstly, the characteristic 2 nt 3' 
overhangs present in the anti-LTR lhRNAs likely prevented these mimics from being detected by 
the mammalian pathogen recognition receptors retinoic acid helicase type I (RIG-I) and protein 
kinase R (PKR). RIG-I plays a central role in the discrimination between self and non-self 
cytoplasmic RNAs by eliciting a downstream cascade of cytokines including type I interferons 
that in turn up-regulate expression of IFN-inducible genes and affect protein production, cell 
cycle growth and apoptosis [reviewed in (Kawai and Akira 2008)]. Blunt-ended dsRNAs and 
those with 5' overhangs complex stably with RIG-I in the presence of ATP, causing downstream 
binding of IFN signalling molecules. In contrast 3' overhanging dsRNAs do not bind RIG-I tightly 
and are released (Takahasi, Yoneyama et al. 2008; Schlee, Roth et al. 2009). PKR also binds 
dsRNAs but requires the presence of a 5' triphosphate (Sledz, Holko et al. 2003; Kim, Longo et 
al. 2004) to cause phosphorylation of eukaryotic translation initiation factor 2 (eIF2) and 
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subsequent cellular apoptosis [(McAllister and Samuel 2009) and reviewed in (Borden, Sen et al. 
2007)]. As the anti-LTR lhRNAs described in this thesis were expressed from a Pol III (U6) 
promoter, the 5' ends do not have triphosphates and the sequence design ensured that the 
overall hairpin folded into a structure with a 2 nt 3' overhang.  
The mammalian IFN cascade is not only elicited via the recognition of dsRNA ends. 
Indeed, regardless of the presence of 3' overhangs, longer siRNAs (> 33 bp) have been shown 
to elicit an IFN response (Puthenveetil, Whitby et al. 2006; Nallagatla and Bevilacqua 2008). 
Investigations revealed that PKR has multiple dsRNA binding domains and that numerous PKR 
complexes can assemble on the same siRNA duplex in vitro (Puthenveetil, Whitby et al. 2006). 
Importantly, modification of the sense strand of the siRNA duplex inhibited PKR binding but did 
not decrease the potency of the siRNAs (Nallagatla and Bevilacqua 2008). This suggests that 
the G:U mismatches included within the sense strands of the anti-LTR lhRNAs described in 
Chapter 2 may play a role in decreasing the immunostimulatory potential of these constructs. 
Several groups have reported potent target-specific inhibition using long dsRNAs (38 to 448 bp) 
without G:U mismatches but these constructs did not contain hairpin loops, and were either 
chemically synthesised (Akimov, Kabilova et al. 2009; Chang, Kang et al. 2009) or transcribed 
from T7 promoters. This is in direct contrast earlier reports (Elbashir, Harborth et al. 2001; 
Akashi, Miyagishi et al. 2005; Akimov, Kabilova et al. 2009) as well as the current body of work 
but the reasons for the discrepancies remain unclear.  
It has been suggested that certain sequence motifs can elicit an IFN response, although 
this usually occurs when viral nucleic acids interact with toll-like receptors (TLRs) located on 
endosomes [(Forsbach, Nemorin et al. 2008) and reviewed in (Montero Vega and de Andrés 
Martín 2008)]. Importantly, because expressed constructs (such as the anti-LTR lhRNAs and pri-
miRNA mimics described in this work) are introduced cytoplasmically, they do not encounter 
TLRs. Of greater concern, is the capacity for expressed mimics to overwhelm components of the 
endogenous RNAi pathway. Acute liver toxicity and mortality in mice following expressed shRNA 
administration (Grimm, Streetz et al. 2006) as well as toxic effects in the brains of mice treated 
with expressed shRNAs targeted to Huntington‘s Disease-specific mRNAs (McBride, Boudreau 
et al. 2008) has been observed. Accumulation of shRNA precursors in the livers of mice 
suggested that the observed toxicity was due to saturation of the export machinery (Exp5) 
(Grimm, Streetz et al. 2006). This was supported by the observation that a decrease in shRNA 
expression reduced liver damage although more recent data suggested that TRBP and AGO2 
could also be the bottleneck (Castanotto, Sakurai et al. 2007). Lowering shRNA expression 
levels did not abrogate toxicity in the brains of mice and poor detection of unprocessed mimics in 
those samples suggested that export machinery saturation was not responsible for the adverse 
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effects observed. Alternatively OTEs may have been involved as all three shRNAs tested, 
regardless of sequence, elicited toxicities (McBride, Boudreau et al. 2008).  
Since siRNA-mediated activity requires a match of only six nucleotides (seed region), at 
least one hit can be expected by random chance every 16 384 nucleotides within a stretch of 
DNA or RNA (Jackson, Burchard et al. 2006; Mahajan, Drake et al. 2008) making OTEs 
statistically inevitable. The data in Chapter 4 describes an unintended yet significant OTE that 
occurred as a result of an asRNA targeted to a single site within the promoter region of HIV. 
While TGS was the intended outcome, the opposite result occurred and involved a complex 
cascade of interactions including a gene of unknown function. This result emphasises the 
importance of using potent RNAi effector sequences that are effective at low concentrations. 
One option to address this is to express RNAi mimics of choice from less active promoters such 
as H1 or tRNA. Transcription from these Pol III promoters generates RNAi mimics with 
characteristic 5' and 3' ends but at low concentrations that do not induce cellular 
immunostimulation (Scherer, Frank et al. 2007). Furthermore, as tRNALYS3 and tRNAVAL Pol III 
promoter transcripts are processed in the nucleus by tRNA processing enzymes prior to export, 
the transport of these shRNAs may occur via an alternative exportin pathway (Kawasaki and 
Taira 2003; Rodriguez, Dargemont et al. 2004). Another option that would also allow for greater 
flexibility in terms of expression is the use of Pol II promoters. These latter promoters provide 
inducible and tissue-specific expression but as they do not generate transcripts with defined 5' 
and 3' ends, pri-miRNAs would be the mimic of choice. Interestingly, expressed pri-miRNA 
scaffold versions of the same shRNAs used in the McBride et al mouse brain study did not 
induce adverse effects and showed similar silencing profiles despite being expressed at lower 
levels (McBride, Boudreau et al. 2008). Similar data was described for expressed pri-miRNA 
mimics targeted to HBV in the livers of mice (Ely, Naidoo et al. 2009). Furthermore, the 
exogenous constructs did not affect the expression of an endogenous liver-specific pri-miRNA 
suggesting that the endogenous miRNA pathway was not disrupted following the introduction of 
these constructs into liver cells.  
Regardless of promoter choice, it remains crucial that each guide sequence within a 
combinatorial RNAi system is expressed at high enough doses to induce potent target 
suppression. The observation that the multimeric Pol II-expressed anti-HIV pri-miRNA mimics 
were highly efficacious against wild type HIV yet almost no guide sequences were detected 
(Figures 31 and 32) suggested that these constructs were effective at very low concentrations. 
In contrast, the anti-LTR lhRNAs were less efficacious against wild type HIV despite readily 
detectable guide sequences. This latter observation was most likely related to the poor Dicer-
mediated processing of these constructs. The tiling arrays described in Chapter 2 demonstrated 
that functional guides were only being processed from the first position relative to the 3' 
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overhang of the lhRNAs (Figures 16 and 17). Thus, these mimics were not functioning as a 
combinatorial system. The design and generation of expressed lhRNAs capable of producing 
functional siRNAs from two to three positions along the duplex has been described (see section 
2.4). These latter mimics are transcribed off a single Pol III promoter (H1 or U6) with two 
similarly expressed lhRNA constructs introduced into cells as a combinatorial system (Saayman, 
Barichievy et al. 2008; Sano, Li et al. 2008; Liu, von Eije et al. 2009). While this approach has 
been shown to induce target specific inhibition for up to 49 days, the use of multiple Pol III 
promoters once again raises the concern of Exp5 saturation (although TRBP or AGO2 may also 
play a role in saturation). One option would be to vary the type of Pol III promoter used (to H1 or 
tRNA for example) or to utilise a completely alternative method of synthetic RNAi mimics such 
as that described by Kumar et al (Kumar, Ban et al. 2008). A CD7-specific single chain antibody 
conjugated to an oligo-9-arginine peptide was used to deliver peptide-bound anti-HIV siRNAs 
directly into T cells of NOD/SCID/IL2rγnull mice (see section 1.12) prior to challenge with HIV. 
The delivery method was highly specific and Dicer was able to efficiently cleave the siRNAs in 
the absence of an IFN response. Subsequent viral replication was controlled and the disease-
associated CD4 T cell loss was dramatically reduced despite the use of a single siRNA (anti-
CCR5). Notably, this strategy provided a pre-infection or prophylactic approach that would be as 
valuable as a post-infection treatment. However, as with the latter option, combinations of 
discrete siRNAs are needed and peptide-bound lhRNAs could be explored in this context.  
In summary, cellular immunostimulation and unintended OTEs can be avoided through 
the use of expressed RNAi mimics that are transcribed from less active promoters or synthetic 
mimics introduced directly to the target site(s) of choice. Pri-miRNA mimics may be better suited 
to this approach but additional data is still required to assess whether or not these mimics can 
induce an IFN response. Expressed lhRNAs will become more applicable if their relative 
expression levels can be controlled and their design improved such that Dicer efficiently 
processes each siRNA within the mimic. 
 
5.4 Into the future: delivery of RNAi mimics to patients 
 
5.4.1 Vectors for the delivery of RNAi mimics 
 
For RNAi to be effective against chronic viral infections such as HIV, constitutive expression of 
combinatorial mimics in the target cells of interest is required. An elegant means to achieve this 
involves delivery of the RNAi constructs to host cells using various vector-based methods. 
Therapeutic delivery of RNAi mimics presents a significant challenge in the context of HIV as 
many cell types are infected by the virus and latent reservoirs of viral pools exist in discrete, 
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inaccessible locations such as the brain. Historically retroviral vectors have been used to deliver 
genetic payloads with reports dating back to the early 1980s. Within the retrovirus family, 
lentiviruses have emerged as the most promising candidate largely due to their ability to 
transduce non-dividing cells and integrate within introns of active transcriptional sites [reviewed 
in (Quinonez and Sutton 2002)]. Since 1996 when an HIV-1 based vector was compared to a 
Murine Leukaemia Virus (MLV) counterpart and only the former was shown to stably transduce 
terminally differentiated rat neurons (Naldini, Blomer et al. 1996; Naldini, Blomer et al. 1996), 
various other lentiviral strains have been tested as gene delivery vehicles. Feline 
Immunodeficiency Virus (FIV), HIV-2, Bovine Immunodeficiency Virus (BIV) as well as Equine 
Infectious Anaemia Virus (EIAV) have all been shown to transduce various cell types and 
express their transgene payloads (Quinonez and Sutton 2002). The introduction of pseudotyping 
allowed these vectors to target specific cell types, with the use of the Vesicular Stomatitis Virus 
Glycoprotein (VSV-G) extending the host range of pseudotyped viruses extensively (Sutton 
2000). However, due to the integrating nature of lentiviral vectors, they are potentially oncogenic 
and recombination with wild type virus already present in cells presents another safety concern. 
Various strategies have been employed to improve the overall safety of lentiviral vectors such as 
the removal of the 5' LTR and accessory genes (Morris and Rossi 2006). This has also provided 
space within the genome to insert genes of interest or RNAi mimic expression cassettes but an 
upper size limit exists related to the packaging of lentiviruses.   
One particular lentiviral vector system, termed a conditionally replicating HIV lentiviral 
vector (crHIV) has provided something of a ‗Trojan horse‘ approach to dealing with HIV infection 
because crHIV vectors can carry an anti-HIV payload as well as compete with natural viral RNAs 
in already infected host cells (Sachdeva, D‘Costa et al. 2007). crHIV vectors carrying a triple 
combination ribozyme targeted to the U5 portion of the LTR, significantly reduced wild type HIV 
replication and the infection of neighbouring cells (Dropulic, Hermankova et al. 1996). The effect 
occurred for 22 days which may be a sufficiently long time period as infected CD4+ T cells 
display a short half life in vivo. Interestingly, cultures that contained both wild type HIV and crHIV 
vectors carrying only single or double ribozymes showed viral escape, emphasising once again 
the importance of targeting multiple sites. The ability of crHIV vectors to spread to uninfected 
CD4 cells (i.e. vector mobilisation) has also been addressed. PBMCs infected with HIV-1 were 
readily transduced with crHIV-2 vectors carrying up to four anti-HIV ribozyme sequences and 
while the antiviral effects of the vector could be passed on to neighbouring cells, the subsequent 
titres were lower as compared to the initial crHIV-2 titre (Morris and Looney 2005). These data 
suggested that crHIV-based vectors with maximum potency are needed due to the decrease in 
vector mobilisation following the initial infection. Notably, the asRNA (LTR-247as) described in 
Chapter 4 was successfully delivered to an HIV reporter cell line using a HIV-2-based 
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conditionally replicating vector and TGS was observed for a minimum of one month (Turner, De 
La Cruz et al. 2009). Addition of the HIV-2 vector alone (devoid of LTR-247 asRNAs) also 
mediated some HIV inhibition suggesting that the vector was competing with wild type HIV for 
proteins involved in replication. This is not a new observation (Dropulic, Hermankova et al. 1996; 
Corbeau and Wong-Staal 1998; An, Morizono et al. 1999) but the effect(s) of ‗parasitic‘ delivery 
lentivectors on the evolution of escape mutants remains to be determined.   
There are a number of concerns related to lentiviral vectors including the production of 
clinically relevant titres and the naturally high recombination rate of HIV that may lead to the 
deletion of multiple RNAi expression cassettes [reviewed in (ter Brake and Berkhout 2007)]. 
Related to the first point, lentiviral vector titres can be significantly lowered due to self-targeting 
when they carry RNAi mimic payloads complementary to lentiviral genes (Banerjea, Li et al. 
2003; Chang, Liu et al. 2005). However, significant advances have been made such as using 
human codon-optimised versions of the target gene or selecting target sequences not present in 
the lentiviral genome (Westerhout, Ooms et al. 2005; Westerhout and Berkhout 2007) and 
numerous examples have been published describing the successful lentiviral-mediated delivery 
of shRNAs (Chang, Liu et al. 2005; Lee 2005; Manjunath, Kumar et al. 2006; von Eije, ter Brake 
et al. 2008). The second concern relates to the recombination prone nature of HIV. During 
transduction, repeat sequences such as multiple copies of the same promoter each driving 
expression of a single shRNA, may be recombined resulting in the loss of the RNAi cassettes 
(An and Telesnitsky 2001; ter Brake, Konstantinova et al. 2006). This can be overcome by using 
different promoter sequences or a different RNAi mimic such as those described in Chapter 3 or 
elsewhere (Liu, Haasnoot et al. 2007; Weinberg, Ely et al. 2007; Ely, Naidoo et al. 2008; ter 
Brake, Hooft et al. 2008). Indeed, a central reason for exploring the ability of four different pri-
miRNA scaffolds to produce highly efficacious anti-HIV guides was to incorporate them into a 
single expressed system that would be averse to recombination events (Chapter 3). Importantly 
though, the use of pri-miRNA mimics introduces an additional problem as Drosha cleavage sites 
within the construct can reduce vector titres due to destruction of genomic DNA when the pri-
miRNA mimic is processed (Berkhout and ter Brake 2009). To date, only one publication has 
described lentiviral packaging of a combinatorial pri-miRNA construct targeted to HIV (Liu, 
Haasnoot et al. 2008). While there was no difference in cell viability between transduced and un-
transduced SupT1 cells, no data was included on the effect(s) of pri-miRNA packaging on vector 
titres. Uncovering ways to enhance vector titre production will further boost the use of 
combinatorial pri-miRNA mimics in a clinical setting. 
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5.4.2 Clinical studies in human patients  
 
The details of some anti-HIV RNA-based clinical trials have already been discussed (see section 
1.13) but the wide-spread application of successful gene therapies in human patients remains a 
contentious topic of discussion. Two major approaches are theoretically feasible: T cell and 
haematopoietic stem cell gene therapies. In the former, an entire T cell population or sub-sets 
thereof are manipulated and grown in vivo allowing for HIV-resistant cells to be expanded 
(Levine, Mosca et al. 1996; Levine, Bernstein et al. 1997). These cells are reintroduced into 
patients and while the safety and persistence data are promising, either no or modest effects on 
viral load have been reported (Rossi, June et al. 2007). CD4, CD8 and T cell receptors have all 
been the foundation of various T cell therapies and are an attractive treatment as the impact on 
the patients is minimal. The best way to measure this is to discontinue HAART and monitor the 
ability of engineered T cells to control viral load and CD4 decline. However, as treatment 
interruption schemes are detrimental to patients this is not advised (Abbas and Mellors 2002). 
The second gene therapy option uses haematopoietic stem cells and is particularly attractive as 
these cells produce all the subsequent cells infected by HIV (CD4+ T cells, macrophages, 
microglia and dendritic cells). Genetic manipulation of these cells to produce an HIV resistant 
precursor could theoretically provide protection to the entire spectrum of HIV susceptible cells. 
Haematopoietic precursors are found in bone marrow and umbilical chord blood and can be 
isolated by their CD34+ cell-surface marker (Sutherland, Keeney et al. 2003). Contrary to T 
cells, CD34+ cells cannot be cultured in vivo but rather require an ex vivo approach and 
subsequently, lower numbers of genetically modified haematopoietic cells are generated. In 
addition, the reintroduction of modified CD34+ cells usually requires complete bone marrow 
ablation of the patient but this is highly toxic and requires intensive patient care. Several clinical 
trials (including the triple combination therapy against HIV described in section 1.13) are 
underway to explore the feasibility of this therapeutic approach but early data suggested that low 
numbers of peripheral blood cells were carrying the transgene indicating poor engraftment of the 
haematopoietic precursors (Amado, Mitsuyasu et al. 2004; Podsakoff, Engel et al. 2005).  
 Clearly this approach is expensive, requires intensive care and the treatment regimen is 
highly invasive and toxic to the patient. Furthermore, while effective on a small scale, this 
therapy is not feasible in Africa where the number of patients would overwhelm the health care 
system. In addition, HIV reservoirs that allow for replication competent forms of the virus to 
accumulate and persist remain inaccessible to treatment (Blankson, Persaud et al. 2002). 
Reservoirs include quiescent CD4+ T cells, lymphoid organs, the genitourinary tract and the 
central nervous system and can persist for the lifetime of the patient despite the use of HAART 
(Finzi, Blankson et al. 1999). Thus for an RNAi-based gene therapy approach to be successful, 
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not only do the RNAi mimics need to be highly efficacious yet non-toxic, they need to be 
delivered to all target sites with a vector capable of transducing actively infected cells as well as 
reservoir sites using a methodology that is feasible and not too demanding on the patient. This 
will require a concerted multi-disciplinary approach but as more data are published, the 
techniques will be refined and improved. Combinatorial RNAi-based approaches such as those 
described in this thesis could form part of either T cell or HSC strategies. Combinatorial pri-
miRNA mimics need to be delivered to the nucleus of cells to ensure Drosha-mediated cleavage 
and lentiviral vectors could be used. Expressed lhRNAs could be delivered by lentiviral vectors 
but as they only require Dicer-mediated cleavage prior to RISC loading, they could be also 
delivered by the method of Kumar et al. Given the incredible success of HAART, perhaps the 
best option would be to combine RNAi therapy with current antiretrovirals using an approach that 
targets infected and susceptible cells. 
 
5.5 Concluding remarks 
 
Evidence from protein conservation across plants and animals suggests that the last common 
ancestor of eukaryotes had siRNA-based mechanisms of RNA regulation and that the modern 
RNAi pathway is an amalgamation of ancestral archaeal, bacterial and bacteriophage proteins 
required for DNA repair and RNA processing (Shabalina and Koonin 2008). The information 
related to RNAi in mammalian biology is continually increasing as more details about the various 
molecular interactions are uncovered and intersecting pathways are described. As our 
understanding of the RNAi pathway is extended, the ability to manipulate the mechanisms 
involved expands. By exploiting the exquisite sensitivity and potency of the pathway, exogenous 
RNAi mimics are often far more efficient than other nucleic acid based strategies and as such, 
the field of antiviral RNAi has received extensive attention [reviewed in (Devincenzo 2009; von 
Eije and Berkhout 2009)]. Various stages of clinical trial are underway in humans to assess the 
safety and efficacies of numerous RNAi mimics targeted against a range of viruses. One of the 
most prolific viruses worldwide is HIV and it has been on the receiving end of many RNAi-based 
therapeutic strategies with the main reason for failure lying in the ability of HIV to rapidly mutate 
and thus escape suppression. HAART has been incredibly successful at decreasing HIV-related 
morbidity and mortality with the chief reason for success lying in the combinatorial approach 
whereby a minimum of three anti-HIV drugs are simultaneously administered. Unfortunately, 
treatment interruption leads to resistance and many factors including poor patient compliance 
due to drug toxicity, intermittent supply of drugs in resource-strained areas or lack of patient 
education can lead to sub-optimal therapies. Thus there is a need for alternatives and RNAi 
provides an emerging and enthralling new gene therapy approach. Akin to HAART, RNAi needs 
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to be applied in combination for the maximum efficacy to be achieved but to date few successful 
combinatorial strategies have been explored.  
In the current body of work presented here, two new discrete methods of combinatorial 
RNAi, namely long hairpin RNAs and multimeric pri-miRNA mimics, were investigated.  
Long hairpins can be expressed off a single promoter but can be concurrently processed into 
numerous active siRNAs thereby providing a combinatorial RNAi option that won‘t lead to 
unintended promoter occlusion and related toxicity. The transcribed region of the HIV 5' LTR 
promoter was shown to be effectively suppressed using lhRNAs that were non-toxic in 
mammalian cells. The portions of the lhRNA duplex that produced the most active siRNAs were 
dissected out and inhibition of an HIV infectious molecular clone as well as a wild type HIV 
isolate was demonstrated. Importantly, this work laid the foundation for subsequent studies that 
went on to improve the design of lhRNAs such that highly active siRNAs could be produced from 
all positions along the stem of the duplex (Saayman, Barichievy et al. 2008; Liu, von Eije et al. 
2009). The second major combinatorial RNAi strategy explored was the use of multimeric pri-
miRNA mimics. The ability of various endogenous pri-miRNA backbones to generate active 
guide sequences complementary to various highly susceptible HIV target sites was analysed 
and it was shown that the backbone affects guide sequence efficacy. A strategy to combine four 
of the most effective pri-miRNA scaffolds into one expression cassette was developed and 
significant inhibition of an HIV infectious molecular clone as well as a wild type HIV isolate was 
demonstrated. Furthermore, it was shown that the suppression mediated by each of the guide 
strands within the multimeric vector was target specific and that the constructs were non-toxic in 
mammalian cells. Finally, indiscriminate cell-wide gene activation was shown to occur as an 
unintended off-target effect following the introduction of short RNAs with partial homology to 
non-target RNAs. These observations demonstrated that caution should be exercised when 
targeting untranscribed regions of promoters such as the HIV LTR. Overall, new and exciting 
data describing the antiviral activities of two novel combinatorial RNAi approaches targeted to 
HIV as well as valuable data related to the application of RNAi effectors was generated.  
These data have laid vital groundwork for what will surely become an important research 
area as antiviral RNAi moves into the clinical arena. The ability to exploit and tailor-make RNAi 
mimics allows them to be widely applied to a vast number of viral pathogens and future 
experiments will need to build on previous work if laboratory applications are to reach patients 
timeously. Given that the development of a successful preventative vaccine for HIV may 
continue to frustrate the scientific community, therapeutics will become even more important. 
Research in the coming years will need to focus not only on combining HAART with new gene 
based therapies such as RNAi, but also on devising methods to introduce antiviral genetic 
modalities in a manner that is suitable to infected patients in the developed and developing 
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world. RNAi was discovered a mere decade ago and yet patients are already enjoying the 
benefits of efforts to exploit the pathway. By furthering the field through the development of 
combinatorial RNAi, we have contributed to the most exciting new therapy in the 21st century.   
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Appendices 
 
 
A1  Standard laboratory methods 
 
A1.1 Bacterial growth, storage and transformations 
 
A1.1.1 Bacterial growth and storage 
 
The host bacterial strain used in this work was Escherichia coli DH5α (Hanahan, 1983). Cultures 
were grown with shaking (350 rpm) in Erlenmeyer flasks at 37 oC in a New Brunswick Series 25 
orbital incubator (New Brunswick Scientific Co, Inc, NJ, USA) in Luria Bertani (LB) broth (10 % 
tryptone powder, 5 % yeast extract, 10 % NaCl (Merck, Darmstadt, Germany) or on LB agar 
plates [10 % tryptone powder, 5 % yeast extract, 10 % NaCl and 10 % agar powder (Merck, 
Darmstadt, Germany)] supplemented with 200 μg/mL Ampicillin antibiotic (Sigma-Aldrich, MO , 
USA). For TA cloning, 40 μL of  X-gal (20 mg/ml stock in dimethyl formamide, Sigma-Aldrich, 
MO, USA) and 4 μL of IPTG (200 mg/ml aqueous solution, Roche, Basel, Switzerland) were 
spread on Ampicillin positive LB agar plates and left to air dry for 20 minutes at 37 oC prior to 
plating. E.coli DH5α strains were stored in 33 % glycerol (Merck, Darmstadt, Germany) at           
-80 oC. 
 
A1.1.2 Preparation of chemically competent E.coli 
 
E. coli cells were grown in 100 mL of LB (see Appendix A1.1.1) until log phase as measured by 
OD600 of 0.4. Cells were chilled for 20 minutes on ice followed by centrifugation for five minutes 
at 4 oC and 59.5 x g in a refrigerated centrifuge (Eppendorf 5415D/R, Eppendorf, Hamburg, 
Germany). The pellet was resuspended in 10 mL of ice cold transformation buffer (60 mM CaCl2, 
15 % glycerol, 10 mM PIPES pH 7.0; Merck, Darmstadt, Germany) and incubated for 20 minutes 
on ice. Followed by centrifugation for 5 minutes at 4 oC and 59.5 x g. Pellets were resuspended 
in 1 mL of ice cold transformation buffer and 100 μL aliquots were stored at -80 oC.  
 
A1.1.3 Bacterial transformations 
 
Plasmid DNA (0.5 μg/μL) was added to a 100 μL aliquot of transformation competent cells 
(thawed on ice) and incubated on ice for 30 minutes before heat shock for 90 seconds at 42 oC. 
Cells were incubated for 60 minutes at 37 oC without shaking following the addition of 800 μL of 
203 
 
LB, to allow for phenotypic expression of antibiotic resistance genes, prior to plating onto 
Ampicillin positive LA plates. 
 
A1.2 Plasmid DNA preparation, electrophoresis and extraction 
 
A1.2.1 Plasmid DNA preparation 
 
Plasmid DNA was prepared using three commercially available kits (Qiagen, Hilden, Germany) 
that differed according to the concentration of DNA required: ‗mini-preps‘ (~150 ng/μL plasmid 
DNA), ‗midi-preps‘ (~800 ng/μL of plasmid DNA) and ‗maxi-preps‘ (~5 μg/μL of plasmid DNA). 
Transformed E.coli DH5α cultures (three mL for mini-preps, 50 mL for midi-preps and 250 mL for 
maxi-preps) were grown in LB (see Appendix A1.1.1) until log phase as measured by OD600 of 
0.4 followed by centrifugation for 20 minutes at 4000 x g (midi and maxi preps) or 16 000 x g 
(mini preps). Pellets were resuspended in 250 μL (mini prep), 4 mL (midi prep) or 10 mL (maxi 
prep) of Buffer P1 (50 mM Tris-HCl pH 8.0, 10 mM EDTA and 100 μg/ml RNAse A). An equal 
volume of Buffer P2 [200 mM NaOH, 1 % SDS (w/v)] was added and mixed by inversion for one 
minute. An equal volume of pre-chilled Buffer P3 (3.0 M potassium acetate pH 5.5) was added 
(for midi and maxi preps; 350 μL for mini preps) and mixed by inversion for one minute prior to 
centrifugation for 20 minutes at 4000 x g for midi and maxi preps or 16 000 x g for mini preps.  
For mini preps, the supernatant was pipetted into a QIAprep spin column, centrifuged 60 
seconds at 16 000 x g followed by the addition of 750 μL of Buffer PE (wash buffer, composition 
not provided) and centrifugation for 60 seconds at 16 000 x g. Flow-through was discarded and 
samples were centrifuged for 60 seconds at 16 000 x g followed by elution into a new microfuge 
tube with 100 μL of Buffer EB (10 mM Tris-HCl pH 8.5) and centrifugation for 60 seconds at      
16 000 x g.  
 For midi and maxi preps, the supernatant was poured into a QIAtip binding column that 
had been pre-cleared with 4 mL (midi prep) or 10 mL (maxi prep) of Buffer QBT [750 mM NaCl, 
50 mM MOPS pH 7.0, 15 % isopropanol (v/v), 0.15  % Triton® X-100 (v/v)] using gravity flow. 
The column was washed with 2 x 10 mL (midi prep) or 2 x 30 mL (maxi prep) of Buffer QC     
[1.0 M NaCl, 50 mM MOPS pH 7.0, 15 % isopropanol (v/v)]. Plasmid DNA was eluted into a new 
50 mL tube using 5 mL (midi prep) or 15 mL (maxi prep) of Buffer QF [1.25 M NaCl, 50 mM Tris-
HCl pH 8.5, 15 % isopropanol (v/v)] followed by the addition of 3.5 mL (midi prep) or 10.5 mL 
(maxi prep) of isopropanol (Merck, Darmstadt, Germany) and samples were centrifuged for one 
hour at 4 oC and 8000 x g. Pellets were air-dried and resuspended in 250 μL or 500 μL of Buffer 
TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0). Plasmid DNA was subjected to 
spectrophotometry using a NanoDrop Spectrophotometer (Thermo Fisher Scientific, Inc, MA, 
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USA) to determine the concentration (at a wavelength of 260 nm, 1 absorbance unit (A260) =     
50 μg/mL dsDNA) and purity (A260/A280 > 1.8).  
 
A1.2.2 Phenol/chloroform extraction of DNA 
  
The chloroform/phenol method of nucleic acid extraction was used to recover DNA for PCR 
analysis following immunoprecipitation (ChIP, see section 4.2.5).  DNA solutions were brought to 
a volume of 500 μL with nuclease-free water (Qiagen, Hilden, Germany). A 500 μL volume of 1:1 
phenol: chloroform, (1 x volume, Merck, Darmstadt, Germany), was added to the samples which 
were briefly vortexed for ten seconds to form an emulsion. The mixture was centrifuged for       
15 seconds at 12 000 x g. Approximately 500 μL of the aqueous phase was transferred to a new 
microfuge tube followed by the addition of one volume of chloroform. The samples were briefly 
vortexed and centrifuged for 15 seconds at 12000 x g. The aqueous phase was removed and 
0.1 volumes of 3 M sodium acetate pH 5.2 and 2.5 volumes of 100 % ice-cold ethanol were 
added. Samples were incubated at -70 oC for 30 minutes followed by centrifugation for 15 
minutes at 13 000 x g and 4 oC. The pellet was washed with 70 % ethanol and samples were air-
dried to remove residual ethanol before being resuspended in 50 μL of nuclease-free water.  
 
A1.2.3 Agarose gel electrophoresis 
 
To make a 0.8 % agarose gel, 0.8 g of agarose powder (Sigma-Aldrich, MO, USA) was 
dissolved in 100 mL of 1 x TBE buffer (890 mM Tris base, 890 mM Boric acid and 32 mM EDTA, 
Merck, Darmstadt, Germany) and heated until the agarose had dissolved. Prior to pouring,     
one μL per 50 mL gel of ethidium bromide (10 mg/mL - Sigma, Germany) was added. DNA 
samples were mixed with an equal volume of loading dye (1.67 mM Tris-HCl pH 7.6, 0.005 % 
bromophenol blue, 0.005 % xylene cyanol FF, 10 % glycerol, 10 mM EDTA, Fermentas, WI, 
USA) and electrophoresed parallel to 2 μL of a DNA molecular weight marker (O‘GeneRulerTM 
Mix, Fermentas, WI, USA) that had been loaded into the wells of a set agarose gel. Gels were 
subjected to electrophoresis at 100 volts.  
 
A1.2.4 DNA purification from agarose gels 
 
DNA fragments were purified from agarose gels using a commercially available kit (Qiagen, 
Hilden, Germany). The DNA fragment of interest was excised from the gel using a scalpel blade, 
weighed and 3 x the volume of a Buffer QG (composition not provided) was added (100 μg = 
100 μL) followed by incubation for ten minutes at 50 oC until melted. One gel volume of 
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isopropanol (Merck, Darmstadt, Germany) was added, the mixture was inverted ten times and 
pipetted into a QIAquick spin column followed by centrifugation for 90 seconds at 16 000 x g. 
Flow through was discarded, 500 μL of Buffer QG was added to the column followed by 
centrifugation for 90 seconds at 16 000 x g. Flow-through was discarded, 750 μL of Buffer PE 
(wash buffer, composition not provided) was added to the column followed by centrifugation for 
90 seconds at 16 000 x g. Flow-through was discarded followed by centrifugation for 90 seconds 
at 16 000 x g to dry the column. DNA was eluted into a new microfuge tube with 50 μL of Buffer 
EB (10 mM Tris-HCl pH 8.5) by centrifugation for 90 seconds at 16 000 x g. Eluted DNA was 
subjected to spectrophotometry using a NanoDrop Spectrophotometer (Thermo Fisher Scientific, 
Inc, MA, USA) to determine the concentration (at a wavelength of 260 nm,                  1 
absorbance unit (A260) = 50 μg/mL dsDNA) and purity (A260/A280 > 1.8).  
 
A1.3 RNA extraction and RNA loading dye for Northern blots 
 
A1.3.1 RNA extraction from adherent mammalian cells seeded in 10 cm dishes 
  
Forty eight hours post-transfection mammalian HEK293 or Huh7 cells that had been cultured in 
10 cm dishes (NuncTM, AEC-Amersham (Pty) Ltd, South Africa) were washed in PBS (Gibco, 
UK), resuspended in one mL of TriReagentTM (Sigma, Germany) and transferred to a microfuge 
tube with 300 μL of chloroform (Merck, Germany) followed by ten seconds of vortexing. Samples 
were centrifuged for 30 minutes at 16 000 x g and 4 oC in a refrigerated centrifuge (Eppendorf 
5415D/R; Eppendorf, Germany). The upper aqueous phase was carefully transferred to a new 
microfuge tube, an equal volume (~ 300 μL) of isopropanol (Merck, Germany) was added and 
samples were centrifuged for 30 minutes at 16 000 x g and 4 oC. The supernatant was discarded 
and the pellets air dried before being resuspended in 30 μL RNAse-free de-ionised distilled 
water (Ambion, Applied Biosystems, USA). RNA was subjected to spectrophotometry using a 
NanoDrop Spectrophotometer to determine the concentration (at a wavelength of 260 nm,          
1 absorbance unit (A260) = 40 μg/mL RNA) and purity (A260/A280 > 2).  
 
 A1.3.2 RNA extraction from suspension mammalian cells seeded in 6 well dishes 
 
Forty eight hours post-transfection mammalian 1G5 cells that had been cultured in 6 well dishes 
(NuncTM, AEC-Amersham (Pty) Ltd, South Africa) were pelleted by centrifugation for five minutes 
at 300 x g, resuspended in 600 μL of Buffer RLT (composition not provided) and transferred to a 
QIAshredder spin column placed within a two mL collection tube followed by centrifugation for 
two minutes at 16 000 x g. An equal volume (~600 μL) of 70 % ethanol (Merck, Germany) was 
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added to the lysate and 700 μL of the sample was transferred to an RNeasy spin column placed 
in a two mL collection tube followed by centrifugation for 15 seconds at 16 000 x g. Flow-through 
was discarded and successive aliquots of sample were centrifuged using the same column until 
all the lysate had been centrifuged. 700 μL of Buffer RW1 (composition not provided) was added 
to the RNeasy spin column followed centrifugation for 15 seconds at 16 000 x g. Flow-through 
was discarded and 500 μL of Buffer RPE (composition not provided) was added to the RNeasy 
spin column followed centrifugation for 15 seconds at 16 000 x g. Flow-through was discarded 
and 500 μL of Buffer RPE was added followed centrifugation for two minutes at 16 000 x g. The 
RNeasy spin column was transferred to a new 1.5 mL collection tube and 50 μL of RNAse-free 
water was added directly to the spin column membrane followed by centrifugation for one minute 
at 16 000 x g. RNA was subjected to spectrophotometry using a NanoDrop Spectrophotometer 
to determine the concentration (at a wavelength of 260 nm, 1 absorbance unit (A260) = 40 μg/mL 
RNA) and purity (A260/A280 > 2).  
 
A1.3.3 RNA loading dye for Northern Blots 
 
A 2 x stock solution of RNA loading dye contained: 1 mM EDTA pH 8.0 (Sigma-Aldrich, MO, 
USA),    0.25 % bromophenol blue (Merck, Darmstadt, Germany) and 0.25 % xylene cyanol FF 
(Merck, Darmstadt, Germany) in 98 % deionised formamide (Merck, Darmstadt, Germany). 
 
A2 Specialised laboratory methods 
 
A2.1 Tissue culture infectious dose (TCID) determination 
 
Total p24 antigen in culture supernatants of cells infected with HIV-1 represented free antigen 
released from lysed cells and p24 from assembled intact virions. Thus the TCID50 assay (50 % 
tissue culture infectious dose) measured the level of replication competent infectious virus from 
culture supernatants. The viral supernatant needed to have a p24 value > 30 pg/mL to yield an 
acceptable TCID50 value (p24 ELISA datasheet, Murex Biotech LTD, Kent, UK) thus a dilution 
series was generated as follows: twenty four hours prior to infection, U87.CD4.CCR5 cells were 
seeded at 50 000 cells per well in 200 μL of growth media (see section 2.2.4) in flat bottomed 96 
well plates (NuncTM, Thermo Fisher Scientific, Inc, MA, USA) The remaining wells were filled 
with 200 μL each of PBS (Gibco, BRL, UK) to reduce dehydration across the plate. The cells 
were allowed to settle overnight and the following day, all supernatant from wells seeded with 
cells was removed. Based on the scheme in Figure A1, 175 μL of growth media was added to all 
wells from 4-4 to 4-16 and negative controls. A stock of FV5 was thawed at 37 oC, immediately 
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diluted 1:12 in growth media (100 μL FV5 + 1.1 mL of growth media) and 200 μL was pipetted 
into each 4-2 dilution well. Using a multichannel pipette (Eppendorf, Hamburg, Germany), moving 
left to right across the late and changing tips in between, 25 μL from one row of wells with the 
same dilution series was transferred to the adjacent row of wells thereby generating a dilution 
series of FV5 across the plate. Twenty five μL was discarded from each well in the last row (4-14) 
and cells were left to incubate overnight. The following day (Day 0), the supernatant from each 
of the 4-2 wells was removed and stored at -80 oC as ‗viral input‘. The supernatant from all other 
wells was discarded and all wells were washed three times each in PBS (Gibco, BRL, UK) 
followed by the addition of 300 μL of fresh growth media to each well. One hundred μL of 
supernatant from each well was collected and stored at -80 oC as ‗Day 0‘ samples. Cells were 
incubated for a further four days when 100 μL of supernatant from each well was collected and 
stored at -80 oC as ‗Day 4‘ samples. 100 μL of fresh growth media was added to each well and 
cells were incubated for a further three days when 100 μL of supernatant from each well was 
collected and stored at -80 oC as ‗Day 7‘ samples. Stored supernatants collected from the 
various days were simultaneously thawed at room temperature and analysed by ELISA (Murex 
Biotech LTD, Kent, UK) for p24 antigen production (see section 2.2.9).  
 To determine a TCID50 value for FV5, the number of wells that had yielded a 
negative p24 ELISA value (based on the cut-off value of mean absorbance of negative controls 
plus 0.050) were totaled (9) and the 50 % endpoint value (M) was calculated according to          
M = xk + d.[0.5 – (1/n)(r)], where xk = dose of the highest dilution, d = spacing between the 
dilutions, n = wells per dilution and r = sum of the negative responses. The M value for FV5 was 
calculated at 4-5.5 which converted (from base 4 to base 10) to a titre of 103.3 and a TCID50/mL 
value of 1 x 104. 
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Figure A1: A schematic representation of the dilution series used to generated a TCID50/mL value in 
U87.CD4.CCR5 cells using p24 ELISA. Blocks labeled ‗P‘ denote wells filled with PBS. The dilution series 
was set up from left to right across the 96 well plate starting with 4
-2
 (green blocks) and ending with 4
-14
 
(far right column of blue blocks). The orange blocks represent wells that were seeded with cells but not 
infected. 
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A3 Other appendices 
 
A3.1 HBV tiling array 
 
To ensure that the pattern of functional siRNA production from a lhRNA construct was not 
specific to anti-LTR lhRNAs, a dual luciferase-based tiling array was conducted using the lhRNA 
HBV cassette targeted to an HBV-specific set of target tiles (see section 2.3.6). A common 3' 
transcription termination signal within all HBV transcripts resulted in HBV mRNAs sharing a 
common 3' sequence (Figure A2 upper panel). This region was chosen for the tiling array as 
inhibition of this target site using shRNAs had previously been shown to be effective in cell 
culture and in vivo studies (McCaffrey, Nakai, et al., 2003; Carmona, Ely, et al., 2006) and 
provided a useful alternative system to explore lhRNA efficacies. A set of five target tile vectors 
that overlapped each other by 14 bp and together spanned the common region within HBV 
(GenBank® accession number V01460) were individually cloned within the 3' UTR of the hRluc 
gene in psiCheck2 (see section 2.2.3). A complete target comprising the entire region was also 
separately cloned into psiCheck2 (Figure A2 middle and lower panels).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2: HBV tiling array sequences and cloning strategy. The upper panel has four arrows to depict 
HBV transcripts that have that same 3' ends due to a common transcription termination sequence and the 
lhRNA HBV target site common to all transcripts is depicted as a turquoise rectangle. In the middle panel 
the complete lhRNA HBV target sequence, as well as five overlapping tiled segments (target Tiles A to E), 
are depicted and the latter are aligned relative to the complete sequence. All six sequences were cloned 
into the 3' UTR of hRluc within the dual luciferase psiCheck2 vector that expressed hFluc from a separate 
HSK TK promoter within the same plasmid (bottom panel).  
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A3.2 Inhibitory efficacies of expressed anti-HIV shRNAs  
 
For a combinatorial RNAi approach against HIV to be effective, a minimum of four target mRNAs 
had been shown to be effective (ter Brake, Konstantinova, et al., 2006; ter Brake, Hooft, et al., 
2008). Many HIV mRNAs had been effectively suppressed using expressed shRNAs and six 
highly efficacious previously published sequences were cloned and assessed in this work using 
a wild type subtype C HIV isolate (FV5). The sequences included shRNAs targeted to Gag 
(Cave, Weinberg, et al., 2006), IN (Nishitsuji, Kohara, et al., 2006), the protease region of Pro 
(ter Brake, Konstantinova, et al., 2006), Tat (Lee, Dohjima, et al., 2002), Nef (Westerhout, Vink, 
et al., 2006) and Env (ter Brake, Konstantinova, et al., 2006) and were renamed in this work 
according to their target site. Specifically, shGag was previously denoted as ‗shRNA A‘ and 
corresponded to co-ordinates 792 to 812 of the gag ORF from HXB2 (GenBank® accession 
number K03455). shIN corresponded with the N-terminal core domain of the int ORF from NL4-3 
(GenBank® accession number AF324493). shPro was previously denoted as ‗pol-protease 
shRNA Pol-1 and Pol-2‘ and correlated with positions 1910 to 1929 of the LAI viral genome 
(GenBank® accession number AF33819). shTat was previously designated ‗site 1‘ and 
corresponded to a tat transcript located 20 bp downstream of a rev translation initiation codon. 
shNef was previously designated ‗wt shNef‘ and corresponded to positions 8553 to 8571 in the 
nef gene of LAI (GenBank® accession number AF33819). shEnv corresponded to the RRE at 
positions 7391 to 7412 of LAI (GenBank® accession number AF33819).  
A two-step PCR approach as described in section 2.2.1 was used to clone shRNAs 
targeted to using a universal U6 Forward primer containing a SpeI restriction site (5' CTA ACT 
AGT GGC GCG CCA AGG TCG GGC AGG AAG AGG G 3'; the SpeI site is underlined) and the 
following reverse oligonucleotide primers: shGag Reverse (5' AAA AAA GGG TGC GAG AGC 
GTC AAT ATT ATG GGT CAG GTA ATA TTG ACG TTC TCG CAC CCG GTG TTT CGT CCT 
TTC CAC AA 3'), shIN Reverse (5' AAA AAA GCC GGA GAG CAA TGG CTA GTG ATT GGG 
TCA GGT AAC TAA CCA TTG CTC TCC GGC GGT GTT TCG TCC TTT CCA CAA 3'), shPro 
Reverse (5' AAA AAA GAC AGG AGC AGA TGA TAC AGT TGG GTC AGG AAT ATA TCA TCT 
GCT CCT GTC GGT GTT TCG TCC TTT CCA CAA 3'), shTat Reverse (5' AAA AAA GCG GAG 
ACA GCG ACG AAG AGC TGG GTC AGG GCT CTT CAT CAC TAT CCC CGC GGT GTT TCG 
TCC TTT CCA CAA 3'), shNef Reverse (5' AAA AAA GTG CCT GGC TAG AAG CAC AAG TGG 
GTC AGG ATT GTA CTT CTA GCC AGG CAC GGT GTT TCG TCC TTT CCA CAA 3') and 
shEnv Reverse (5' AAA AAA CAG CAG GAA GCA CTA TGG GCG TGG GTC AGG AAC ACA 
TAG TGC TTC CTG CTG CGG TGT TTC GTC CTT TCC ACA A 3'). Candidate pTZ57R/T-
based shRNA clones were screened using BamHI and EcoRI as well as sequencing as 
described in section 2.2.1.  
210 
 
The U6-driven shRNAs were expressed as sense-loop-antisense constructs with ~23 bp 
stem regions and 2 bp 3' overhangs required for Dicer recognition (Figure A3). 
 
 
 
 
 
 
 
Figure A3: Design of expressed anti-HIV shRNA cassettes. Pol III (U6) cassettes were designed to 
express individual anti-HIV shRNAs that each folded into a sense-loop-antisense structure with a ~23 bp 
stem and characteristic 2 bp 3' overhangs.  
 
 
In addition to the inclusion of previously published shRNAs, an aim of this work was to generate 
an expressed shRNA targeted to the HIV LTR and to include the guide sequence from this 
mimic in a combinatorial pri-miRNA mimic construct. Eight target sites within the 5' LTR of HIV 
were selected using two web-based programs, GeneLink RNAi Explorer 
(http://www.genelink.com/siRNA/shRNArev.asp) and siRNA Design (http://coh-mfold.sdsc.edu/). 
These included one control site within the TAR loop and seven sequences within the transcribed 
U5 region (Figure A4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4: Diagrammatic representation of anti-HIV shRNA target sites within the 5' LTR. Eight shRNAs 
were designed to target the TAR loop (shTAR) or the transcribed U5 region of the HIV LTR. Positions of 
the shRNAs are approximate and not to scale.  
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A two-step PCR approach as described in section 2.2.1 was used to generate eight expressed 
shRNAs targeted to these regions using a universal U6 Forward primer containing a SpeI 
restriction site (5' CTA ACT AGT GGC GCG CCA AGG TCG GGC AGG AAG AGG G 3'; the 
SpeI site is underlined) and the following reverse oligonucleotide primers: shTAR (5' AAA AAA 
GGA GCT CTC TGG CTA TCT AGG TGG GTC AGG CGT AGA TAG CCA GAG AGC TCC 
GGT GTT TCG TCC TTT CCA CAA 3'), sh1 (5' AAA AAA GCC TCA ATA AAG CTT GCC TTG 
TGG GTC AGG CAA GAC AAG CTT TAT TGA GGC GGT GTT TCG TCC TTT CCA CAA 3'), 
sh2 (5' AAA AAA GAG CTT GCC TTG AGT GCT CTA AGT GGG TCA GGC TTA GAG CAC 
TCA AGG CAA GCT TCG GTG TTT CGT CCT TTC CAC AA 3'), sh3 (5' AAA AAA TTG AGT 
GCT CTA AGT AGT GTG TGT GGG TCA GGC ACA CAC TAC TTA GAG CAC TCA ACG GTG 
TTT CGT CCT TTC CAC AA 3'), sh4 (5' AAA AAA GCT AAG TAG TGT GTG CCC GTC TTG 
GGT CAG GAG ACA AGC ACA CAC TAC TTA GCG GTG TTT CGT CCT TTC CAC AA 3'), sh5 
(5' AAA AAA GTA ACT AGA GAT CCC TCA GAC TGG GTC AGG GTC TGA GAG ATC TCT 
AGT TAC GGT GTT TCG TCC TTT CCA CAA 3'), sh6 (5' AAA AAA GCC CTT TGT GTT AGT 
GTG GAA TGG GTC AGG TTC CAC ACT AAC ACA AAG AGC GGT GTT TCG TCC TTT CCA 
CAA 3') and sh7 (5' AAA AAA GGG TGC GAG AGC GTC AAT ATT ATG GGT CAG GTA ATA 
TTG ACG TTC TCG CAC CCG GTG TTT CGT CCT TTC CAC AA 3'). Candidate pTZ57R/T-
based shRNA clones were screened using BamHI and EcoRI as well as sequencing.  
Inhibitory efficacies of the eight expressed anti-LTR shRNAs were determined using the 
LTRc-hFluc HEK293 stable cell line as described in sections 2.2.5 and 2.2.6 although no 
exogenous Tat was included in the samples so that inhibition of basal mRNA levels could be 
detected. Luciferase activity measured 48 hours post-transfection revealed highly significant 
inhibition (α = 0.99; p < 0.01) for all shRNAs as well as lhRNA LTR 2 that had been included as 
a positive control (Figure A5). Intriguingly, shTAR mediated 66.23 % ± 1.42 % inhibition of the 
LTR supporting previous data that showed the TAR loop to be amenable to lhRNA-mediated 
suppression (see section 2.3.1). The remaining shRNAs mediated varying levels of inhibition 
with shRNAs 1, 3 and 5 achieving greater than 50 % target suppression (65.70 % ± 1.83 %, 
60.23 % ± 5.95 % and 76.63 % ± 6.14 % respectively). As expressed sh5 showed the greatest 
inhibitory efficacy, it was renamed shLTR and included in the panel of anti-HIV shRNAs.  
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Figure A5: Inhibitory efficacies of anti-LTR shRNAs. Expressed shRNAs targeted to the TAR loop (green 
bar) or U5 regions (purple bars) of the HIV LTR were co-transfected with pRSV-Rluc in the LTRc-hFluc 
HEK293 stable cell line. Data are expressed as a ratio of hFluc to hRluc normalised to an empty vector 
control (mock – red bar) determined 48 hours post-transfection (n = 3, ± SEM). lhRNA LTR 2 (orange bar) 
was included as a positive control.  
 
Having generated a panel of anti-HIV shRNAs that included one previously unpublished 
sequence (shLTR), the inhibitory efficacy of each mimic was assessed using the subtype C HIV 
isolate FV5 as described in section 2.2.9. U87.CD4.R5 cells were transfected in triplicate with 
either an empty vector control (mock) or one of the anti-HIV shRNAs before being challenged 
with FV5 using a TCID50 of 1000/mL. Inhibition of HIV was assessed 4 days post-infection by 
determining p24 antigen levels (Figure A6). Cells that received only FV5 or empty vector (mock) 
treated cells showed no significant differences (α = 0.99; p > 0.05) indicating that the viral isolate 
was infectious and the empty vector itself did not induce non-specific inhibition. All seven 
shRNAs showed highly significant inhibition of HIV replication as compared to mock infected 
cells (α = 0.99; p < 0.01) with percentage suppression as follows: shRNA Env = 70.50 % ± 0.07 
%, shRNA Nef = 92.00 % ± 0.01 %, shRNA Pro = 97.50 % ± 0.07 %, shRNA IN = 98.00 % ± 
0.01 %, shRNA Gag = 98.00 % ± 0.01 %, shRNA LTR = 98.50 % ± 0.07 % and shRNA Tat = 
98.50 % ± 0.07 %. From these data it was clear that shRNAs Nef, Pro, IN, Gag, LTR and Tat 
were effective at inhibiting FV5. This observation was particularly noteworthy as the isolate 
comprised a pool of non-isogenic viral sequences. As a result of these data the guide sequences 
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from shRNAs IN, Gag, LTR and Tat were selected for incorporation into a combinatorial pri-
miRNA mimic strategy (see section 3.2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A6: Challenge assay to assess anti-HIV shRNAs against a subtype C viral isolate of HIV. All seven 
shRNAs as well as an empty vector control (mock- red bar) were transfected into U87.CD4.R5 cells prior 
to challenge with viral isolate FV5 at a TCID50 of 1000/mL. Viral Gag p24 antigen levels were determined 
4 days post-infection by ELISA (450 nm). Values were converted to ng/mL using a standard curve 
supplied with the ELISA kit and data are expressed as p24 antigen levels in ng/mL (n = 3, ± SEM).  
 
 
A3.3 Sequencing analysis of an ineffective multimeric anti-HIV pri-miRNA mimic 
 
The multimeric pri-miRNA mimic pCi-LTR-Tat did not show levels of inhibition comparable to 
pCi-Gag-LTR when targeted against psi-LTR or psi-Tat target vectors (see section 3.3.3). Thus 
sequence analysis was performed as described in section 2.2.1 to assess if there were 
mutations present within the guide sequences of the mimic. From sequence alignments it was 
clear that numerous mismatches, insertions and deletions were present within both guide 
sequences of pCi-LTR-Tat (Figure A7). Disruption of three or more base pairings in the seed 
region of a guide strand had been shown to have a marked deleterious effect on silencing and 
single point mutations had been shown to reduce but not obliterate target inhibition (Zeng and 
Cullen, 2003). Thus the numerous mutations present within pCi-LTR-Tat suggested that poor 
binding of the guide sequences to their target regions negatively affected the ability of this mimic 
to inhibit psi-LTR and psi-Tat target reporters.   
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Figure A7: Alignment of sequenced and expected guide regions from pCi-LTR-Tat. The multimeric pri-
miRNA mimic comprised of pri-miR30a LTR and pri-miR122 Tat was sequenced and the guides of each 
pri-miRNA component were aligned with the expected sequences derived from shLTR and shTat 
respectively. Mismatches are highlighted in bold with green boxes. Insertions and deletions are indicated 
with a hyphen. 
 
 
A3.4 Microarray analysis of LTR-247as+7-mediated off-target gene expression 
  
A total of 185 genes showed altered mRNA expression following 247as+7 treatment relative to 
GFPas controls in 1G5 cells. A description of each gene as well as the fold change in expression 
in the presence of LTR-247as+7 is presented in Table A3.4.1. 
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Table A3.4.1 Genes with significantly altered expression profiles when co-transfected with LTR-247as+7  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
